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A BIOCHEMICAL CHARACTERIZATION OF THE FUSION PROTEINS 
FROM ENVELOPED RNA VIRUSES 
 
Enveloped viruses must bind target cells and then fuse the viral membrane 
with a cell membrane to enter a host cell.  These viruses use one or more surface 
glycoproteins to carry out these critical functions. The surface glycoprotein that 
carries out the fusion function, termed a fusion protein, is divided into three classes 
based on structural similarities.  Some of the most studied human viral pathogens, 
such as human immunodeficiency virus (HIV), Ebola virus, influenza, measles, and 
the recently emerged severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), possess class I fusion proteins. Following synthesis, class I fusion proteins 
associate as non-covalently linked homo-trimers, and remain as trimers 
throughout the fusion process. Key proteolytic processing events and subsequent 
receipt of a triggering signal, drive the fusion protein to undergo large, irreversible 
conformational changes to facilitate the merging of the viral and host cell 
membranes. Using this same fusion process, several class I fusion proteins can 
also promote cell-cell fusion.  
Previous work has demonstrated that protein-protein interactions within the 
transmembrane region of some fusion proteins may play a role in the overall 
trimeric association. Utilizing fusion protein from viruses in the family 
Paramyxoviridae and Pneumoviridae, we targeted interactions in the 
transmembrane (TM) regions, disrupting overall protein stability and fusion 
function, thus demonstrating a novel target for antiviral therapeutic development.  
To further delineate the role of residues within the Hendra virus fusion protein TM 
domain, we performed alanine scanning mutagenesis of the N-terminal end of that 
region, demonstrating that residues M491/L492 appear to play a role in the protein 
fusion process.  In early 2020, we shifted to investigating the fusion protein of 
     
 
SARS-CoV-2 (spike) and examined spike protein stability, proteolytic processing, 
and factors involved in cell-cell fusion.  Through this work we assessed cleavage 
patterns, identified residues that modulate the fusion process, and showed that 
protein processing impacts the trimer stability.  Finally, we examined the fusion 
protein of respiratory syncytial virus (RSV). In this study we characterized protein 
trafficking, cleavage, and post translational modification differences between the 
fusion proteins from the two RSV subtypes, A and B.  Using mutagenesis, we 
investigated the role of the two cleavage sites that are present and conserved 
between these subtypes to better understand the cleavage and subsequent fusion 
processes of the RSV fusion protein.  Since these fusion proteins are located on 
the viral surface and are crucial for viral entry, they are key therapeutic targets.  
Therefore, understanding the mechanisms and interactions that drive protein 
function and novel ways to target this protein are critical.  
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CHAPTER 1.  VIRAL MEMBRANE FUSION PROTEINS AND THE 
TRANSMEMBRANE DOMAINS  
Portions of this chapter were adapted and reprinted with permission from 
Viruses: Barrett CT, Dutch RE. 2020. Viral Membrane Fusion and the 
Transmembrane Domain. Viruses. 12(7):693.  
 
Enveloped viruses include many important pathogens, such as human 
immunodeficiency virus type 1 (HIV-1), Ebola virus (EBOV), influenza (IAV), 
measles (MeV), rabies virus, and severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2). Enveloped viruses can possess a double-stranded DNA genome 
or a single-stranded RNA genome. Members of the families Coronaviridae, 
Paramyxoviridae, and the recently assigned Pneumoviridae fall into the latter 
category. Viruses in the family Coronaviridae have a positive-sense RNA genome, 
while members of Paramyxoviridae and Pneumoviridae have a negative-sense 
RNA genome. Each of these viral families contain unique respiratory viral 
pathogens that pose significant threats to human health.  
Paramyxoviruses 
Significant human pathogens in the Paramyxovirdae family include measles 
virus (MeV), mumps virus (MuV), and the human parainfluenza viruses (PIV). 
These viruses cause infections in the respiratory tract, transmit via airborne 
particles, and can be highly contagious [1]. In addition to causing human infections, 
paramyxoviruses can infect a number of animal hosts [1, 2]. More recently, several 
zoonotic paramyxoviruses have emerged, notably Hendra virus (HeV) in 1994 [3] 
and Nipah Virus (NiV) in 1998 [4, 5].  
Paramyxovirus particles are generally pleomorphic, but vary between 
spherical or filamentous shapes, and range from 150 to 500 nm in diameter [1]. 
The non-segmented negative sense RNA genomes of paramyxoviruses are 15-19 
kilobases in length and encode for six to ten proteins, with a viral envelope derived 
from the host cell [1, 6-9]. Proteins encoded for include a large RNA-dependent 
RNA polymerase (L), a nucleoprotein (N), a phosphoprotein (P), a matrix protein 
(M), a small hydrophobic protein (SH), a fusion protein (F), and an attachment 
 2 
 
protein (G/HN/H) (Fig. 1.1) [2, 9].  Viral entry is initiated by attachment to and fusion 
with a target cell, mediated by the surface glycoproteins G/HN/H and F proteins, 
respectively.  Once the virus membrane fuses with a target cell membrane, the 
ribonucleoprotein complex (RNP) enters the cell cytoplasm to begin transcription.  
The RNP consists of the RNA genome coated with the N protein and associated 
with L, and P.  P and N serve as accessory proteins to L, as it uses the negative-
sense RNA genome as a template to synthesize mRNA that is then translated by 
the machinery of the host cell to make viral proteins.  The negative-sense genome 
is also used as a template to make positive-sense genome. Once the positive-
sense genome is made, it can then be used to make additional negative-sense 
genome copies that form new RNP complexes and traffic to the cell membrane for 
assembly with the viral proteins M, G/HN/H, and F.  The necessary viral 
components are then assembled and new virions bud from the cellular plasma 
membrane [6, 7, 10, 11].   
Due to the high degree of genetic similarity, comparable pathogenesis, and 
a wide host range, the zoonotic paramyxoviruses, HeV and NiV were classified 
into their own genus, Henipavirus [12-14]. HeV was first isolated in 1994, in a 
suburb of Brisbane, Australia during an outbreak that caused the deaths of 13 
horses and one trainer [3, 15].  In horses, HeV infection causes respiratory 
symptoms and high fevers.  HeV infection in humans typically causes respiratory 
symptoms that can advance to severe pneumonia or bronchiolitis, and in some 
cases the infection may progress to a neurologic infection, resulting in encephalitis 
[14-18]. Since its initial emergence, small HeV outbreaks have occurred 
throughout Australia, exhibiting an 89% fatality rate among infected horses and a 
57% fatality rate in humans [17, 18].  All human cases have been the result of 
close contact with an infected horse and the transmission of HeV has been 
suggested to be from bat to horse and horse to human. The natural reservoir host 
for HeV was identified as Australian flying fox fruit bats in the genus Pteropus [12, 
19, 20]. Just a few years after the initial HeV outbreak in 1999, NiV emerged in 
Malaysia causing an outbreak of respiratory and neurologic disease on pig farms 
[4, 21].  During this initial outbreak, 265 humans were infected and 105 of them 
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died [22].  Subsequent outbreaks of NiV have occurred in Malaysia, Singapore, 
Bangladesh, and India with the most recent occurring in Kerala, India in 2018 and 
2019 [21, 23]. Similar to the zoonotic transmission route demonstrated for HeV, 
NiV has been postulated to transmit from bat to pig, and pig to human, with 
Pteropus flying foxes as the likely reservoir [12, 19]. In some cases, NiV 
transmission may occur directly from bats to humans, and direct human-to-human 
transmission has also been documented [21, 24].  No vaccines or antiviral 
treatments for either HeV nor NiV have been approved for human use [19, 21, 25]. 
This fact, along with their zoonotic transmission, and high fatality rates led to their 
classification as biosafety level 4 agents.   
Pneumoviruses  
 
Pneumoviridae, originally a subfamily of the Paramyxoviridae family, was 
reclassified in 2016 to its own viral family [26]. Similar to paramyxoviruses, 
pneumoviruses have enveloped virions and negative-sense single stranded RNA 
genomes.  Their genome is 13 to 15 kilobases in length and encodes nine to eleven 
proteins, depending on the virus. While several proteins encoded are similar to 
those described for paramyxoviruses (Fig 1.1), the presence of the M2 gene is 
unique to this viral family [9].  The M2 gene encodes for the proteins M2-1, a 
processivity factor, and M2-2, involved in the switch from viral transcription to 
replication. M2 proteins also help form the RNP complex that coats the genome.  
Pneumoviruses are further divided into two genera, orthopneumovirus and 
metapneumovirus, with slight genomic differences between the two. 
Orthopneumoviruses have a different gene organization from metapneumoviruses 
and possess two additional genes, NS1 and NS2, upstream of the N gene [9]. The 
proteins encoded for by these genes help interfere with host immune response 
and prevent apoptosis of infected cells.   
The pneumoviruses respiratory syncytial virus (RSV) and human 
metapneumovirus (HMPV) cause significant human disease, presenting as 
respiratory infections that can advance to severe pneumonia and bronchiolitis in 
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some cases [9, 27, 28]. RSV and HMPV pose particular threats to young children, 
immunocompromised, and the elderly.  RSV is the leading cause of 
hospitalizations for the children under the age of two [29-32]. Both viruses can 
transmit through respiratory droplets and appear seasonally, with onset occurring 
in the winter months [27, 33].  Despite the yearly occurrence, there is currently only 
one FDA approved antiviral treatment for RSV, a prophylactic monoclonal antibody 
[29]. There are no vaccines or antiviral therapeutics for HMPV.   
 Coronaviruses  
Viruses in the family Coronaviridae are also enveloped RNA viruses, 
however their genome is composed of 26 to 32 kilobases of single stranded 
positive-sense RNA, significantly larger than the genomes of paramyxo- and 
pneumoviruses [2]. This genome encodes for replicase polyprotein (pp1ab), spike 
protein (S), envelope protein (E), membrane protein (M), and nucleocapsid protein 
(N) [34].  Additionally, the replicase protein is cleaved to form 16 non-structural 
proteins, including the replication proteins such as an RNA-dependent RNA 
polymerase, RNA helicase, and an exoribonuclease [34]. 
Coronaviruses (CoVs) can cause disease in mammals and birds, with 
several CoVs known to cause common colds in humans [34, 35]. In 2003, severe 
acute respiratory syndrome coronavirus (SARS-CoV) emerged in Asia [36].  
Research has demonstrated that this outbreak likely originated from a spillover 
event from bats to humans, or bats to palm civets, and then from palm civets to 
humans [36, 37]. SARS-CoV caused severe respiratory symptoms, spreading 
mainly through respiratory droplets, and ultimately infected just over 8,000 people 
worldwide, with a mortality rate of 9% [38]. Since 2004, there have been no 
documented cases of SARS-CoV. In 2012, middle eastern respiratory syndrome 
coronavirus (MERS-CoV) emerged, again resulting from a spillover event from a 
bat reservoir [36-38]. MERS-CoV infection often causes severe respiratory 
symptoms, similar to SARS-CoV, however additional gastrointestinal disease is 
common as well [38]. MERS-CoV continues to pose a significant human threat 
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with small outbreaks occurring almost yearly in the Middle East and Asia, resulting 
in the death of 35% of infected patients [39, 40].  Despite this, there are currently 
no approved vaccines or antiviral treatments for either MERS or SARS-CoV. 
Another novel CoV emerged in late 2019, named severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) [40]. In March of 2020, SARS-CoV-2 
reached a pandemic level, having spread throughout the world. Infection causes 
severe respiratory illness, gastrointestinal issues, and in some cases neurologic 
complications. As of January 2021, SARS-CoV-2 has infected over 100 million 
people, resulting in death for just over 2 million of those cases. About a year after 
the SARS-CoV-2 pandemic started, in December 2020, the FDA granted 
emergency use approval for two vaccines to this virus [41, 42].  Both vaccines were 
composed of mRNA for the fusion protein (S) of SARS-CoV-2, although several 
other vaccination strategies are under investigation [43, 44]. Of the other vaccines 
currently in phase III clinical trials, two are using inactivated virus, four are using 
adenovirus vectors with the S protein, and one is using a recombinant 
nanoparticle, again expressing S protein, demonstrating that S is highly sought-
after therapeutic target [43, 44].   
Dissertation Overview  
For viral entry, enveloped RNA viruses must bind to target cells and then 
fuse the viral membrane with a membrane of the host.  These viruses use one or 
more surface glycoproteins to carry out these critical functions. The surface 
glycoprotein that carries out the fusion function, termed a fusion protein, is divided 
into three classes based on structural similarities.  Some of the most studied 
human viral pathogens, such as human immunodeficiency virus (HIV), Ebola virus, 
influenza, measles, and the recently emerged SARS-CoV-2, possess class I fusion 
proteins. Following synthesis, class I fusion proteins associate as non-covalently 
linked homo-trimers, and remain as trimers throughout the fusion process. Key 
proteolytic processing events and subsequent receipt of a triggering signal drive 
the fusion protein to undergo large, irreversible conformational changes to facilitate 
the merging of the viral and host cell membranes. Using this same fusion process, 
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several class I fusion proteins can also promote cell-cell fusion. Throughout my 
graduate research I have investigated the viral fusion proteins of Hendra virus 
(HeV), respiratory syncytial virus (RSV), and the recently emerged, SARS-CoV-2.   
For HeV to facilitate viral entry, it uses an attachment protein (G) to bind a 
target cell, and a fusion protein (F) to merge the viral and host cell membranes. 
Previously, we have shown that the TM domain of the F protein, separate from the 
rest of the protein, is present in a monomer-trimer equilibrium. This TM-TM 
association contributes to the stability of the prefusion form of the protein, 
supporting a role for TM-TM interactions in the control of F protein conformational 
changes. In Chapter 3, we hypothesize that the TM region of HeV F can be 
targeted to destabilize the pre-fusion conformation of the protein.  To do this, 
constructs expressing the HeV F TM with limited flanking sequences were 
synthesized. Co-expression of these constructs with HeV F resulted in dramatic 
reductions in the stability of F protein expression and fusion activity in a sequence 
specific manner. To further examine this, a TM peptide homologous to the PIV5 F 
TM domain was synthesized. Addition of the peptide prior to infection inhibited 
infection with PIV5 but did not significantly affect infection with human 
metapneumovirus, a related virus. To complete the assessment the role of the TM 
region in protein function, we performed alanine scanning mutagenesis of the N-
terminal TM region of HeV F in Chapter 4.  Through the N-terminal mutagenesis, 
we discovered that changes to residues M491/L492 significantly reduce F fusion 
without drastically altering protein expression.  Additionally, we show that residues 
S490, S493, and Y498 play important roles in protein processing, a critical step for 
fusion, consistent with previous work [160, 173].  Our studies in these two chapters 
demonstrates that targeted disruption of TM-TM interactions significantly impact 
viral fusion protein stability and function, presenting these interactions as a novel 
target for antiviral development 
As SARS-CoV-2 emerged and caused the global pandemic in early 2020, 
we shifted to investigating the fusion protein of SARS-CoV-2 S. S is the sole viral 
protein responsible for both viral binding to a host cell and the membrane fusion 
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event needed for cell entry. In addition to facilitating fusion needed for viral entry, 
S can also drive cell-cell fusion, a pathogenic effect observed in the lungs of SARS-
CoV-2 infected patients [234-237]. While several studies have investigated S 
requirements involved in viral particle entry [179, 181, 182, 238, 239] , examination 
of S stability and factors involved in S cell-cell fusion remain limited. In Chapter 5, 
we aim to understand factors that mediate S cell-cell fusion, including proteases 
involved, and cleavage events required. We demonstrate that S must be 
processed at the S1/S2 border in order to mediate cell-cell fusion, and that 
mutations at potential cleavage sites within the S2 subunit alter S processing at 
the S1/S2 border, thus preventing cell-cell fusion. We also identify residues within 
the internal fusion peptide and the cytoplasmic tail that modulate S cell-cell fusion.  
Additionally, we examine S stability and protein cleavage kinetics in a variety of 
mammalian cell lines, including a bat cell line related to the likely reservoir species 
for SARS-CoV-2, and provide evidence that proteolytic processing alters the 
stability of the S trimer.  This work therefore offers insight into S stability, proteolytic 
processing, and factors that mediate S cell-cell fusion, all of which help give a more 
comprehensive understanding of this highly sought-after therapeutic target.  
RSV, a member of the Pneumoviridae family, is ubiquitous and an important 
respiratory pathogen, particularly dangerous for children under two, elderly, and 
the immunocompromised. Despite the global importance of RSV, there is currently 
only one FDA approved treatment for it, a prophylactic monoclonal antibody.  
Similar to HeV and SARS-CoV-2, RSV possesses a class I fusion protein (F) that 
is critical for facilitating the membrane merging needed for viral entry, making F a 
key therapeutic target. While there is an incredible amount of work being done to 
target F for vaccine and antiviral treatment development, studies that analyze the 
proteolytic processing requirements and factors that impact F function remain 
limited.  Additionally, a majority of the current work being completed on RSV F 
focuses on a F protein from strain A2, a RSV strain that has been cultured in a 
laboratory setting for many decades.  Analysis of RSV F from the B subtype of this 
virus, or from clinically relevant strains of either subtype, has not been previously 
done.  In Chapter 6, we hypothesize that RSV F from different subtypes has 
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different requirements for membrane fusion, including timing and proteolytic 
cleavage events.  Our work, therefore, focused on characterizing differences in the 
RSV F proteins from both lab-adapted and clinical F proteins from both A and B 
subtypes. Through a series of mutations, we investigated the proteolytic 
processing, stability, protein trafficking kinetics, and fusion function of RSV F 
proteins from the difference subtypes.  Collectively, the work presented here 
investigates the fusion proteins from several important human enveloped RNA 
viruses, providing insight into proteolytic processing, protein stability, and factors 
that influence cell-cell fusion. Importantly, this work provides insight into these 
highly sought-after therapeutic targets. 
Viral Membrane Fusion and the Transmembrane Domain 
A critical early step for all enveloped viruses in the entry and infection process 
is the fusion of the viral membrane with a target cell membrane [45-48]. This 
process is mediated by at least one viral surface membrane glycoprotein, often 
referred to as the fusion protein. Since this is a critical step for viral entry, and these 
fusion proteins sit on the virion surface, they are a key therapeutic target. Viral 
fusion proteins generally fall into one of three classes, based on structural 
similarities. However, despite these structural differences, the overall mechanism 
of how fusion proteins facilitate membrane merging is relatively conserved. 
Membrane fusion promoted by viral fusion proteins can occur either at the surface 
of the cell or within an endosome [49], and the location of this event is often 
determined by factors within the fusion protein or viral attachment protein ligand.  
For most viral fusion proteins, two key steps are needed to allow for the large 
conformational changes which bring the viral membrane and cell membrane 
together [50]. The first is a priming step, a proteolytic cleavage by a cellular 
protease that exposes the highly hydrophobic fusion peptide (FP) or fusion loop 
(Fig. 1.4A). This cleavage can occur in the trans-Golgi network as the viral protein 
traffics to the cell surface, in recycling endosomes after initial transport to the cell 
surface, upon receptor binding or viral particle endocytosis into a target cell, or as 
the virus is released from a cell (Fig. 1.2). Additionally, this cleavage can occur to 
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either the fusion protein itself (Class I fusion proteins) or an accessory viral protein 
(Class II). The second step is a triggering event. Triggering of the protein can be 
completed in a number of ways, including the fusion protein binding to a ligand, 
the viral attachment protein binding to a ligand and subsequent interaction of the 
attachment protein with the fusion protein, or exposure of the fusion protein to the 
low pH environment of an intracellular compartment (Fig. 1.4B).  
Once a fusion protein has been activated and receives a triggering signal, the 
large, essentially irreversible conformational changes begin. The protein first 
extends away from the viral membrane to insert the FP or loop into the target 
membrane (Fig. 1.4C). The merging of the viral envelope with the target cell 
membrane involves a high kinetic barrier, despite ultimately being a 
thermodynamically favorable reaction [46, 47, 51-53]. Because of this kinetic 
barrier, the energy contained in the fusion protein must help drive this process. 
While the depiction in Figure 1.4 is a Class I fusion protein, all the classes of viral 
fusion proteins share a similar end to the fusion pathway. This similarity arises 
during the pre-hairpin intermediate, where all fusion proteins studied to date share 
a homo-trimeric association [54]. The subsequent steps of fusion are hypothesized 
to involve a refolding of the protein back on itself to bring the fusion peptide and 
transmembrane regions into close proximity, and thus the two opposing 
membranes together (Fig. 1.4D–F). During the membrane merger, there is likely 
first a hemi-fusion state between the viral and target cell membrane (Fig. 1.4E), 
which then continues to a complete integration of the membranes resulting in the 
formation of a fusion pore which allows the genetic material of the virus to enter 
the cell (Fig. 1.4F). Structures for the pre-fusion and post-fusion forms of multiple 
viral fusion proteins have been published [55-69], and the intermediate steps of 
this process, while previously unknown, are now being analyzed in a number of 
single particle studies, some of which will be discussed later [70-74]. Due to this 
intricately orchestrated process, studying all regions of these viral fusion proteins 




The transmembrane domain (TMD) of viral fusion proteins remains one of the 
more poorly understood components of the membrane fusion process. Over time, 
the views of fusion protein TMDs have evolved as the field has shifted from 
considering them as simple membrane anchors to active players in membrane 
fusion [75]. In the 1990s, several seminal studies on influenza hemagglutinin (HA) 
and parainfluenza virus fusion proteins demonstrated that replacing this region of 
the protein with a glycosylphosphatidylinositol (GPI) membrane anchor resulted in 
loss of fusion but not outer leaflet mixing [76-79], suggesting the need for a 
proteinaceous membrane-spanning region for the hemi-to-full fusion transition. 
Subsequent studies analyzed sequence-specific requirements by creating 
chimeric fusion proteins in which the native TMD was replaced and found that 
some fusion proteins have sequence requirements while others do not [80-85]. 
Additional results suggested that there is a TMD length requirement for viral fusion 
proteins, as the TMD of these proteins needs to be long enough to span both 
leaflets of the viral envelope to facilitate the fusion process [80]. These studies 
suggest that TMDs of these viral fusion proteins play several functional roles in 
viral entry, including a role in the hemi-fusion to full-fusion transition, in promotion 
of outer leaflet mixing, and in fusion pore enlargement. Recently, significant 
advances have been made in understanding TMD interactions and the role of the 
TMD in fusion protein stability, structure, and function. In this review, we will 
discuss findings from the last decade that broaden our knowledge of the viral 
fusion protein TMD and the important role it plays in the overall membrane fusion 
process. 
Class I Fusion Proteins 
Some of the most studied viral families, including orthomyxoviruses (IAV), 
paramyxoviruses (HeV), pneumoviruses (RSV), retroviruses (HIV), coronaviruses 
(SARS-CoV-2), filoviruses, and arenaviruses, possess class I fusion proteins. 
Class I fusion proteins exhibit a homo-trimeric association in both the pre-fusion 
and post-fusion states, and most of the secondary structure of these proteins is α-
helical in both states. While these fusion proteins have been extensively studied 
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for decades, there have been numerous advances on their mechanisms of action 
in the past ten years including work aimed at structurally and functionally 
characterizing the TMDs 
Influenza 
The fusion protein of IAV, also known as hemagglutinin (HA), is one of the 
best studied viral fusion proteins. HA is a homo-trimeric protein that requires 
proteolytic processing to cut the protein into two subunits, HA1, important for 
binding to target cell receptors, and HA2, which facilitates membrane fusion. 
Previous work on the TMD of HA has implicated this region as playing a functional 
role, as there is a specific amino acid length requirement for this region and it was 
shown to be critical in late stage aspects of membrane fusion, such as fusion pore 
formation and enlargement [76, 77, 80, 86, 87]. Recent studies have continued to 
elucidate the important role of the HA TMD in the function of the full-length protein. 
In this section, we will discuss the contemporary findings that provide insight into 
the structure of the HA TMD, its role in the dynamic intermediates, the post-fusion 
conformation, and in HA interactions with the membrane environment during the 
fusion process. 
While structures of the ectodomain of HA have been available for several 
decades [56, 57, 88-95], the first structure of the full-length HA protein, including 
the TMD, was published in 2018 [96]. When compared to previously published 
structures of the HA ectodomain alone, the ectodomain of the full-length HA 
structure is very similar, indicating that inclusion of the TMD does not profoundly 
affect the ectodomain conformation. Interestingly, the TMD was found at angles 
between 0° and 52°, with respect to the ectodomain region (Fig. 1.5A), revealing 
the presence of a flexible linker region between the ectodomain and the TMD. This 
flexible linker region consists of a conserved glycine followed by a small five-
residue α-helix and a four-residue extended chain (residues 175–184). When the 
structure was solved in complex with a FISW84 Fab, this angle was restricted to 
20° or less. Analysis of the structure showed that the base of the ectodomain lies 
in a horizontal orientation relative to the membrane. Conserved glycine residues 
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at the C-terminus of the ectodomain and the end of the helix in the flexible linker 
allow for side chain turning to facilitate flexibility in this region. A conserved 
isoleucine begins the bundled α-helices of the TMD, which extend for 16 residues 
to a conserved leucine, then glycine residue. Within this α-helical bundle, a tyrosine 
residue provides a linkage point between the helices. Although the TMD extends 
seven residues past the conserved glycine, the helices become less ordered in 
this region. It is likely that the three conserved glycine residues are critical to allow 
the large degree of tilt of the TMD with respect to the ectodomain observed in the 
solved structures. Furthermore, in these different tilted forms, the helices in the 
TMD maintain their secondary structure but rotate with respect to the other helices 
in the trimeric bundle. In all the tilted forms, there are consistent contacts with the 
central tyrosine, indicating this may be crucial for maintaining inter-helix contacts. 
This independent movement of the individual TMDs of HA is consistent with 
previous molecular dynamics simulations of the TMD in isolation which found that, 
when inserted into a DMPC lipid bilayer, there was no direct contact observed 
between multiple TMDs [97]. Additionally, a single HA TMD peptide exhibited a tilt 
angle of about 60° in the membrane in molecular dynamics simulations. When 
three TMD peptides were present, the tilt angle increased by 10o, and the peptides 
arranged in a triangular manner, similar to the arrangement in the full-length 
structure [96]. When mutations were introduced into the TMD peptide, the helicity 
of the peptides was altered, but no overall effect was seen on the tilt angle of the 
peptide in the membrane. These studies indicate that the tilt of the TMD of HA with 
respect to the membrane may play a role in membrane fusion, as different angles 
may be needed to compensate for the large conformational change experienced 
by the ectodomain of the protein. Additionally, the finding that the TMD peptides 
alone arranged into trimers suggests that the TMD may play a role in the overall 
trimerization of the protein. 
In the cascade of HA viral membrane fusion, there are likely a series of 
intermediate protein arrangements between the metastable pre-fusion HA 
conformation and the post-fusion form, but these have been difficult to capture. 
Recent studies have succeeded in identifying protein intermediates in the fusion 
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process [98], and two have used the full-length protein [71, 99], providing important 
new information. The first used cryo-microscopy and cryo-tomography to visualize 
viral particles fusing with liposomes upon low pH treatment [99]. Images captured 
showed that prior to full viral-liposome fusion, the viral particle has several contacts 
with the liposome membrane. These contacts were seen as thin, continuous lines 
between the viral particle and the liposome, with the length of these lines 
consistent with an extended conformation of the HA protein, with the TMD still 
embedded in the viral particle and the FP in the liposome membrane. Around these 
zones, the liposome membrane exhibited a dimpling effect out towards the viral 
particle, potentially as a result of multiple FP insertions into the target membrane. 
Additionally, bent versions of the extended structure were observed, consistent 
with the protein folding back on itself as it moved towards the post-fusion structure. 
Radiating outward from the central dimpled region were dense bars of HA protein. 
These bars appeared even before full fusion pore formation, which may be the 
result of either already folded back HA proteins or HA proteins that triggered but 
did not insert in the target membrane. This work confirms the presence of a full 
extended intermediate of HA along the fusion cascade and demonstrates several 
other intermediate forms. 
Another study analyzed conformational changes of the protein that occur prior 
to the full extension intermediate of HA. To analyze the HA protein in a single 
molecule study, a Forester resonance energy transfer (FRET) HA protomer, which 
includes the full-length HA from the strain H5N1, with its TMD, was created [71]. 
The addition of two fluorophores to the HA2 subunit allowed for reporting of a pre-
fusion conformation (high FRET) or a post-fusion conformation (low FRET). 
Analysis of this tagged HA protein within the context of a single viral particle found 
that even at neutral pH (pH = 7.0), the protein spent time in three distinct 
conformations, a high FRET, an intermediate FRET, and a low FRET state. As the 
pH was decreased from neutral pH, the HA protein demonstrated an increase in 
occupancy of the low FRET state in a stepwise manner. The amount of protein 
found in the intermediate state stayed consistent regardless of the pH. 
Interestingly, samples that were exposed to low pH for short periods of time were 
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able to revert back to high FRET states upon return to neutral pH. However, those 
that were exposed to low pH for extended times (30 minutes or more), were unable 
to return to high FRET states. This indicates that the protein may sample low pH 
conformations prior to irreversibly converting to the post-fusion conformation. 
FRET experiments were also completed in the presence of stalk-targeting 
antibodies, the HA receptor sialic acid, and a target membrane. Co-expression 
with stalk-targeting antibodies prevented transition of the protein to the low FRET 
state while increasing the occupancy of the protein in both the high and 
intermediate FRET states. The presence of sialic acid increased the overall 
kinetics of the conversion between high and intermediate to low FRET states, while 
the presence of a target membrane increased the amount of protein that was found 
in the irreversible low FRET state. This suggests that there is a breathing 
movement of the full-length HA protein prior to the extended intermediate in the 
fusion cascade. This dynamic movement may help temporally control the fusion 
process by allowing HA to sample its environment, thus ensuring conditions are 
correct for a full fusion event to occur. Movement of the TMD with respect to the 
ectodomain, conferred by the flexible linker region [96], may be important for these 
dynamic intermediates to occur. 
In the post-fusion form of the HA protein, the FP and the TMD are in close 
proximity. Previous work has demonstrated that these regions can form a complex 
within the membrane environment [100], though the role of this complex is 
unknown. To address this, a recent study examined the effect of the HA FP and 
TMD both alone and together on membranes using electron spin resonance [73]. 
Both the FP and TMD alone have an ordering effect on several different types of 
membranes, with a synergistic effect observed when both the TMD and FP are 
present in the same membrane. When FP is alone, pH affects the membrane 
ordering, but the FP-TMD membrane ordering is not affected by changes in pH. 
While it has been previously shown that the TMD alone induces distinct micro-
domains in the membrane [101], the FP-TMD complex is also able to induce these, 
to a greater extent than the TMD alone [73]. To further examine the FP-TMD 
relationship, mutations known to affect membrane fusion were made to FP 
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residues. When an FP with a G1S mutation, known to block fusion at the hemi-
fusion step [102], is present, some lipid ordering still occurs, but no synergistic 
effect was observed when the wildtype TMD peptide was added. In contrast, 
addition of the fusion-blocking mutation G1V to the FP resulted in complete loss of 
lipid ordering, suggesting this glycine residue in the FP is critical for the FP-TMD 
complex formation. A mutation at Y14, also previously shown to block fusion, was 
still able to induce membrane ordering when the TMD was present, suggesting 
that this mutation does not block the FP-TMD interaction. In the TMD, mutations 
K183E and L187A have been demonstrated to abolish the membrane ordering 
effect of the TMD itself [101]. Analysis of these mutations using electron spin 
resonance to measure membrane ordering in the presence of the FP suggested 
that L187 played a key role in the FP-TMD interaction, while the mutant K183E did 
not. This suggests that the FP-TMD interaction is strongly influenced by the N-
terminal portion of the FP and the hydrophobic segment of the TMD. Furthermore, 
the insertion depth into the membrane of the N-terminus of FP was found to 
increase in the presence of the TMD, again supporting an interaction between the 
two. 
Contrary to the work described above, a study from 2018 on the FP-TMD did 
not provide evidence of complex formation [103]. Using hydrogen–deuterium 
exchange mass spectrometry (HDX-MS), Ranaweera et al. studied the full-length 
HA2 subunit or the HA2 ectodomain with either the FP or the TMD present. 
Extensive exchange was observed when the FP region was present in both the 
full-length and the truncated protein, while the TMD demonstrated very little, 
supporting a model in which the FP lies along the membrane face a portion of the 
time, allowing for exchange, while the TMD traverses the membrane. The results 
did suggest, however, that the orientation of the FP and TMD with respect to each 
other and the HA ectodomain may play a role in creating positive membrane 
curvature to help with fusion pore expansion. The contrasting results from these 




Since the TMD does not exist in isolation but in the context of the membrane 
environment, several studies have examined the relationship between HA and the 
lipids of the membrane [104-107]. HA contains two raft targeting signals, one on 
the outer leaflet of the TMD and one at the interface of the TMD and cytoplasmic 
tail [108-112]. Mutation of the signal in the outer leaflet of the TMD caused slower 
transport through the Golgi, whereas mutation of the second signal did not delay 
transport [104], and both mutants displayed reduced association with rafts at the 
plasma membrane. To further delineate the relationship between membrane lipids 
and HA, a study analyzed the effect of mutating a conserved cholesterol binding 
motif, YKLW, found at the interface of the TMD and the flexible linker in HA proteins 
from the phylogenetic group 2 [105]. This work demonstrated cholesterol directly 
binds to HA through this region. Mutation of this motif to alanines resulted in a 
reduction in viral replication, HA and cholesterol incorporation into viral particles, 
and HA fusion activity. This mutation appears to specifically affect the extent and 
kinetics of lipid mixing during the hemi-fusion state, suggesting that an HA TMD-
cholesterol interaction is critical for this aspect of membrane fusion. However, work 
completed in 2015 suggests these interactions may not be critical for all subtypes 
of HA. Using high-resolution secondary ion mass spectrometry on stable cell lines 
expressing HA (H2 subtype, phylogenetic group 1), the colocalization of HA with 
common membrane lipids was assessed [106]. HA demonstrated little 
colocalization with either cholesterol or sphingolipids, suggesting HA, at least from 
this subtype, does not associate with membrane raft domains. These contrasting 
data may be due to the difference in HA subtypes used, but further exploration of 
the interactions of HA with the surrounding membrane is warranted. 
Recent work has illuminated the influenza HA TMD structure and has 
characterized a flexible linker region that lies between the ectodomain and the 
TMD [71, 96, 97, 99]. Additionally, studies have shown that some subtypes of HA 
bind cholesterol in the TMD, suggesting that, together with the FP, the TMD plays 
a role in the membrane manipulation needed to facilitate the merging of the viral 
and target membrane [73, 103-106]. While this section reflects the immense 
amount of work completed on HA TMD over the past several years, it is clear from 
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the number of conflicting studies that more work needs to be completed. Though 
there is some conservation of the TMD of different HA subtypes [113], the TMD of 
each subtype may have its own unique properties that need to be investigated. 
 
Human Immunodeficiency Virus (HIV) 
The fusion protein of HIV is known as the Envelope protein (Env). Similar to 
the influenza HA protein, HIV Env (gp160) consists of two subunits, a gp120 
receptor-binding domain and a gp41 membrane-spanning domain that mediates 
viral fusion. There is a high degree of conservation in the TMD of gp41 from 
different HIV strains, and that conservation was first used to implicate the TMD as 
more than just a membrane anchor [114]. Similar to influenza HA, there has been 
extensive work over the past decade on the gp41 TMD. In this section, we review 
studies which illuminate the structure of the TMD, the dynamic nature of FP-TMD 
interactions, the role of the TMD region as a modulator of immune function, and 
the role of the TMD in overall protein trafficking. 
The number of structural studies of the TMD or TM proximal regions of Env 
gp41 exemplify the considerable amount of work recently completed in this area. 
In the past decade alone, there have been studies examining the TMD in isolation 
[115-117], the TMD with the membrane proximal external region (MPER) [118-
120], the gp41 ectodomain with the FP proximal region and the MPER [121], as 
well as a full-length structure of gp41 (including the TMD) [122]. All-atoms 
molecular simulation models and nuclear magnetic resonance (NMR) have been 
used to probe the structure of the HIV Env TMD in isolation [115-117]. These 
studies suggested that the TMD forms a closely assembled trimer [115, 116]. The 
conserved residue R696 serves as a midpoint between two distinct domains in the 
TMD, an N-terminal coil-coiled domain, and a C-terminal hydrophilic core domain. 
The N-terminal coil-coiled contains a GXXXG oligomerization motif, but the data 
showed that only the first G in the motif lies at the interface of the trimer, while the 
other lies away from it [115]. This suggests that for trimer formation using a GXXXG 
motif, only the first G is essential. Further analysis demonstrated that the N-
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terminal half of the TMD appeared to be less structurally stable than the C-terminal 
half [116]. These studies did not report on the orientation of the TMD with respect 
to membrane, though an all-atoms molecular dynamics simulation determined that 
a single protomer of the TMD formed a stable tilted α-helical region [117]. 
To situate the TMD in relation to the ectodomain of gp41, a series of structural 
studies were completed with peptides containing both the TMD and the MPER of 
gp41 [118-120], but interestingly the findings vary. The earliest study found that 
the MPER and N-terminal portion of the TMD create an aligned α-helix, while the 
C-terminal region of the TMD is also α-helical, but is not in frame with the rest of 
the protein [120]. Subsequent work demonstrated that the MPER exists in two 
distinct α-helices which are connected to the TMD through a kink at residue K683 
[118]. In agreement with this, another study demonstrated a turn at residue 683, 
but their data suggested that both the MPER and TMD consisted of a single α-
helical region each [119]. These discrepancies may be due to the use of bicelles 
in the first two studies [118, 120] and phospholipid bilayers in the latter [119], 
differences in the peptide purification method, and the use of a tag on the peptide 
[120], or the differences may reflect different states of these regions along the 
fusion cascade. Regardless, further work is needed to delineate the structure of 
these regions in context to each other, and studies using the full-length protein 
may help better understand the relationship of these regions. 
Work that includes the entire full-length protein, or just portions of the 
ectodomain, does not yet resolve these questions [121-124]. When the entire 
protein was present, the TMD and MPER were unable to be resolved, suggesting 
either different conditions are needed for structural analysis or there is an increase 
in flexibility in this region when the entire ectodomain is present [122]. When all 
protein domains, other than the FP and the TMD, are structurally determined in the 
post-fusion form gp41, the ends of the FP proximal region and the MPER splay 
outward from each other [121], suggesting the FP and TMD may not be in close 
proximity to each other in the post-fusion structure. The structure of an MPER 
trimer in isolation also supports this by demonstrating a splaying out of the helices 
of the trimer as they approach the membrane [123]. Both of these studies also 
 19 
 
found some MPER insertion into the detergent micelle, suggesting that the MPER 
has some degree of interaction with the membrane. 
During the viral-membrane fusion process, the ectodomain of gp41 undergoes 
a large conformational change, moving from a pre-fusion state and refolding to a 
post-fusion conformation. This change brings the TMD and FP in close proximity, 
similar to HA, but there is some debate as to whether these hydrophobic regions 
physically interact. One study demonstrated that gp41 FP- and TMD-derived 
peptides directly associated with each other and together were able to induce lipid 
mixing in membranes [125]. Work with a synthetized protein that included the FP, 
a small region of the ectodomain at the C-terminus of FP, MPER, and TMD with a 
short flexible region connecting the FP proximal region and the MPER, revealed 
that the FP has mostly β-sheet structure and is partially inserted into the 
membrane, while the TMD region is α-helical and traverses the membrane [126]. 
In contrast to the previous work, this study showed no evidence for FP-TMD 
interactions. These data, however, do suggest that protein conformations 
associated with a hemi-fusion intermediate step exist between the pre-fusion and 
post-fusion conformations of the protein. 
While the dynamic nature of the gp41 ectodomain is apparent by the 
differences in pre-fusion and post-fusion structures, the dynamic nature of the TMD 
is just beginning to be uncovered. Work that replaced the TMD of gp41 with a TMD 
of another viral fusion protein or another membrane-spanning protein found that 
fusion inhibition occurred, likely due to alterations in the ectodomain conformation 
of the protein, suggesting differences in interactions within the TMD play a critical 
role in the overall protein conformation [127]. Further illuminating the dynamics of 
the TMD, several studies have investigated conformational changes that occur in 
the TMD during the fusion process, with many of these focusing, at least in part, 
on a mid-TMD arginine residue (R696). R696 is highly conserved among different 
HIV subtypes and has been implicated as critical for membrane fusion [128]. 
Molecular dynamic simulations suggest the position of R696 with respect to the 
membrane leaflets likely plays a role in facilitating the fusion event. R696 can 
snorkel to interact with the inner leaflet of the membrane, allowing for water 
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penetration into the membrane and membrane thinning needed for membrane 
fusion [129]. Additional simulations investigated the relationship between 
cholesterol and R696 [130]. It was determined that R696 allows for water 
penetration in a variety of membranes, but cholesterol-containing membranes help 
localize the overall membrane thinning associated with this water penetration to 
the mid-span arginine residue, likely by regulating the tilt angle of the TMD relative 
to the membrane. There is evidence that R696 also acts in concert with the C-
terminal hydrophilic core of the TMD to allow for water penetration into the 
membrane [131]. This concerted action is consistent with R696 snorkeling to the 
inner membrane leaflet (towards the C-terminus), allowing for membrane 
perturbations consistent with those needed to facilitate viral entry. There are two 
additional conserved basic residues (K683 and R707) in the TMD of gp41 [129]. 
These residues likely interact with the head groups of the outer and inner 
membrane lipids, respectively. Observations from membrane dynamics 
simulations conclude that these head groups anchor the TMD to the edges of the 
membrane so that when R696 snorkels, the pull on both of these residues also 
contributes to the membrane thinning. 
HIV-1 infection of cells disrupts normal immune responses, allowing the 
virus to avoid detection. Both Toll-like receptor (TLR) activity and T cell receptor 
(TCR)/cluster of differentiation 3 (CD3) complex formation are down-regulated in 
HIV infection, and gp41 can disrupt TCR and CD3 complex formation to inhibit 
immune activity [132, 133]. However, this disruption was only recently shown to be 
due to direct binding of the gp41 TMD with the TMD of both TCRs and CD3. These 
interactions occur within the membrane environment and specifically use the 
GXXXG motif found in the TMD of these proteins [134, 135]. Down-regulation of 
TLRs was also found to involve interaction with the TMD of gp41 through the 
GXXXG motif, suggesting that this motif could play a role in other interactions that 
disrupt the immune response during an infection [136]. The isolated peptides from 
the gp41 FP region also interact with the TMD of TCRs through a similar motif, 
AXXXG, which suppresses TCR immune activity [133, 137-139]. When the 
AXXXG motif was present in FP-mimicking peptides, lipid mixing could be induced, 
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but when this motif was mutated, lipid mixing did not occur, suggesting this motif 
may be important in the transition from hemi-fusion to fusion pore formation during 
membrane fusion. 
Induction of broadly neutralizing antibodies (bNAbs) is a critical part of 
current HIV vaccine strategies. bNAbs to the HIV Env protein have several different 
targets, one of which is the MPER region bordering the TMD. However, stabilized 
soluble trimer mimics of Env, termed SOSIPs, lacking a majority of the MPER and 
all of the TMD are commonly used in HIV vaccine development. Recent research 
has demonstrated that antibody binding differences may be dependent on which 
regions of the Env protein are present [140, 141]. A direct comparison of a SOSIP 
trimer to a full-length Env trimer showed that SOSIP trimers had less complex and 
less processed glycans compared to the full-length protein. Glycans are part of 
several binding epitopes for bNAbs, and the differences in complexity in SOSIP 
trimers resulted in lower binding affinity of these antibodies compared to the full-
length Env. This comparison also revealed that the full-length protein had more 
conformational flexibility than SOSIPs and therefore exposed epitopes that also 
bound the non-neutralizing antibodies tested. Inclusion of the TMD with an MPER 
peptide has been shown to increase the binding affinity of bNAbs to these 
peptides, although there is conflicting data on whether a trimeric TMD further 
increases this affinity. One set of binding assays completed in nanodiscs suggests 
that the addition of a trimeric-TMD recapitulates the bNAb binding of native-like 
Env protein [140], while another suggests inclusion of a single MPER-TMD peptide 
in each nanodisc increased the percentage of antibody bound to that peptide [142]. 
It has been shown by both NMR modeling [120] and crystallography with molecular 
dynamics simulations [143] that bNAbs targeting the MPER region of gp41 bind 
residues within the TMD as part of their epitope, explaining why the presence of 
the TMD increases binding affinity. Additionally, analysis of one specific MPER 
bNAb demonstrated that this antibody also interacted with membrane lipids [143]. 
This suggests that the conflicting results on the effect of TMD oligomerization on 
MPER-TMD bNAb binding may be due to the presence or absence of certain lipids. 
Taken together, these studies suggest that efficient testing and analysis of bNAbs 
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targeting Env MPER should include the TMD and potentially a representative 
membrane environment. Beyond just enhancing the testing efficacy of MPER-
targeting bNAbs, utilizing versions of the full-length protein may be a way to further 
improve current vaccine candidates. 
During an HIV infection, Env is synthesized in the endoplasmic reticulum 
and traffics through the Golgi and secretory pathway to reach the plasma 
membrane [144]. The TMD of the Env (gp41) protein has been implicated in this 
protein trafficking. As previously described, the TMD contains both a GXXXG 
oligomerization motif and a mid-span arginine that are highly conserved. When the 
distance between the last G in the GXXXG motif and the mid-span arginine is 
increased by the addition of an alanine residue, a defect in membrane fusion is 
seen [145]. This was shown to be due to a defect in protein transport through the 
endoplasmic reticulum (ER) and Golgi. This transport delay may be due to 
disrupted contacts of the individual trimer TMs with each other or through 
disruption of protein-membrane interactions. Further analysis of this region 
demonstrated that R696 does not confer a strict ER localization on the gp41 
protein, despite the presence of charged residues within a TMD being a well-
recognized ER localization motif [146]. Therefore, other elements in the HIV Env 
TMD, including its length, override the potential retention signal. 
It is clear that the HIV gp41 TMD plays an essential part in the structural 
stability, function, and trafficking of the gp41 protein. This recent work has 
demonstrated that the gp41 TMD is critical for processes such as virus-to-cell 
fusion, immune modulation, antibody recognition, fusion protein trafficking, and 
several aspects of the membrane fusion cascade. These studies also continue to 
uncover vaccine and antiviral targets for this important human pathogen by 
understanding key molecular and cellular interactions. 
Paramyxoviruses and Pneumoviruses 
Paramyxoviruses have Class I fusion (F) proteins that require both a 
proteolytic cleavage event and receptor binding to facilitate fusion. However, unlike 
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the previously discussed IAV HA and HIV Env proteins, the receptor binding 
function of this process is executed by a separate viral surface glycoprotein, the 
attachment protein (HN, N, or G). There are a number of different methods for 
proteolytic priming of the paramyxovirus and pneumovirus F proteins. The majority, 
including measles F, PIV5 F, and mumps F, undergo a single cleavage by furin in 
the trans-Golgi network [46, 50, 147]. A small number, including HMPV F and 
Sendai, are cleaved by exogenous proteases [148, 149]. The proteolytic 
processing of HeV F occurs in recycling endosomes.  HeV F is initially synthesized 
and trafficked to the cell surface.  From there it is endocytosed, shuttled through 
recycling endosomes, where it is cleaved by cathepsin L, and then returned to the 
cell surface for particle assembly (Fig. 1.2b) [150, 151].  HeV F protein cleavage 
exposes a hydrophobic fusion peptide, and leaves the protein as a disulfide linked 
heterodimer (F1 and F2), (Fig. 1.3a).  RSV F, on the other hand, is cleaved in the 
trans-golgi network, likely by the cellular protease furin, during the initial protein 
trafficking to the cell surface (Fig. 1.2a)[152, 153].  Interestingly, RSV F contains 
two furin cleavage sites, 27 amino acids apart.  The second cleavage site exposes 
the hydrophobic fusion peptide, however the role and timing of cleavage of the first 
cleavage sites remains unknown (Fig. 1.3b) [154-156].  
Work in the last decade has demonstrated a role for the TMD in the overall 
structure of the fusion protein. In addition, it has also been shown to be important 
for pre-fusion stability, membrane fusion, post-fusion FP-TMD interactions, fusion 
protein trafficking, and viral particle assembly. 
Crystal structures have been solved for the ectodomain portions of several 
paramyxovirus fusion proteins [55, 61, 62, 67-69], but structural insights into the 
TMDs of these proteins remain limited [157, 158]. Solid-state NMR analysis of 
isolated TMD peptides of parainfluenza virus 5 (PIV5), separate from the rest of 
the protein, found that portions of the TMD display some membrane-dependent 
conformational plasticity. Both ends of the TMD adopt a β-strand conformation in 
phosphatidyl ethanolamine (PE) rich (negative curvature) membranes but form a 
continuous α-helix with the central portion of the peptide in phosphatidyl choline 
(PC)/cholesterol rich membranes [157, 158]. These flexible regions of the TMD are 
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rich in β-branched residues. This indicates both termini of the TMD could play a 
role in the membrane perturbation needed to mediate membrane fusion. The 
central portion of the TMD, however, was shown to form a core α-helical region 
that associates as a trimer with neighboring TMDs regardless of the membrane 
composition. This 12-residue, leucine-rich stretch may serve as the central 
trimerization domain needed for overall protein oligomerization. 
Despite limited structural data, biochemical and biophysical studies have also 
probed the trimeric nature of paramyxovirus TMDs. Initial work that substituted the 
residues in the predicted TMD of PIV5 F with cysteine residues to induce disulfide 
bonds within the membrane demonstrated that the TMD of F existed as α-helices 
and formed a helical bundle with the other TMDs of the protein trimer [159]. Further 
analysis of the TMD helical bundle was completed using sedimentation equilibrium 
analytical ultracentrifugation (SE-AUC). Using this technique, the fusion protein 
TMD of Hendra, human metapneumovirus (HMPV) (now in the Pneumoviridae 
family [26, 158]), and PIV5 were demonstrated to exist in a monomer–trimer or 
monomer–trimer–hexamer equilibrium when studied in isolation [160]. 
To examine the effect of this TMD association on overall protein folding and 
function, two common oligomerization motifs, a AXXXG motif [160] and a Leucine-
Isoleucine Zipper (L-I Zipper) [161], were mutated in the Hendra F protein. 
Mutations of the glycine in the AXXXG motif led to a decrease in cell surface 
expression and a decrease in fusion activity at levels consistent with the reduced 
protein expression. Single alanine mutations of each residue in the L-I Zipper had 
varying effects on protein expression and fusion activity, suggesting that each has 
a unique role. However, when all four residues in the L-I Zipper were mutated to 
alanine, a decrease in the expression of the protein was shown, and the fusion 
activity of the protein was abolished. Further analysis with SE-AUC showed a 
1000-fold decrease in the association constant in the monomer–trimer equilibrium, 
indicating TMD-TMD associations were destabilized when the L-I Zipper was 
altered [161]. A heat-induced triggering assay demonstrated that mutations which 
altered TMD-TMD association also led to a decrease in stability of the pre-fusion 
form of the Hendra F protein, suggesting TMD-TMD associations are important for 
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holding the F protein in the prefusion conformation prior to triggering. Replacement 
of the TMD of Newcastle disease virus (NDV) with either related or non-related 
viral protein TMDs demonstrated alterations in conformation-specific antibody 
binding [162], suggesting that, similar to Hendra, specific TMD-TMD associations 
are needed for the stability of the proper pre-fusion conformation of the fusion 
protein. Interestingly, mutation of the L-I zipper motif in the TMD of PIV5 to alanine 
had no effect on the total expression or pre-fusion stability of the protein and only 
a minor effect on surface expression, but fusion activity was abolished [159, 163]. 
Taken together, these data suggest that the contribution of leucine zippers in 
fusion protein TMDs to the overall protein stability and function may be virus 
specific. 
Following triggering, the F protein of paramyxoviruses undergoes large 
conformational changes that include insertion of the FP into the target membrane, 
followed by the protein refolding back on itself to facilitate formation of the six-helix 
bundle. While the details of the TMD throughout this process are still being 
investigated, there is clear evidence for an active role of the TMD and TMD-TMD 
interactions along the fusion cascade [158, 159, 162-165]. Illustrating the role of 
the TMD in the fusion process, replacement of the NDV F protein TMD with the 
TMD of a related viral fusion protein abolished fusion, including hemi-fusion 
intermediates, despite the chimeric fusion protein being expressed and cleaved at 
the cell surface [162]. This lack of fusion may be due to an inability of these proteins 
to form complexes with the NDV HN protein which is critical for membrane fusion, 
though other mechanisms are also possible. 
To further probe specific residues of the TMD that are critical for fusion, several 
studies performed mutagenesis on paramyxovirus F protein TMDs and analyzed 
differences in fusion activity [159-161, 163-165]. Alanine scanning mutagenesis 
found that β-branched or just branched amino acid residues at the C-terminus of 
the TMD appear to play an important role in fusion in both PIV5 [159] and Hendra 
[165]. Analysis of these branched residues in PIV5 demonstrated that mutating 
them likely blocks fusion during the hemi-fusion or fusion pore formation stages, 
indicating they may play a role in lipid mixing. This hypothesis is further supported 
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by the structural analyses that revealed conformational flexibility found in the β-
branched-rich TMD termini of PIV5 and showed this flexibility promotes changes 
within the membrane needed for fusion to occur [157, 158]. Recent work also 
suggests that TMD-TMD associations in paramyxovirus F proteins are important 
for controlling the fusion cascade. Mutating the L-I Zipper motif in the F protein 
TMD completely suppressed fusion activity in both PIV5 and Hendra, despite there 
being cleaved protein at the cell surface in both cases [161, 163]. Interestingly, 
introduction of disulfide bonds to prevent TMD-TMD dissociation also disrupts 
fusion in Hendra [164], as does introduction of disulfide bonds directly N-terminal 
to the TMD in PIV5 F [166]. These studies suggest that TMD-TMD association and 
dissociation must be intricately controlled for membrane fusion to occur. 
The final steps of fusion involve a zippering together of the N- and C-terminal 
heptad repeat regions [46, 47, 167, 168], and this refolding brings the FP and the 
TMD in close proximity to one another. Solid-state NMR analysis of the FP and 
TMD of PIV5 F in a lipid membrane suggests these do not form a tightly associated 
bundle. The data, however, did indicate weak interactions occur between the FP 
and TMD, since when they are found in the same membrane, the conformation of 
both was largely α-helical regardless of the membrane composition [169]. In 
contrast, using SE-AUC, the FP was found to have a strong interaction with TMD 
peptides in detergent micelles [170]. Analysis of the FP or TMD alone found that 
regions of both adopted β-strand conformations in a lipid-dependent manner [158, 
171]. Furthermore, when the FP and TMD were in the same membrane, a 
synergistic effect induced significant negative curvature in the membrane. When 
either the FP or TMD was alone, induction of negative curvature occurred only in 
membranes that tend towards negative curvature domains (PE membranes). 
These conflicting results suggest the need for additional analysis of the FP–TMD 
relationship in paramyxovirus F proteins. 
Recent studies have also implicated residues within the TMD as crucial for F 
protein trafficking and therefore efficient viral particle assembly [172-174]. Hendra 
and Nipah F proteins have a unique trafficking pattern. After synthesis in the ER, 
the F proteins traffic through the secretory pathway to the plasma membrane as 
 27 
 
an uncleaved trimer. The F protein is then endocytosed and cleaved in recycling 
endosomes by the protease cathepsin L before returning back to the surface in its 
activated pre-fusion form [150, 151, 175]. Two polar residues within the TMD, S490 
and Y498, were shown to be critical for endocytosis and recycling of the F protein, 
specifically the hydroxyl group of S490 and aromatic ring of Y498. Mutating Y498 
decreased trimer association, as judged by association constants from SE-AUC, 
indicating this residue participates in TMD-TMD associations [173]. Thus, changes 
in the TMD association may contribute to alterations in intracellular trafficking 
decisions. Further analysis showed that the proper endocytosis and recycling of 
the F protein, mediated by residues S490 and Y498, were critical for proper virus-
like particle (VLP) formation [172]. This suggests that residues in the TMD 
participate in viral assembly by facilitating specific intracellular trafficking in Hendra 
and Nipah viruses, but the extent and mechanism remain unclear, as there are 
conflicting results on the nature of F trafficking and incorporation in Nipah VLPs 
[176, 177]. Residues in the F protein ectodomain likely also assist in proper F 
protein incorporation into viral particles, since a chimera of the Rabies virus particle 
ectodomain and NDV TMD and CTD demonstrated inefficient incorporation into 
NDV viral particles [174]. 
Over the past decade, the understanding of the roles of the TMD of 
paramyxovirus fusion proteins has significantly expanded, demonstrating the 
critical nature of this region. These studies have shown that the TMDs of 
paramyxovirus fusion proteins have an active role in both spatial and temporal 
regulation of the F protein, mediating viral entry, and may be important for efficient 
viral particle assembly. 
 
Other Class I Viral Fusion Proteins 
The above sections review recent findings on the three most intensively 
studied families of Class I fusion proteins, but additional important studies on the 
fusion proteins from the Filoviridae and Coronaviridae families, as well as on Env 
proteins from retroviruses other than HIV have illuminated the roles of TMDs. The 
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fusion proteins of EBOV and coronaviruses (CoV), such as SARS-CoV, MERS-
CoV and SARS-CoV-2, are known as GP (for glycoprotein) and S (for Spike), 
respectively. Both proteins have dual functions in receptor binding and membrane 
fusion, similar to the HIV Env protein, and both have to undergo proteolytic 
processing to be primed for membrane fusion. The S protein of SARS-CoV-2, 
investigated in this dissertation, contains two subunits, S1 and S2.  S1 is 
responsible for the receptor binding function and S2 is responsible for carrying out 
membrane fusion.  Analysis of the CoV-2 S protein revealed three potential 
cleavage sites [178]: A canonical furin site at the border of S1/S2, shown to be 
cleaved during protein trafficking to the cell surface (Fig 1.2a and 1.3c) [179, 180], 
a site 10 amino acids downstream of the border, shown to be cleaved in SARS-
CoV S by cathepsin (Fig. 1.3c), and one 100 amino acids downstream of the border 
termed the S2’ (Fig. 1.3c), thought to be cleaved by TMPRSS2 during receptor 
binding or viral particle endocytosis (Fig. 1.2c and d) [181-183].  
The TMDs of both EBOV GP and the SARS-CoV S proteins have been 
shown to exhibit monomer–trimer–hexamer oligomerization equilibrium when 
analyzed in isolation by SE-AUC [184]. Analysis of the EBOV GP MPER and TMDs 
using NMR revealed that both regions appear to be continuous helices 
independent of the pH, with a turn in between the two adjacent regions [185], 
similar to the MPER-TMD HIV structure discussed previously [118-120]. The 
MPER of the GP protein appears to lie on the membrane face, with tryptophan and 
threonine residues mediating contact with the membrane interface. This 
orientation may represent only one of several potential conformations of the MPER 
in relation to the TM, as an in situ structure of the full-length EBOV GP protein 
within the membrane demonstrated that the MPER helices and TMD helices are 
in line with each other in some conformations of the protein [186]. Biochemical 
analysis of the GP protein from Marburg virus (MARV), a virus closely related to 
EBOV, showed MARV GP existed as a monomer in lipid-mimicking environments, 
further indicating that protein conformations and oligomerization may be 
dependent on host environmental factors such as lipid composition or pH [187]. 
While structural analysis has not been completed on the TMDs of CoV S proteins, 
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modeling predictions place a tryptophan-rich region immediately proximal to the 
TMD [188]. This tryptophan-rich region and its location with respect to the highly 
hydrophobic coil of the S protein TMD is critical for S-mediated membrane fusion. 
This study also suggests there is flexibility in the region adjacent to the membrane 
region [189], with flexibility in the region between the MPER and the TMD critical 
for large-scale conformational changes of the overall protein. Flexibility between 
the TMD and the upstream region is characteristic of many Class I fusion proteins, 
as it has been demonstrated for several different families (Flexible linker IAV, 
MPER-TMD HIV), though data from paramyxovirus F proteins do not support 
flexibility for that system [190]. 
The TMD region of the EBOV GP protein also plays a role in counteracting 
the host protein tetherin, which can inhibit viral particle release from infected cells 
[191], in contrast to the mechanism used by HIV-1, which counter-acts tetherin 
using an accessory viral protein (Vpu) [192]. The first characterization of the role 
of the EBOV GP protein TMD in counteracting tetherin showed that substituting 
the TMD of EBOV GP with the Lassa virus GP TMD prohibited EBOV VLPs from 
inhibiting tetherin activity [193, 194]. Further analysis discovered that a GXXXA 
motif within the EBOV GP protein TMD was responsible for counteracting tetherin 
activity [195]. This motif was also found to be critical for EBOV filamentous particle 
release from cells. Mutating this GXXXA motif in EBOV GP decreased viral particle 
release in a cholesterol-dependent manner [196]. Together, these data suggest a 
model in which GP trimers, aided by GXXXA motifs within the TMD region, form a 
lattice along the surface of infected cells in cholesterol rich regions of the 
membrane. This lattice serves as a particle budding site, eventually closing around 
actin filaments that are driving this region outward. Particle release then relies in 
part on this same GXXXA motif interacting with tetherin present within the 
membrane to counter-act its particle tethering ability. 
Using cryo-electron tomography and cryo-electron microscopy (cryo-EM), 
the structure of full-length Foamy Virus Env was determined [197]. Foamy Virus 
Env is composed of the gp18 leader peptide, the gp80 surface subunit, which 
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contains the receptor binding site, and the gp48 transmembrane subunit. TMD 
helices were observed in both the gp48 subunit and the gp18 leader peptide. This 
structure showed three central coiled helices that were in contact with one another, 
likely one from each gp48 of the protein trimer. Outside of this coiled-coil, TMD 
helices from gp18 each appeared to interact with a single helix from the gp48 
subunit. Since the TMDs of gp48 likely need to dissociate to mediate membrane 
fusion, this structure suggests a model in which the gp18 TMD helices block the 
dissociation of the gp48 until the fusion cascade promotes movement of the entire 
TMD complex. Computational analysis of the TMD subunits of several Foamy virus 
strains revealed a conserved lysine–proline motif that suggests a break may exist 
in the gp48 TMD helix [198], but this was not observed in the structural analysis. 
However, this motif could serve as a flex point during the conformational changes 
of the fusion process. Predictions also place a tryptophan-rich region of the protein 
in the MPER, similar to the MPER in other Class I fusion proteins [118, 188]. 
The fusion proteins (GPs) from arenaviruses have an additional membrane 
spanning component to consider, the stable signal peptide (SSP). Unlike HIV Env 
and IAV HA, GPs of arenaviruses form three distinct subunits, G1, responsible for 
receptor binding, G2, responsible for membrane fusion, and a 58-amino acid SSP 
[199]. These SSPs have been shown to play a role in the pH-dependent membrane 
fusion process [200]. Analysis of SSPs has demonstrated they have two 
membrane-spanning domains, and residues within the membrane participate in 
interactions with the TMD of the G2 subunit [201-203]. These interactions likely 
serve to prime the G2 subunit for the membrane fusion event. 
The past ten years have yielded numerous insights into the TMD of Class I 
fusion proteins: the first TMD structures have been solved, the active role of this 
region in several steps of the fusion cascade has been better characterized, and 
this region has been implicated in protein trafficking and immune function. While 
these contributions have been groundbreaking, contradictory studies indicate that 
important work remains to understand this important TMD. 
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Class II Fusion Proteins 
In 2001, a new class of viral fusion proteins was created because of the 
large difference in structure of these fusion proteins from Class I fusion proteins 
[204]. Class II viral fusion proteins include members from the togavirus, flavivirus, 
and bunyavirus families. While a large amount of α-helical secondary structure is 
found in Class I fusion proteins, Class II fusion proteins contain three distinct 
ectodomain regions consisting almost entirely of a β-sheet secondary structure 
with helical TMDs. These viral fusion proteins associate as homodimers upon 
synthesis but also form heterodimers with a companion protein. This creates a 
four-protein complex consisting of two fusion proteins and two companion proteins. 
Interestingly, for Class II viral fusion proteins, it is the companion protein, not the 
fusion protein, that requires a proteolytic cleavage event. The companion protein 
cleavage event primes the fusion protein for the low pH-triggered fusion reaction 
that occurs in all Class II fusion proteins. To facilitate fusion after exposure to the 
low pH environment of the endosome, the fusion protein homodimers dissociate 
into monomers, exposing the previously buried fusion loop, allowing for insertion 
of this hydrophobic loop into a target membrane. After insertion of the loop into the 
target membrane, there is a re-association of the monomers into trimers. They 
remain in a trimeric association throughout the rest of the fusion reaction, 
completing a series of steps similar to the refolding of the trimer hairpin structure 
described previously for Class I [205]. In contrast to the extensive work that has 
been completed on the TMDs of Class I viral fusion proteins over the last decade, 
only a small number of studies have been performed on the TMDs of Class II viral 
fusion proteins. These data do, however, provide important structural insight into 
the TMDs of several Class II fusion proteins [206-209] and demonstrate a 
functional role for this region in membrane fusion [210, 211]. 
Using cryo-EM, studies have solved the structures of complete viral 
particles from Dengue virus, Zika virus (both Flaviviruses), and Venezuelan equine 
encephalitis virus (VEEV) (Alphavirus), which include the in situ full-length fusion 
proteins, E and E1, respectively [207-209]. The structure of E proteins for Dengue 
(Fig. 1.5B) and Zika show two anti-parallel TMD α-helices, as well as three peri-
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membrane α-helices that lie perpendicular to the TMD helices on the exterior 
surface of the viral membrane, with each helix connected to the next by a loop 
[207, 208]. Analysis of the Dengue E protein structure showed that the loops of the 
TMD helices are buried within the head-group region of the inner leaflet of the viral 
membrane. The two TMD helices form a coiled-coil, with hydrophobic residues 
facing outward, and multiple serine/threonine hydrophilic residues facing inward 
on the coiled-coil [207]. These highly hydrophilic interactions appear to have a role 
similar to the leucine zipper oligomerization motifs found in some Class I fusion 
proteins [161]. The VEEV E1 protein TMD is composed of two α-helices, with a 
highly conserved glycine–glycine (GG) kink between them [209]. Since these 
studies encompassed the full viral particle, they also provide data for TMDs of their 
respective companion proteins, M for Dengue and Zika and E2 for VEEV. The M 
protein, similar to E, has two TMD helices that lie anti-parallel to one-another. 
Despite being situated in close to proximity to the TMD helices of E, the data did 
not demonstrate any protein-protein contacts between M and E within the 
membrane space. It was revealed, however, that the presence of both the M and 
E TMDs provided some lateral order to the membrane, and the membrane was 
bent to accommodate the short length of the TMD helices, indicating that protein–
lipid interactions were likely occurring. The TMD of VEEV E2 was visualized as a 
long, straight α-helix. When VEEV E1 and E2 were analyzed together, the GG kink 
in the TMD of E1 appeared to allow TMD flexibility so that the lower portion of the 
E1 TMD could associate with the E2 TMD helix. 
Computational modeling has also provided structural insights into the TMDs 
of the surface glycoproteins from a pestivirus known as bovine viral diarrhea virus 
(BVDV) [206]. The two surface glycoproteins of BVDV, E1 and E2, are required for 
viral entry, with charged residues in the TMD critical for this process [211]. E2 has 
two TMD α-helices (tmH1 and tmH2), with extensive hydrophobic interactions 
between them and an arginine residue (R1047) in the loop between the helices 
which interacts with the phospholipid head groups on the inner leaflet of the 
membrane. Additionally, hydrogen bonding between the helices at serines S1035 
and S1060 may further stabilize the TMD-TMD interactions occurring between 
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tmH1 and tmH2. The TMD of the second surface protein, E1, has two peri-
membrane α-helices (pmH1 and pmH2), as well as a single transmembrane α- 
helix (tmH). As shown by modeling of the E1-E2 hetero-tetramer complex based 
on ectodomain structural constraints and previously published biochemical 
constraints, the TMD helix of E1 is in close proximity to the tmH1 of E2, with 
hydrophobic contacts and a single hydrogen bond (T688 from E1 and Y1056 E2) 
occurring between the two. This suggests that TMD-TMD associations between 
E1 and E2 may be important for overall complex formation. Similar to membrane 
disruptions caused by the TMDs of the Dengue E and M proteins [207], residue 
R1047 of E2 and charged residues in E1 appear to interact with the phospholipid 
head groups of the membrane, potentially causing thinning of the membrane which 
could further assist the viral fusion process. These data together present a model 
for Class II fusion proteins in which TMD-TMD interactions occur between the 
fusion protein TMD and the companion protein TMD, with residues in both of these 
regions interacting with membrane phospholipid headgroups. These interactions 
may play a role in fusion protein stability and the membrane distortion needed for 
proper viral entry. 
The role of TMD-TMD interactions in the Class II fusion process is also 
suggested by biochemical studies of the flavivirus E protein, which showed the 
functional relevance of the second TMD helix [210]. To probe the role of this region 
in tick-borne encephalitis virus (TBEV), mutants were created with the second 
TMD helix deleted, or one or both TMD helices substituted with the corresponding 
helix of the closely related flavivirus, Japanese encephalitis virus (JEV). None of 
the mutants, even a full deletion of the TMD2, affected early steps in fusion. 
However, each of these mutants was found to destabilize the post-fusion E trimer 
which did not allow for the formation of a fusion pore. Interestingly, the chimeras 
which substituted the full length of both TMDs with a related virus were still able to 
facilitate the full fusion process, albeit less efficiently than the wild type protein. 
This suggests a concerted role for interactions between the TMDs in late steps of 
the fusion pathway, potentially through intra-helix interactions or interactions with 
the fusion loop in the post-fusion conformation of the protein [210]. 
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While less information is available on Class II fusion proteins compared to 
recent studies on Class I fusion proteins, critical structural insights into the unique 
TMDs of these fusion proteins have recently been made. Furthermore, this work 
has begun to illuminate the extensive TMD-TMD interactions that occur in Class II 
fusion proteins, potentially similar to those in Class I fusion proteins that may be 
required for fusion complex formation and complex stability in the fusion process. 
These recent studies also demonstrate the joint effort of the fusion protein TMD 
and the TMD of the companion protein in mediating viral entry. 
Class III Fusion Proteins 
In 2006, ectodomain structures of fusion proteins from both vesicular 
stomatitis virus (VSV) [63] and herpes simplex virus type 1 (HSV-1) [58] were 
solved. The VSV G and HSV-1 gB proteins have remarkably similar structures 
despite a lack of sequence homology. These fusion protein structures are distinct 
from both Class I and Class II, prompting the creation of a new class of fusion 
proteins, Class III [212]. This class now encompasses fusion proteins of viruses in 
the rhabdovirus, herpesvirus, and baculovirus families [213]. 
Since 2006, ectodomain structures of the post-fusion forms of HSV-1 gB 
[58], Epstein–Barr Virus gB [214], and baculovirus gp64 [215] have been solved, 
and both pre- [64] and post-fusion structures [63] have been solved for VSV G. In 
the post-fusion form, these fusion proteins are trimeric in nature, similar to both 
Class I and II proteins. Each fusion protein ectodomain consists of five distinct 
domains. Starting with domain I that contains fusion loops that lie on the end of 
extended β-sheet structures, to domain V which forms an α-helical structure that 
serves as an interacting interface between the proteins in the trimer, and serves to 
connect the ectodomain with the TMD and cytoplasmic tail portion of these fusion 
proteins [213]. Unlike the fusion processes in Class I and II, the conformational 
changes experienced by Class III fusion proteins appear to be reversible in nature. 
Initial work completed on Class III fusion proteins provided limited insight into the 
TMD. However, several studies over the past decade have provided structural 
 35 
 
details and evidence for a role of the TMD in membrane fusion and viral particle 
assembly. 
Recent work demonstrated the crystal structure of a full-length fusion 
protein from Class III, HSV gB, in its post-fusion form. This structure includes the 
MPER, TMD, and cytoplasmic tail domain (CTD), all of which were absent in 
previous structures [216]. The MPER-TMD-CTD regions form a pedestal-like 
structure through the membrane, with the ectodomain resting on top. The MPER 
regions of a gB trimer form dynamic helices that lie along the surface of the 
membrane. At the C-terminus of these helices is a linker with conserved proline 
and glycine residues that likely contribute to flexibility in this region. C-terminal to 
this linker lies the TMD, which forms a straight helix that extends through the 
membrane, with each TMD of the trimer contributing to one side of an inverted 
teepee structure. The N-terminus of these regions is splayed apart, and each TMD 
crosses the others at a ~46° angle. The C-terminal portions of the three TMDs do 
not have cross-promoter linkages, but are in close proximity, in a structure 
stabilized by knob-and-hole packing and the presence of conserved, small glycine 
and alanine residues which allow for close fit of the helices. Residues at the C-
termini of TMD likely participate in hydrophilic interactions with the CTD. The CTD 
of each gB monomer in the trimer forms two α-helices (h1a and h2) and one 310 
helix (h1b). Immediately following the TMD, h1a and h1b form a zig-zag with 
proline residues at the interfaces between each helix. Then, an unresolved linker 
connects to the h2 helix that extends back up toward the membrane. Each CTD 
region has several contacts with other CTDs of the gB trimer, further stabilizing 
this base (Fig. 1.5C). 
Characterization of the location of mutations within the TMD or CTD 
previously shown to either enhance or reduce cell–cell fusion allowed for additional 
insight into gB fusion regulation. Most hyperfusogenic mutants were found to be at 
residues or regions that would disrupt the trimeric interfaces or the membrane 
binding of the CTD. Mutants that reduced fusion mainly shorten hydrophobic side 
chains that participate in interactions at the CTD trimer axis, thus reducing CTD 
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trimer stability and likely causing protein misfolding. Taken together, this suggests 
that this structure of the CTD also exists in the prefusion conformation of the gB 
protein, forming a triangular base that may serve as a clamp to hold the TMDs in 
place until appropriately stimulated, leading to conformational changes required to 
mediate fusion. This would suggest a model for Class III membrane fusion in which 
a release of the gB CTD clamp is needed for viral entry to occur, seemingly serving 
a similar latch role to that of the M protein for flavivirus E [207]. The release of this 
clamp may be facilitated in part by TMD-TMD interactions between the gH protein 
and the gB, as work that replaced the gH TMD in pseudorabies virus rendered the 
virus non-fusogenic [217]. 
Even before the creation of the new class of fusion proteins, several studies 
demonstrated the functional role of the TMD of VSV G in membrane fusion [218, 
219], highlighting specifically that glycine residues in the TMD of VSV G were 
critical for fusion activity [220]. In the past decade, additional studies have further 
characterized the contribution of the TMD in rhabdovirus fusion protein function. 
Substituting the TMD and CTD of rabies virus (RV) fusion protein (G) with similar 
regions from NDV fusion protein to attempt to aid with incorporation in NDV viral 
particles as a vaccine vector strategy, showed lower incorporation of this chimera 
protein in NDV viral particles, despite the chimeric protein having overall cellular 
protein levels similar to the wild type RV G protein [174, 221]. Surface expression 
of the chimeric protein was not analyzed. Additionally, when mice were vaccinated 
with NDV particles containing the chimeric RV G protein, virus-induced neutralizing 
antibodies to rabies virus were lower than those induced by vaccination with NDV 
particles with the WT RV G protein. This may suggest that successful incorporation 
into particles relies in part on the TMD or CTD of RV G protein, indicating that 
signals in the TMD or CTD of RV may play a role in overall particle assembly. 
These regions may also have a role in the host immune response to viral infection, 
similar to the production of bNAbs specific to the MPER-TMD produced during HIV 
infection [120, 142]. 
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Analysis of the VSV G TMD in isolation demonstrated a role of this region 
as a catalyst for membrane fusion [221]. In early stages of membrane fusion (the 
transition to hemi-fusion), addition of the VSV G TMD increased positive curvature 
stress and membrane disorder by facilitating acyl-chain movement into the space 
between the two bilayers. In later stages of fusion, the VSV G TMD created further 
positive curvature stress at the edges of these induced regions, allowing for the 
transition between hemi-fusion and fusion pore formation. This suggests that the 
TMD of VSV G proteins could serve in part to help overcome the large energy 
barrier to a membrane fusion event by creating physical changes to the membrane. 
Targeting the TMD 
As work continues to show the importance of TMDs in viral fusion protein 
function, it is not surprising that there has also been tremendous growth in the 
understanding of the role of TMD in the function of other proteins. TMD-TMD 
interactions are important in the creation of amyloid-β, an important factor in 
Alzheimer’s disease [222]; the dimerization of both neuropilin-1 [223] and tyrosine 
kinase receptor ErbB2 [224]; the inhibitory function of the IgG Fc receptor, FcγIIB 
[225]; and induction of the signaling cascade by frizzled receptors [226]. The 
growing understanding of a role for TMD-TMD interactions has led to the 
development of a unique area of therapeutic research studying small molecules 
that disrupt TMD-TMD interactions [227]. Disrupting the dimerization of neuropilin-
1 has been shown to suppress glioma tumor growth in vivo [228]. Plexin-A1 TMD-
mimicking peptides disrupt complex formation between neuropilin-1 and Plexin-
A1, a complex that forms in gliomas with poor prognoses, and the Plexin-A1 TMD 
peptides slow both tumor growth and metastasis in cell culture models [229]. 
Overexpression of p75NTR has been associated with advanced stages of 
melanoma progression, but a small molecule was able to inhibit tumor growth in a 
mouse model by targeting the TMD of p75NTR to disrupt oligomerization and 
downstream signaling of this receptor [230]. Additionally, small molecules targeting 
the TMD of Epstein–Barr virus latent membrane protein 1 prevent trimerization of 
the protein, blocking oncogenic activation [231]. 
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TMDs of viral fusion proteins have also been investigated as a novel anti-
viral therapeutic strategy. Targeting TMD-TMD interactions as a potential anti-viral 
therapeutic has been successfully demonstrated for both Class I and Class II 
fusion proteins in initial studies. HIV-1 virions that were treated with peptides 
derived from the FP or TMD of HIV Env exhibited a dose-dependent decrease in 
infectivity. The Env TMD peptides were able to directly associate with WT full-
length Env protein, suggesting that the decrease in virus infectivity is due to the 
peptide disrupting the native TMD-TMD association [125]. Similarly, work in this 
thesis showed that co-expression of small proteins mimicking the TMD of the 
Hendra F protein led to de-stabilization of the full-length F protein, consistent with 
the presence of additional TMDs reducing the trimeric interactions needed for pre-
fusion stability (Chapter 3)[232]. The TMD proteins also disrupted cell–cell fusion 
when co-expressed with WT full-length Hendra fusion protein (Chapter 3, Fig. 3.3). 
The ability of TMD peptides to interfere with fusion protein function was also 
demonstrated in viral infection, as TMD peptides homologous to the TMD of the 
PIV5 F protein decreased PIV5 infection when incubated with the virus prior to 
cellular infection (Chapter 3, Fig. 3.5). This inhibition was sequence specific, as 
pre-incubation with PIV5 F TMD peptides did not decrease the infection of a related 
virus (HMPV) [232]. A similar antiviral strategy was demonstrated using peptides 
derived from the MPER of Flavivirus E protein. Inclusion of hydrophobic residues 
corresponding to the TMD of the E protein to the C-terminus of MPER-derived 
peptides increased the viral inhibitory function of these peptides [233]. These 
inhibitory effects occurred in a sequence-specific manner, similar to the study 
completed in paramyxoviruses [232]. 
Apart from specifically targeting the TMD of fusion proteins as a method to 
inhibit viral entry, inclusion of the TMD appears to be useful for other viral inhibition 
strategies. The binding strength of neutralizing antibodies to the MPER region of 
HIV-1 Env increased when the TMD of the protein was included. Furthermore, 
when a trimeric TMD was included with the MPER peptide of HIV Env, binding was 
similar to that of binding the native protein [140, 141]. These studies suggest that 
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targeting the TMD or including portions of the TMD in anti-viral therapeutic 
development may be important. 
Conclusions and Questions 
The past decade has provided significant insight into the TMDs of viral 
fusion proteins from all three classes, further building our understanding of the 
intricate nature of these regions. Structures have been elucidated for TMDs of 
each class of fusion proteins, and a function for the TMD in viral fusion has been 
shown for each class, whether it be in early, intermediate or late stages of the 
fusion cascade. Significant work has also demonstrated the role of the TMD of 
fusion proteins outside of the membrane fusion process, implicating it in antibody 
recognition, host immune responses to viral infection, overall viral particle 
assembly, and protein trafficking. Despite the large amount of work, critical 
questions remain unanswered concerning the TMD of viral fusion proteins. How 
does the conformation of the fusion protein TMD change throughout the membrane 
fusion cascade? What membrane components influence the TMD for each virus? 
Are there other interactions between viral or host proteins with the TMD of the 
fusion protein? Do interactions with the fusion protein TMD exist that influence the 
overall viral lifecycle? Hopefully, future studies over the next decades will provide 






Figure 1-1 Paramyxovirus and pneumovirus particle schematic.  
Virions of paramyxo- and pneumoviruses contain a single stranded, negative-
sense RNA genome that is coated with the nucleoprotein.  The genome is 
encapsulated within a lipid membrane derived from a host cell.  This membrane is 
studded with the fusion and attachment proteins, as well as a small hydrophobic 








Figure 1-2 Viral fusion protein proteolytic cleavage 
All class I viral fusion proteins must be cleaved in order to facilitate viral membrane 
fusion.  a.) This cleavage can occur in the trans-golgi network as the protein is 
trafficking to the cell surface following synthesis (a), protein endocytosis and 
recycling back to the cell surface prior to particle assembly (b), after viral 
attachment to a target cell by a cell surface protease (c), or within a endosome 






Figure 1-3 Cleavage of viral fusion proteins.  
a) HeV F is synthesized in an uncleaved form (F0) and trafficked to the cell surface.  
Following this, the protein is endocytosed and cleaved by cathepsin L in recycling 
endosomes to expose a highly hydrophobic fusion peptide (FP), leaving the protein 
as a disulfide linked heterodimer (F1 and F2).  The F1 portion of the protein contains 
two heptad repeat regions (HRA and HRB), a transmembrane domain (TM), and 
a cytoplasmic tail (CT).  b) RSV F is also synthesized in an uncleaved form (F0), 
however the protein is cleaved by furin or a membrane of the furin family during 
protein egress to the cell surface.  RSV F has two potential cleavage sites, one 
that exposes a hydrophobic FP, and one is 27 amino acids upstream whose 
function is unknown. If both sites are processed a small peptide (P27) is released 
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from the resulting disulfide linked heterodimer. Similar protein domains to HeV F 
are found in RSV F. c) SARS-CoV-2 S is a large 1275 amino acid protein, 
composed of an S1 and S2 subunit.  S1 contains a signal peptide (SP), an N-
terminal domain (NTD), and a receptor binding domain (RBD). The S2 subunit 
contains a FP, an internal fusion peptide (IFP), two heptad repeat regions (HR1 
and HR2), a transmembrane domain (TM), and a cytoplasmic tail (CT).  S is 
processed at the S1/S2 border during protein trafficking to the cell surface by furin 
or a member of the furin family. There are two other potential cleavage sites within 
the S2 subunit, one 10 amino acids downstream of the S1/S2 border, a conserved 
site used by SARS-CoV S, and one is 100 amino acids downstream of the border, 
termed the S2’ site. Cleavage at S2’ reveals an internal fusion peptide (IFP), 





Figure 1-4 A model of viral membrane fusion function.  
This figure depicts a model of fusion mediated by a Class I viral fusion protein; 
however, related processes occur in the case of Class II and III viral fusion proteins 
as well. (A) The fusion protein situates itself in the viral membrane (yellow). The 
first step of viral fusion is a priming event; in the case of Class I proteins, the protein 
itself undergoes the proteolytic processing to prime it for fusion. For Class II fusion 
proteins, it is a companion protein that gets proteolytically processed; (B) Once 
primed, the viral fusion protein remains in a metastable, pre-fusion conformation 
until it receives a triggering signal; (C) Upon receipt of the triggering signal, the 
protein extends out, forming a pre-hairpin structure, allowing for the fusion peptide 
or fusion loop (dark blue) to enter the target membrane (red); (D) This extended 
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structure then begins to fold back on itself, bringing the N-terminal and C-terminal 
heptad repeats closer (dark green and light green, respectively), and in turn pulling 
the viral membrane and target membrane together; (E) As the N-terminal and C 
terminal heptad repeats zipper together to form a six-helix bundle, the target and 
viral membrane reach a hemi-fusion state, in which the outer leaflets have started 
to mix (orange); (F) Finally, the fusion peptide and transmembrane domain (light 
blue) come into close proximity to complete the merging of the two membranes 
and opening of the fusion pore. This final structure of a trimer of hairpins is a 





Figure 1-5 Full-length structures of viral fusion proteins.  
While the ectodomain structures of numerous viral fusion proteins have been 
solved, only a few solved structures of full-length viral fusion proteins, including the 
transmembrane domain (TMD) have been solved. (A) Full-length influenza 
hemagglutinin (HA) was solved in 2018 [96]. Two structures were published, 6HJQ 
(far left) and 6HQR (far right). The first is HA in its pre-fusion conformation, and 
the ectodomain is in line with the TMD helices (middle left, zoomed in). In the 
second structure, the ectodomain is tilted 52° with respect to the TMD helices 
(middle right, zoomed in); this likely represents a scenario that is an intermediate 
state of fusion. In each zoomed-in area, a linker region is indicated (slate), and this 
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region remains flexible to help compensate for this tilt. (B) In 2013, the structure of 
full-length Dengue virus E protein was solved [207]. This structure showed the 
hetero-tetramer complex of two E proteins (light and dark purple) and 2 M proteins 
(gray) with their respective TMD helices (3J2P). Flavivirus E proteins have two 
TMDs that have extensive hydrophobic interactions between them. The structure 
also includes three peri-membrane helices that lie on the outer surface of the viral 
membrane, approximately perpendicular to the TMD helices. (C) Full-length 
Herpes simplex virus 1 gB protein was published in 2018 [216]. This structure 
(5V2S) shows the three TMD helices situated in a triangular teepee structure; the 
MPER (dark grey) is a helix that lies almost perpendicular to the orientation of the 
TMD helices. The solved structure also includes a large portion of the cytoplasmic 
tail (CTD, light gray). Each CTD has two helices, the first of which is a small helix 
that links to a larger helix which then angles back towards the inner leaflet of the 
viral membrane. Because of the orientation, these CTDs may act as a clamp that 
assists in holding the gB TMDs in specific conformation, and the angle of the CTD 
may work in concert with the TMD helices to dictate the overall conformation of the 





CHAPTER 2. MATERIALS AND METHODS 
Hendra Fusion Protein Projects 
Cell lines  
Vero cells (ATCC) and BSR-T7/5 cells (generously provided by Karl-Klaus 
Conzelman, Pettenkofer Institute) were maintained in Dulbecco’s modified Eagle’s 
media (DMEM; Invitrogen) supplemented with 10% fetal bovine serum (FBS).  
BSR T7/5 cells were selected for the expression of the T7 polymerase by the 
addition of G418 sulfate (Gibco/Invitrogen) every third passage to the DMEM.    
Plasmids, Viruses, and Antibodies 
Plasmids containing Hendra F or G were generously provided by Dr. Lin-Fa 
Wang (Australian Animal Health Laboratory). The Hendra F TM constructs were 
designed to include the predicted HeV F signal peptide, varying lengths of the HRB 
domain, the full-length TM domain, the C-tail and an HA tag. The Hendra F TM 
constructs were synthesized by GenScript and provided in the pUC57 vector. Each 
construct was sub-cloned into the eukaryotic expression vector pCAGGS, as 
described previously for Hendra F [165]. Anti-peptide antibodies to residues 527-
539 of the Hendra F cytoplasmic tail were used to pull down F and the TM proteins. 
Additionally, mAb 5G7, provided by Dr. Christopher Broder (USUHS), was used 
for immunoprecipitation to detect Hendra F. Co-immunoprecipitation studies were 
performed with a mouse anti-HA antibody (12CA5, Roche). For 
immunofluorescence, a rabbit anti-HA antibody (Abcam ab9110) was used at a 
1:300 dilution to detect the TM proteins. Secondary antibodies used for 
immunofluorescence were goat anti-mouse-FITC and goat anti-mouse-TRITC 
(Jackson Immuno Research). The recombinant HMPV (rgHMPV) was kindly 
provided by Peter L. Collins and Ursula J. Buchholz (NIAID, Bethesda, MA). The 





Vero cells (confluency 80-90%) in 60-mm dishes were transiently 
transfected using Lipofectamine and Plus reagent (4µg of DNA) according to 
manufacturer’s protocol (Invitrogen). For co-expression experiments, the ratio of 
DNA transfected was 2:1 HeV F:TM, unless otherwise noted. Eighteen to twenty-
four hours post-transfection, cells were washed with PBS and starved for 45 min 
in DMEM deficient in cysteine and methionine. Cells were labeled for 3 h with 
DMEM deficient in cysteine and methionine, containing Tran35S-label (100µCi/mL; 
MP Biomedicals), biotinylated with 1 mg/ml EZ-Link Sulfo-NHS Biotin (Pierce) 
diluted in pH 8.0 PBS, at 4oC for 35 min, followed by 15 min at room temperature. 
Cells were then lysed in RIPA lysis buffer; supernatants were cleared by 
centrifugation at 135,000xg for 15 minutes at 4oC.  4µl of an anti-peptide Hendra 
F antibody was added to the supernatants, and incubated at 4oC for 3 hr with 
rocking, and was then incubated for 30µl of protein A-Sepharose beads (GE 
Healthcare).  Immunoprecipitated proteins were then washed two times with each 
of the following in order: RIPA buffer containing 0.3M NaCl, RIPA buffer containing 
0.15M NaCl, and SDS wash II buffer.  Samples were then boiled away from beads 
in 10% SDS.  Ten percent of the protein was removed as the TOTAL sample, and 
the remainder (SURFACE) was diluted in biotinylation dilution buffer and incubated 
with immobilized streptavidin beads (Pierce) at 4oC for 1 hr.  Samples were again 
washed as described above.   Samples were analyzed by 15% SDS-PAGE, 
exposed to a phosphor-screen, and visualized using the Typhoon imaging system 
(GE Healthcare), as previously described (11). Band densitometry using 
ImageQuant 5.2 was performed for each experiment to quantitate the amount of F 
expressed which was reported as % expression, the sum of F0 and F1, normalized 
to the F+mock control.  
Time Course Immunoprecipitation 
Hendra virus F protein was co-expressed with the TM constructs in 
subconfluent Vero cells using Lipofectamine and Plus (Invitrogen) as previously 
 50 
 
described. The next day cells were washed with PBS and starved for 45 min at 
37°C in cysteine-methionine-deficient DMEM. Cells were then labeled for 30min 
with Trans[35S] metabolic label (100µCi/mL; MP Biomedicals). At different time 
points, cells were washed three times with PBS and lysed with RIPA lysis buffer. 
Immunoprecipitation with the anti-peptide Hendra F antibody and protein A-
Sepharose beads and analysis was performed as described for surface 
biotinylation.  
 
Higher molecular weight immunoprecipitation and native gel electrophoresis 
Hendra virus F protein was co-expressed with the TM constructs in 
subconfluent Vero cells using Lipofectamine and Plus (Invitrogen) as previously 
described. The next day cells were washed with PBS and starved for 45 min at 
37°C in cysteine-methionine-deficient DMEM. Cells were then labeled for 30 min 
with Trans[35S] metabolic label (100µCi/mL; MP Biomedicals). Cells were then 
washed three times with PBS and allowed to incubate at 37°C for indicated chase 
times. Cells were washed three times with PBS and lysed with RIPA lysis buffer. 
Lysates were incubated with anti-peptide antibodies to residues 527-539 of the 
Hendra F cytoplasmic tail for 3 hours, and subsequently protein A-Sepharose 
beads for 30 minutes, as described for surface biotinylation.  After washing steps 
were completed, 30 µl of 2X loading buffer without DTT was added to each of the 
samples.  Samples were then boiled away from beads at 60oC, 80oC, or 100oC as 
indicated, for 10 minutes and analyzed on a 3.5% acrylamide gel under non-
reducing conditions, the gel was imaged on the same system described for surface 
biotinylation.    
Syncytium assay  
Subconfluent Vero cells in 6-well plates were transiently transfected with 
Hendra F, Hendra G, TM protein at a ratio of 1:3:1 using Lipofectamine and Plus 
Reagent (Invitrogen) per manufacturer’s protocol. Syncytia formation was 
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observed 24 to 48h post transfection. Images were taken using a Nikon digital 
camera mounted atop a Nikon TS100 microscope with 10X objective.  
 
Luciferase Reporter Gene Assay  
Vero cells (70-90% confluent) in 12-well plates were transiently transfected 
with 0.15ug of pCAGGS-Hendra F or one of the HeV F mutants, 0.45ug of 
pCAGGS-Hendra G, and 0.4ug of a T7 promoted Luciferase plasmid. 
Transfections were performed using Lipofectamine and Plus reagent (Invitrogen) 
according to the manufacturer’s protocol. At 24 h post transfection, BSR T7/5cells 
were lifted with trypsin, resuspended in DMEM supplemented with 10% FBS were 
overlain on to Vero cells that were washed once with PBS. These were incubated 
for 4 h at 37C. Then, cells were lysed with reporter lysis buffer (Promega) and 
analyzed for Luciferase activity using the luciferase assay system (Promega) per 
manufacturer’s instructions. A SpectraMax iD3 plate reader (Molecular Devices; 
Sunnyvale, CA) was used to read the luminescence. Results were normalized to 
cells expressing WT Hendra F and G, after subtracting the background (HeV G 
only).     
Peptide inhibition assay  
Recombinant GFP expressing HMPV or PIV5 were pretreated for 30 min at 
room temperature with TM peptide corresponding to the TM domain sequence of 
the PIV5 F protein. The peptide was synthesized by LifeTein with the following 
sequence: 485VLSIIAICLGCLGLILIILLSVVVWKLL512 (accession #P04849). The 
peptide was solubilized in sterile DMSO. Virus was diluted in OPTI-MEM for an 
infection with a MOI=1 pfu/cell. Vero cells (70-90% confluency) were washed twice 
with PBS and incubated with 500 µL of peptide treated virus for 4 hr at 37°C. After 
the incubation, the infection media was removed, cells were washed 2X with PBS, 
and cells were left overnight with DMEM+FBS. The following day, cells were 
imaged for GFP-positive cells with a Nikon Axiovert-100 microscope. For flow 
cytometry analysis, the cells were lifted with 100 uL of trypsin-EDTA and fixed with 
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an equal volume of PBS + 2% paraformaldehyde + 50 mM EDTA. For each 
sample, 50,000 cells were counted for flow analysis. Analysis was performed on 
the LSR II flow cytometer by the UK Flow Cytometry Core.  
Immunofluorescence 
Cells grown in 6-well plates containing coverslips were co-transfected with 
HeV F and the TM constructs. After 24hr, cells were washed in PBS and fixed in 
4% paraformaldehyde for 15 minutes at room temperature. Cells were then 
permeabilized in 1% Triton X-100 for 15 minutes at 4°C followed by blocking in 1% 
normal goat serum. Cells were incubated with the corresponding primary antibody 
overnight at 4°C. The following day, cells were washed with 0.05% tween-PBS, 
secondary antibodies were added, and cells were incubated at 4°C for one hour. 
Coverslips were then mounted on glass slides using Vectashield mounting media 
(Vectorlabs, Burlingame, CA). Pictures were taken using a Nikon 1A confocal 
microscope and analyzed with the NIS-Elements software. All images were 
processed in Adobe Photoshop, with equivalent adjustments made to all panels. 
SARS-CoV-2 Spike Project 
Cell lines and culture 
Vero (ATCC), BSR T7/5 cells (provided by Karl-Klaus Conzelmann, 
Pettenkofer Institut), mouse embryonic fibroblasts (MEFs) from cathepsin L 
knockout mice (Cath L- MEFs) (a gift from Terence Dermody, University of 
Pittsburgh), and P. alecto bat cells harvested from fetus (pt. fetus) and lung (pt. 
lung) (a gift from Linfa Wang, Duke-NUS) [240] were all maintained in Dulbecco’s 
modified Eagle’s medium (DMEM, GE Healthcare), with 10% fetal bovine serum 
(FBS) and 1% penicillin/streptomycin.  Every third passage, 0.5mg/ml of G-418 
(Invitrogen) was added to the culture media of BSR T7/5 cells to select for the 
expression of the T7 polymerase.  A549 and human colon carcinoma LoVo cells 
(both purchased from ATCC) were cultured in F12 Kaighns Modification media 
(GE Healthcare) with 10% FBS and 1% penicillin/streptomycin.   
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Plasmids, Antibodies, and Mutagenesis 
pCAGGS-SARS-CoV-2 spike was obtained from BEI Resources.  
pcDNA3.1(+)-hACE2 and pcDNA3.1(+)-TMPRSS2 were provided by Gaya 
Amarasinghe (Washington University).  Human Neuropilin-1 was expressed with 
an exogenous PTPα signal sequence from the pLEXm vector (from Craig Vander 
Kooi, University of Kentucky). SARS-CoV-2 S was subcloned into pUC57 and all 
S mutants were created in pUC57 using the QuikChange site-directed 
mutagenesis kit (Strategene) with primers purchased from Eurofins.  Constructs 
were then subcloned back into the pCAGGS expression vector. Other plasmids 
utilized include pSG5-Cathepsin L (from Terence Dermody, University of 
Pittsburgh), pCAGGS-furin (Promega), and T7 promoted-luciferase (Promega).  
Antibodies anti-SARS spike glycoprotein (ab252690) and anti-hACE2 (ab15348) 
were purchased from Abcam, and anti-TMPRSS2 (H-4) was purchased from Santa 
Cruz Biotechnology, Inc.   
Gel electrophoresis and western blotting 
Proteins were separated on a 10% sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE).  For western blot analysis, 
proteins were transferred to a polyvinylidene difluoride (PVDF) membrane (Fisher 
Scientific) at 60V for 100 minutes.  After blocking with 5% milk in tris-buffered saline 
+ Tween-20 (tTBS) for 1 hour, membranes were incubated with respective 
antibodies (anti-SARS S 1:5000 dilution, anti-TMPRSS2 1:1000 dilution, anti-
hACE2 1:1000 dilution) at 4°C overnight.  Membranes were then washed with tTBS 
and incubated with (Li-Cor) secondary antibodies at 1:10000 dilution in 5% milk 
solution for 1 hour.  Membranes were washed again with tTBS and diH2O, before 
being imaged on the Odyssey Image Analyzer (Li-Cor).   
Syncytium Assay 
Cells (Vero or A549s) in 6 well plates were transiently transfected with 2μg 
of either wild-type or mutant SARS-CoV-2 S protein plasmid with Lipofectamine 
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3000 (Invitrogen) at a ratio of 1:2:2 DNA: P3000: Lipofectamine 3000. For 
experiments with the addition of proteases, the total DNA transfected was kept 
constant at 2μg, in those cases we used 1μg of S and 1μg of the indicated 
protease.  Syncytia formation was imaged at 24 and 48 hours post transfection on 
a Nikon Ti2 at 20X magnification.   
Luciferase Reporter Gene Assay  
Effector cells (Vero or A549s) were plated in 12-well plates at 70-90% 
confluency and transfected with 1μg of total DNA (0.4μg of a T7 promoted 
luciferase plasmid, 0.6μg of wild-type (wt) or mutant S protein or S protein with 
additional proteases).  At the same time BSR cells (constitutively expressing a T7 
promoter) seeded in 6-well plates were transfected with 2μg either empty pCAGGS 
or pcDNA3.1(+)-hACE2.  Eighteen to twenty-four hours post transfection BSR cells 
were lifted using trypsin, centrifuged for five minutes at 1500 rpm, resuspended in 
normal DMEM+10% FBS, and overlaid onto the S expressing cells at a ratio of 1:1.  
Overlaid samples were then incubated at 37°C for 9 hours (or as described in the 
text).  Samples were lysed in 100μL of Reporter Gene Lysis buffer (Promega) and 
frozen overnight.  Plates were then scraped on ice, lysates were vortexed for 10 
seconds, centrifuged at 13,000 rpm for 1 minute at 4°C, and 20μL of the 
supernatant was added to an opaque 96 well plate.  Luciferase activity was 
measured on a SpectraMax iD3 (Molecular Devices) using a Luciferase Assay 
System (Promega).  Background values were subtracted (empty pCAGGS in 
BSRs and effector cells) and luciferase activity was expressed as a percentage of 
wt S (effector cells) and hACE2 (BSR cells).   
Surface Biotinylation 
Two μg of wt or mutant S protein was transfected into Vero or A549 cells 
using the Lipofectamine 3000 system (Invitrogen; ratios described above).  
Eighteen to twenty-four hours post transfection, cells were starved in Cys-/Met- 
media (Gibco) for 45 minutes, and metabolically labelled for six hours using 50μCi 
of S35 (PerkinElmer) incorporated into Cys and Met (S35 Cys/Met).  After the label, 
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cells were washed once with PBS (pH 8) and incubated with 1 mg/ml of EZ-link 
Sulfo-NHS-biotin (Thermo Fisher) in PBS (pH 8) at 4°C for 35 minutes, and then 
at room temperature for 15 minutes.  Next the cells were lysed in 500μl of RIPA 
buffer (100 mM Tris-HCl [pH 7.4], 0.1% SDS, 1% Triton X-100, 1% deoxycholic 
acid) containing 150 mM NaCl, protease inhibitors (1 U aprotinin, 1mM PMSF, 
[both from Sigma-Aldrich]), 5 mM iodoacetamide, and cOmplete EDTA-free 
Protease Inhibitor Cocktail Tablets (all from Sigma-Aldrich). Cell lysates were 
centrifuged at 55,000 rpm for 10 minutes, and the supernatant was incubated with 
anti-SARS S polyclonal antibody at 4°C for three hours. Following incubation, 
Protein A conjugated to Sepharose beads (Cytiva) were added to the samples, 
and incubated at 4°C for an additional 30 minutes. Post-incubation samples were 
washed two times with each RIPA Buffer+0.3M NaCl, RIPA Buffer+0.15M NaCl, 
and SDS-Wash II buffer (50mM Tris-HCl [pH 7.4], 150mM NaCl, and 2.5mM 
EDTA).  After buffer aspiration and addition of 10% SDS, samples were boiled for 
10 minutes. The supernatant was removed to a separate tube.  15μl of supernatant 
was removed and added to an equal portion of 2X SDS loading buffer and labeled 
“TOTAL”.  Biotinylation buffer (20 mM Tris [pH 8], 150mM NaCl, 5mM EDTA, 1% 
Triton X-100, and 0.2% BSA) and Streptavidin conjugated beads were added to 
the remaining supernatant, and this was incubated at 4°C for one hour.  Samples 
were again washed as described above and 2X SDS loading buffer was added 
following the washes.  Samples were boiled for 15 minutes and run on a 10% SDS-
PAGE gel. Gels were dried and exposed on a phosphoscreen for two to four days, 
then visualized using a Typhoon Imaging System (GE Healthcare).  Bands were 
quantified using band densitometry using the ImageQuant software (GE 
Healthcare).   
Time Course Immunoprecipitation 
Two μg of wt or mutant S was transfected into Vero or A549 cells using the 
Lipofectamine 3000 system (Invitrogen; ratios described above).  Eighteen to 
twenty-four hours post transfection, cells were starved in Cys-/Met- media (Gibco) 
for 45 minutes, and metabolically label for one hour using 50μCi of S35 Cys/Met.  
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After the one-hour label, cells were washed once with PBS and normal DMEM + 
10% FBS was added for indicated times.  Cells were then lysed in 500μl of RIPA 
lysis buffer.  Anti-SARS S polyclonal antibodies were used to immunoprecipitate 
the CoV-2 S protein as previously described and the protein was analyzed on a 
10% SDS-PAGE gel.  Gels were dried and exposed on a phosphoscreen for 2-4 
days and visualized using a Typhoon Imaging System (GE Healthcare).  Bands 
were quantified using band densitometry using the ImageQuant software (GE 
Healthcare).   
Non-reducing Gel Electrophoresis 
Two μg of wild-type or mutant S was transfected into Vero or A549 cells 
using the Lipofectamine 3000 system (Invitrogen; ratios described above).  
Eighteen to twenty-four hours post transfection, cells were starved in Cys-/Met- 
media (Gibco) for 45 minutes, and metabolically labeled for six hours using 50μCi 
of S35 Cys/Met.  Lysed cells were immunoprecipitated as described above, 
however after the washing steps, 30μl of 2X SDS loading buffer without 
dithiothreitol (DTT) was added to each sample.  Samples were treated at 50°C or 
100°C, as indicated, for 20 minutes and analyzed on a 3.5% acrylamide gel under 
non-reducing conditions.  The gel was dried, exposed, and imaged as described 
for surface biotinylation.    
Immunofluorescence experiments 
Sub-confluent cells on coverslips in 6 well plates were transfected with 2μg 
of DNA using the Lipofectamine 3000 transfection system (Invitrogen).  Eighteen 
to twenty-four hours post transfection cells were fixed with 4% PFA for 15 minutes 
at room temperature.  Cells were permeabilized in a solution of 1% Triton X-100 in 
PBS+0.02% Sodium Azide (PBSN) for 15 minutes at 4°C.  After permeabilization, 
coverslips were moved to a humidity chamber and blocked with 1% normal goat 
serum (NGS) in PBSN for 1 hour at 4°C.  Cells were labeled with anti-SARS S 
antibody (1:2000 dilution) in blocking buffer overnight at 4°C or for three to five 
hours at room temperature.  Samples were washed with PBSN+0.01% Tween-20 
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seven times and incubated for 1 hour at 4°C with goat anti-rabbit FITC (1:2000 
dilution).  Samples were again washed with PBSN+0.01% Tween seven times and 
mounted onto slides using Vectashield mounting media (Vector Laboratories). 
Slides were imaged on an Axiovert 200M (Zeiss) at 63x magnification using 
Metamorph to collect Z-stacks and processed using Nikon NIS Elements.   
Statistical analysis 
Statistical analysis was performed using Prism 7 for Windows (GraphPad).  
A p value of <0.05 was considered statistically significant.  Multiple comparison 
tests were generated using one-way or two-way analysis of variance (ANOVA) 
with Dunnett’s multiple comparison test.  *: p<0.05, **: p<0.01, ***: p<0.0005, ****: 
p<0.0001 
RSV Fusion Protein Project 
 
Cell lines  
Vero cells, LLC-MK2 cells, and BSR-T7/5 cells were maintained in 
Dulbecco’s modified Eagle’s media (DMEM; Invitrogen) supplemented with 10% 
fetal bovine serum (FBS; Sigma).  BSR T7/5 cells were selected for the expression 
of the T7 polymerase by the addition of G418 sulfate (Gibco/Invitrogen) every third 
passage to the DMEM.   HEp-2 cells (a gift from AstraZeneca) were maintained in 
Opti-MEM (Invitrogen) supplemented with 2% FBS.  All cells were grown at 37°C 
and 5% CO2. 
Plasmids, Viruses, and Antibodies 
pVAX plasmids containing RSV F A2 and B9320 were generously provided 
by Dr. Hong Jin (AstraZeneca). A MP340 plasmid contained RSV F from the D53 
strain was provided by Dr. Mark Peeples (Nationwide Children’s Hospital, 
Columbus, OH) [241]. Mutagenesis was completed in the pVAX vectors using the 
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QuikChange sit directed mutagenesis kit with primers purchased from Eurofins.  
Palivizumab (a gift from AstraZeneca), a mAb to RSV F, was used to pull down 
RSV F (2 μl at a concentration of 1μg/μl).  Recombinant green fluorescent protein 
expressing human respiratory syncytial virus A2 (rgRSV) long, RSV A Clinical, and 
RSV F B clinical strains were used at MOIs indicated (gifts from 
Medimmune/AstraZeneca).   
Syncytia, Surface Biotinylation, and Immunofluorescence  
These assays were completed in the cell lines indicated as described for 
the SARS-CoV-2 and HeV Fusion projects.  
Time Course Immunoprecipitation 
RSV F protein into cells indicated using the Lipofectamine 3000 (Invitrogen) 
system, as previously described. The next day cells were washed with PBS and 
starved for 30 minutes at 37°C in cysteine-methionine-deficient DMEM. Cells were 
then labeled for 15 min with Trans[35S] metabolic label (50μCi/mL; MP 
Biomedicals). At indicated time points, cells were washed three times with PBS 
and lysed with RIPA lysis buffer. Immunoprecipitation with the anti-RSV F 
antibody, Palivizumab (2 μl at a concentration of 1μg/μl, then protein A-Sepharose 
beads and analysis was performed as described for surface biotinylation.  
Luciferase Reporter Gene Assay  
Veros overlaid on BSR/T7  
BSR/T7 cells in 12-well plates were transiently transfected with 1μg pVAX-
RSV F. Vero cells in 6-well plates were transiently transfected with 0.8μg of a T7 
promoted Luciferase plasmid and 1.2μg of empty vector. Transfections were 
performed using Lipofectamine and Plus reagent (Invitrogen) according to the 
manufacturer’s protocol. At 18-24 h post transfection, Vero cells were lifted with 
100μl of trypsin/well, resuspended in DMEM supplemented with 10% FBS were 
overlain on to BSR/T7 that were washed once with PBS. These were incubated 
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for 9-24 h (as indicated) at 37C. Then, cells were lysed with reporter lysis buffer 
(Promega) and analyzed for Luciferase activity using the luciferase assay system 
(Promega) per manufacturer’s instructions. A SpectraMax iD3 plate reader 
(Molecular Devices; Sunnyvale, CA) was used to read the luminescence. Results 
were normalized to cells expressing WT RSV F A2, after subtracting the 
background (EV only).     
 
BSR/T7 overlaid on Veros  
Vero cells in 12-well plates were transiently transfected with 0.4μg of a T7 
promoted Luciferase plasmid and 0.6μg of pVAX-RSV F. Transfections were 
performed using Lipofectamine and Plus reagent (Invitrogen) according to the 
manufacturer’s protocol. At 18-24 h post transfection, BSR T7/5cells were lifted 
with trypsin, resuspended in DMEM supplemented with 10% FBS were overlain on 
to Vero cells that were washed once with PBS. These were incubated for 9-24 h 
at 37C. Then, cells were lysed with reporter lysis buffer (Promega) and analyzed 
for Luciferase activity using the luciferase assay system (Promega) per 
manufacturer’s instructions. A SpectraMax iD3 plate reader (Molecular Devices; 
Sunnyvale, CA) was used to read the luminescence. Results were normalized to 




CHAPTER 3. USING THE PARAMYXOVIRUS FUSION PROTEIN 
TRANSMEMBRANE DOMAIN TO MODULATE FUSION PROTEIN 
STABILITY 
Portions of this chapter were adapted and reprinted with permissions from 
the American Society for Microbiology: Barrett CT, Webb SR, Dutch RE. 2019. 
A hydrophobic target: Using the paramyxovirus fusion protein transmembrane 
domain to modulate fusion protein stability. J. Virol. 93(17): e00863-19 
Copyright © American Society for Microbiology [Journal of Virology, 93(17), 
e000863-19, 10.1128/JVI.00863-19] 
**This work was completed in collaboration with Stacy Webb, who contributed 
intellectually to this work.  Stacy created the TM constructs and peptides, 
performed immunofluorescence, surface biotinylation, time course 
immunoprecipitation, syncytium assays, and PIV5 TM peptide infection 
experiments, as well as the respective figure generation.  I performed co-
immunoprecipitation experiments, luciferase reporter gene assays, transfection 
ratio experiments, high molecular weight detection assays, and respective figure 
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Introduction  
The importance of TM domains in protein oligomerization has been shown 
for several cellular proteins. For example, the amyloid precursor protein (APP) TM 
must dimerize for the generation of amyloid-β, which is linked to Alzheimer’s 
disease [222]. The TM domain of neuropilin-1 (NRP1), a co-receptor for vascular 
endothelial growth factor receptor 2, contains a GxxxG motif that is required for 
dimerization and ultimately downstream signaling [223]. It has been shown that 
targeting the NRP1 TM domain with synthetic peptides could inhibit glioma tumor 
growth in vivo [228]. Together, these studies exemplify the potential of targeting 
the transmembrane domain to disrupt protein function and/or trafficking, which 
could lead to potential therapeutic targets. Moreover, the importance of TM-TM 
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interactions in protein function is apparent from these studies. In the case of viral 
systems, replacement of the viral fusion protein TM domain with other fusion 
protein TM domains or lipid anchors has been shown to alter fusion protein function 
in examples including influenza, Newcastle disease virus, vesicular stomatitis 
virus, parainfluenza virus 5, and measles virus [79, 162, 242-245]. Additionally, 
mutation of motifs within the TM domain known to promote protein oligomerization, 
such as GxxxG motifs, affects fusion protein function. For example, mutation of the 
GxxxG motif of the Hendra virus fusion (F) protein TM domain resulted in a 
reduction of active fusion protein at the cell surface, possibly as a result of reduced 
protein stability or changes in protein trafficking [160, 165]. Mutation of the GxxxG 
motif of HIV gp41 also affected intracellular trafficking of the HIV Env protein [145, 
246].  
The life cycle of an enveloped virus requires fusion of the viral envelope 
with a target cell membrane. There are several points in the early stages of the 
paramyxovirus fusion process that can be targeted for disruption: the receptor 
binding step mediated by the attachment protein, the interaction between the 
attachment protein and fusion protein that facilitates triggering of F, and the overall 
refolding of the fusion protein necessary for membrane fusion [247]. Class I fusion 
proteins, including those of the Paramyxoviridae family, are folded as trimers [46] 
and it has been shown that the TM domain is important for proper protein folding 
and function [125, 145, 161, 162, 243, 245, 248]. To drive membrane fusion, the 
fusion protein must undergo dramatic conformational rearrangements from the 
meta-stable pre-fusion conformation to the post-fusion conformation. The 
triggering process of the fusion protein is an essentially irreversible process, so 
spatiotemporal control of the triggering and refolding events is crucial. While there 
is little sequence homology among class I fusion proteins, the steps critical for 
membrane fusion appear to be conserved [46]. 
Previously, we have shown that the HeV F protein TM domain associates 
in a monomer-trimer equilibrium in isolation and contributes to overall F protein 
stability. More specifically, we have shown that HeV F TM-TM association is 
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sequence specific, with a L/I zipper motif significantly contributing to the interaction 
[161, 165]. The HeV F protein is synthesized as a trimer with a domain structure 
composed of two heptad repeat domains (HRA and HRB), a highly hydrophobic 
fusion peptide (FP), a TM domain, and a cytoplasmic tail (CT) (Fig 3.1A) [7, 22]. 
Since the TM domain self-associates and has been shown to be important for F 
protein trafficking and function [173], we hypothesized that introduction of 
exogenous TM proteins homologous to the native F protein would competitively 
disrupt the TM-TM interactions in the native F protein, resulting in premature 
triggering or protein misfolding. To test this, exogenous constructs containing 
the Hendra F TM and limited flanking sequences were co-expressed with the full-
length F protein. We demonstrate that the homologous TM protein constructs 
interacted with F and reduced the expression and fusion activity of the full-length 
protein. Furthermore, we show that the effects seen upon co-expression of the TM 
proteins are sequence specific. Since HeV is a BSL-4 pathogen, parainfluenza 
virus 5 (PIV5), another paramyxovirus, was used to test whether F protein function 
could be disrupted in viral particles. A synthetic TM peptide homologous to the 
PIV5 F TM domain successfully inhibited viral infection in cells and the effect was 
specific, as treatment of human metapneumovirus (HMPV) with the PIV5 F TM 
peptide did not significantly affect infectivity. Together, these results emphasize 
the importance of the TM domain in fusion protein function and present fusion 
protein TM-TM interactions as a potential antiviral target.  
Results 
HeV F TM proteins interact with the full length HeV F 
To test whether addition of homologous TM domains affect F protein folding, 
trafficking or protein function, exogenous constructs containing the TM were 
designed based on the HeV F protein sequence. Three constructs were 
synthesized to contain a signal peptide, a variable-length linker, the full-length TM 
domain and C-tail, and an HA-tag (Fig 3.1A). A signal peptide was included to 
target the TM constructs to the endoplasmic reticulum during translation. The linker 
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represented varying lengths of the HRB domain upstream of the TM domain added 
to assist with protein solubility, as it was unclear how stable the only the TM domain 
would be by itself.  These different constructs will be designated as short linker 
(SL), long linker (LL), or HRB TM (HRB) (Fig 3.1A), throughout the remainder of 
the study.  The C-tail was included to maintain proper protein trafficking [151, 249], 
as well as for antibody detection and the HA-tag was added for antibody detection 
purposes.   During HeV F synthesis, the inactive form of the protein (F0) is trafficked 
through the ER to the plasma membrane, endocytosed, cleaved to its active form 
(F1) by cathepsin L, and trafficked back to the plasma membrane where it can 
ultimately promote membrane fusion. To determine if the signal peptide directed 
the TM proteins to the secretory pathway, immunofluorescence was performed to 
determine the co-expression of HeV F with each of the TM constructs. Wild type 
HeV F (green) and each of the TM proteins (red) co-localized in similar regions 
throughout the cell (Fig 3.1B). A strong signal appeared near the nucleus at the 
expected location of the ER, which was to be expected with the addition of the 
signal peptide on the TM proteins. These constructs were then co-expressed with 
the full length HeV F protein in Vero cells at a DNA transfection ratio of 2:1 (F:TM). 
Cells were radiolabeled for 30 minutes and chased for 1.5 hrs, then a pull down 
with an anti-HA antibody was used to examine if the full length HeV F protein would 
co-immunoprecipitate with the HA-tagged TM proteins. As a control, a plasmid 
encoding an HA tagged HeV F was co-transfected with the mock control and then 
FHA was immunoprecipitated with the anti-HA antibody (Fig 3.1C). When the TM 
constructs were co-transfected with wt F, the uncleaved form, F0, was pulled down 
with the SL and LL TM constructs.  Interestingly, the HRB TM construct did not 
appear to pull down F.  These results demonstrated that the TM proteins co-
localize and that the SL and LL constructs interact with the full-length F protein. 
Exogenous TM proteins affect HeV F expression and protein stability 
To facilitate fusion the HeV F protein must be at the surface and in its 
cleaved, F1+F2, form. Previous work has shown that disruption of the HeV TM 
interactions significantly lowered the amount of F protein expressed at the cell 
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surface [161].  To determine whether the F protein was trafficked to the cell surface 
in the presence of the exogenous TM proteins, proteins were analyzed with a 
radiolabel surface biotinylation assay. When HeV F was co-expressed with an 
empty vector and cells were radiolabeled for 3 hours, the F protein was observed 
as two bands, F0 (uncleaved) and F1 (cleaved) in both total expression and the 
surface population. Upon co-expression of each of the TM constructs, total and 
surface expression of HeV F was reduced to 20-30% when compared to the HeV 
F expressed with empty vector (Fig 3.2A, B). Additional transfection ratios were 
tested using a radiolabel IP, but the 2:1 of HeV F:TM construct ratio resulted in the 
greatest change in F protein expression levels and was the transfection ratio used 
for the rest of the experiments, unless otherwise noted (Fig 3.2D). Though the 
presence of the exogenous TM constructs dramatically reduced the levels of HeV 
F detected in cells, a small population of cleaved, potentially fusogenically active 
F was detected at the surface. A pulse-chase experiment was performed to 
determine whether the TM proteins affected initial F protein synthesis or stability 
over time (Fig 3.2C). When co-expressed with mock vector at the early time points, 
F was detected in its uncleaved form, F0. By 8 h, the majority of F was present in 
the cleaved form ( F1+F2, only F1 visible on the gel), consistent with the previously 
reported time necessary for cathepsin L cleavage [150]. Co-expression of HeV F 
with the SL TM protein resulted in a dramatic decrease in expression starting at 
early time points. However, the overall expression of F was not affected at the 
earlier time points for LL or HRB TM protein co-expression, indicating that the 
presence of these proteins does not affect initial protein synthesis. The co-
expression of the LL TM protein instead affected the overall stability of HeV F over 
time, as shown by the reduced amount of either form of F detected at the 6h and 
8h time points. The HRB TM protein appeared to have a less dramatic effect, but 
still showed a reduced amount of either form of F at 8h, indicating that some protein 
destabilization may be occurring.  In the presence of each of the TM proteins at 
the earlier time points (0-2h), a band appeared between the F0 and F1 bands, which 
may be a degradation product or the result of a change in glycosylation. Co-
expression with any of the three TM proteins still allowed for some level of cleavage 
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(F1+F2, only F1 visible on the gel) by the 2hr time point, which is when the most 
cleaved product is detected for the mock co-expression. Differences in protein 
expression between Fig 2 panels A and C can be accounted for by differences in 
metabolic labeling and chase time; A represents a 3-hour label and no chase, while 
C represents a 30 min label and chase times are indicated. These findings suggest 
that the presence of the exogenous TM proteins, especially the LL and SL, 
destabilized the full-length F protein, but did not affect the ability of synthesized 
protein to be cleaved to its fusogenically active form.  
Since HeV F associates as a homo-trimer, an assay to detect higher 
molecular weight complexes was performed to determine if destabilization of the 
protein in the presence of exogenous TM proteins was due to a destabilization of 
F trimerization.  Cells transfected with F alone or F plus the TM constructs were 
radiolabeled for 45 minutes, and chase media was added for 30 minutes.  Cell 
lysates were then immunopreciptated with anti-HeV F antibody to the c-tail, heated 
at various temperatures to destabilize oligomeric interactions, as indicated, and 
separated on a gel under non-reducing conditions (Fig 3.2E).  When HeV F protein 
was expressed alone, a majority of the protein migrated as a monomer, however 
heat stable trimers and dimers are also detectable. These results are consistent 
with previous reports on other paramyxoviruses that have shown that uncleaved 
forms of the fusion protein can migrate as stable trimers even up to 100C [250].   
However, when any of the TM proteins are present, a large amount of the protein 
migrated in the monomeric form. These results suggest that the presence of the 
TM proteins may destabilize HeV F protein trimeric associations at early time 
points in protein synthesis.  Interestingly, this destabilization of protein 
oligomerization appears to occur even before protein expression levels are 
affected in the presence of the LL and HRB constructs (compare LL and HRB in 
3.2E to 1-2-hour time point in 3.2C). 
Exogenous TM proteins reduce HeV F fusion activity   
A syncytia fusion assay was used to determine whether the TM proteins 
affected F protein function. The F protein and its homotypic attachment protein, G, 
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were co-expressed in Vero cells with each of the TM constructs at a transfection 
ratio of 3:1:1 for G:F:TM. After 24hr, the cells were imaged to visualize syncytia 
formation. HeV F and G co-expressed with empty vector resulted in syncytia 
formation, as indicated by the white arrows. When the TM constructs were co-
expressed with HeV and G, syncytia formation was ablated (Fig 3.3A). The 
reduced overall expression levels of HeV F might explain a reduction in syncytia 
formation. However, a small population of fusogenically active HeV F was still 
detected in the surface population in the presence of the TM proteins (Fig 3.2A), 
so reduced levels of fusion activity, rather than a complete loss, would be 
expected. Previous work demonstrated that reduction of HeV F expression to 20-
30% of wild-type resulted in fusion levels at 30-40% of wild-type [251]. 
Interestingly, co-expression of the TM constructs reduced HeV F expression to 
these levels, but fusion activity was completely ablated. The lack of fusion seen 
may be the result of pre-mature triggering or misfolding of the fusion protein 
present at the plasma membrane. Alternatively, the presence of the TM proteins 
could prevent the fusion protein from being able to fully trigger or affect further 
conformational changes needed to drive fusion.    
 To further investigate the fusion activity of F in the presence of the TM 
constructs, a luciferase reporter gene assay was performed. HeV F, G, a luciferase 
plasmid under the control of a T7 promoter (labeled as T7-Luciferase in Fig 3.3B), 
and each of the TM constructs were co-expressed in Vero cells.  At 18-24 hours 
post transfection, BSR cells that constitutively express the T7 polymerase were 
overlaid onto the Vero cells at a ratio of 1:1 and allowed to incubate for 3 hours 
(Fig 3.3B, Experimental Condition #1). After 3 hours, cells were lysed, incubated 
with luciferin, and then the luminescence was measured as an output of the fusion.  
Relative luminescence compared to HeV F and G without the TM constructs 
indicated that fusion was significantly reduced with each construct (Fig 3.3C).  The 
presence of the SL and LL constructs reduced the fusion to background levels, 
suggesting again that the SL and LL constructs interfere with the fusion activity of 
HeV F beyond just reducing the protein surface expression.  Fusion in the 
presence of the HRB construct, however, reduced fusion to levels consistent with 
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that expected with the cleaved population of F present at cell surface (Fig 3.1B).  
However, when considering these results with the lack of syncytia formation (Fig 
3.3A) and the destabilization of protein oligomerization (Fig 3.2E) seen in the 
presence of the HRB construct, it may suggest that this construct is having an 
effect on F protein fusion pore expansion or other cellular rearrangements needed 
for syncytia formation.  
 Upon triggering, HeV F extends into a hairpin structure that inserts the 
fusion peptide into the target membrane. Since interactions between viral fusion 
protein TMs and the fusion peptide have previously been shown [252], a luciferase 
gene reporter assay was again employed to investigate the effect the exogenous 
TM peptides had when located in the target cell membrane (Fig 3.3B, Experimental 
Condition #2).  Relative luminescence compared to WT HeV demonstrated that 
when the SL and HRB TM proteins were present in the target cell membrane there 
was a 20-30% reduction in fusion (Fig 3.3D).  The LL TM protein did not produce 
a significant decrease in fusion. This reduction may be due to a disruption of proper 
refolding of HeV F or a destabilization of the fusion peptides caused by the 
exogenous TM proteins associating with the fusion peptide. Though an effect was 
seen under these conditions, it is apparent that the TM peptide effects are most 
significant when the peptides are co-expressed with HeV F.  
The effects of the exogenous TM proteins are sequence specific 
The previous results demonstrated that HeV F protein levels were reduced 
upon co-expression of homologous TM constructs. To determine whether the HeV 
F TM proteins were specifically targeting the HeV F protein, analogous 
experiments were performed with another class I fusion protein of the 
paramyxovirus family, parainfluenza virus 5 (PIV5) F. The predicted TM domain 
sequences of HeV F and PIV5 F exhibit approximately 40% homology, as 
calculated with the ExPASy SIM alignment tool (Fig 3.4A). Co-expression of the 
exogenous HeV F TM constructs with PIV5 F in Vero cells demonstrated no 
significant change in PIV5 F protein expression levels. The TM proteins also did 
not coIP the PIV5 F protein in its F0 or F1 form (Fig 3.4B, C). Immunofluorescence 
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of PIV5 F with the HeV F TM constructs was also performed. While, the HRB TM 
protein did not appear to co-localize with PIV5 F in immunofluorescence staining, 
the SL and LL TM proteins expressed in similar cellular compartments as PIV5 F 
(Fig 3.4E), and the PIV5 F protein was able to drive membrane fusion and promote 
syncytia formation in the presence of all three exogenous TM constructs, as 
indicated by white arrows (Fig 3.4D). Together, these data indicate that the TM 
constructs designed to target the HeV F TM domain do not produce the same 
effects on PIV5 F expression or fusion activity, suggesting that the effect is 
sequence specific.  
TM peptides reduced viral infection 
The results presented thus far utilized transient transfection experiments to 
test whether the TM domain can be targeted to affect fusion protein expression 
and function. To determine if the F protein TM domain could be targeted in the 
context of a viral particle, an infection assay was performed. As Hendra virus is a 
BSL-4 pathogen, TM peptide effects were examined in two other closely related 
enveloped viruses, PIV5 and human metapneumovirus (HMPV), which both utilize 
class I fusion proteins to mediate membrane fusion. The predicted TM domains for 
these two viruses, however, only exhibit approximately 26% sequence homology. 
Recombinant viruses contained a GFP gene for either virus to allow for 
visualization of infection.  A peptide was designed based on the sequence of the 
PIV5 F TM domain, not including the C-tail or HRB domain, and the highly 
hydrophobic peptide was resuspended in DMSO.  HMPV or PIV5 virus was 
incubated with varying concentrations of peptide for 30 min and then added to Vero 
cells to allow for infection (MOI=1 pfu/cell). After 24 hr, the cells were imaged and 
prepared for flow cytometry to count GFP expressing cells (Fig 3.5A). When the 
viruses were mock treated with DMSO (0 μM peptide), the infection for both was 
widespread. Treatment with TM peptide reduced the number of GFP expressing 
cells for PIV5 (Fig 3.5B). Addition of 10μM of peptide resulted in approximately 
75% reduction in PIV5 infection, as determined by flow cytometry (p<0.0001 
Student’s t-test). The HMPV samples treated with peptide did not exhibit a 
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significant reduction in GFP expressing cells, suggesting that the effect of the TM 
peptide utilized was specific to PIV5 F. Together, these results demonstrate that 
the TM domain can be targeted to disrupt F protein function and viral infection in a 
sequence specific manner.    
Discussion  
Viral fusion proteins drive the fusion of viral and cellular membranes, a key 
early step in the entry of enveloped viruses. We have previously shown that the 
TM domains of several paramyxovirus fusion proteins associate in isolation and 
that disruption of TM-TM association by mutagenesis of a key L/I zipper motif 
resulted in a HeV F protein that triggered prematurely [160, 161]. Based on these 
previous studies, we examined the ability of paramyxovirus TM-TM interactions to 
be targeted with exogenous proteins containing the TM domain to cause a 
disruption in overall protein structure and function (Fig 3.6).  With the creation of 
three constructs containing the HeV F TM domain, we confirmed that co-
expression of the native HeV F protein with any of the three constructs resulted in 
a reduction of HeV F protein expression (Fig 3.2A), protein stability (Fig 3.2C), and 
a disruption of the trimeric interactions of HeV F (Fig 3.2E).  Interestingly, the 
successful cleavage and presence of HeV F on the cell surface (Fig 3.2A), as well 
as the cleavage patterns seen in the pulse chase experiment (Fig 3.2C) suggests 
that the exogenous TM containing proteins were not altering proper trafficking of 
the F protein that successfully exited the ER.  Additionally, examination of protein 
stability and oligomerization suggests that either the destabilization of trimeric 
interactions and/or premature triggering could cause early protein degradation, as 
it has been previously shown that prematurely triggered protein is quickly degraded 
[253].   
The fusion process by which paramyxoviruses enter cells involves a series 
of steps including: attachment protein mediated receptor binding, a triggering event 
of the fusion protein facilitated by the attachment protein, a dramatic, irreversible 
conformational change to merge the cellular and viral membranes to form a fusion 
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pore, and fusion pore expansion [10].  Not only were protein expression, stability, 
and stable oligomerization of native HeV F disrupted in the presence of the TM 
constructs, the co-expression of the TM constructs also dramatically reduced the 
fusion activity of HeV F (Fig 3.3).  The presence of the SL and LL constructs 
reduced fusion to background levels in both syncytia (Fig 3.3A) and reporter gene 
fusion assays (Fig 3.3C), suggesting the presence of these constructs may disrupt 
key steps in the membrane fusion process such as protein triggering or protein 
conformational changes.   Interestingly, the presence of the HRB construct 
appeared to completely abolish syncytia formation (Fig 3.3A) similar to the other 
constructs, however in reporter gene fusion experiments HeV F was still able to 
facilitate about 20-30% of fusion compared to WT levels (Fig 3.3C).  It has been 
previously shown that there is a correlation between cell surface expression and 
fusogenic activity [251], while the reporter gene results in the presence of HRB 
construct would fit with that correlation, the lack of syncytia formation would not. 
This discrepancy may be due to the presence of HRB constructs disrupting late 
stages of fusion, such as the fusion pore expansion or further cellular 
rearrangements, as reporter gene fusion assays only require fusion pore opening 
and expansion, while syncytia formation requires additional dramatic cellular 
rearrangements. A previous study has shown that several enveloped viruses 
demonstrated luciferase fusion activity, while not showing syncytia formation [254], 
suggesting that downstream cellular rearrangements may be blocked even when 
fusion pore formation and expansion has occurred.  Additionally, the reporter gene 
assay results with the exogenous TM constructs inserted into the target membrane 
(Fig 3.3, Experimental Condition #2), provided evidence that the nature of TM 
construct disruption was not simply due to global membrane alterations.  
Interestingly, there was a small, but significant decrease seen with the addition of 
the SL and HRB constructs in the target membrane (Fig 3.3D).  Since it has been 
previously shown that the TM domain and fusion peptide of HeV F interact [252], 
the presence of these constructs may be interfering with the ability of the fusion 
peptide to induce membrane disorder needed for cell-cell fusion.  Alternatively, the 
HRB construct may be interfering with the formation of the six helix bundle 
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formation, a critical step in paramyxovirus membrane fusion [7], as it has been 
shown for the viral family that peptides mimicking the HRB region can interact with 
the HRA in the hairpin intermediate to block viral fusion [255].   
 While the presented experiments in this paper support a model where 
disruptions to TM domain interactions cause lower proteins expression and 
function, the created constructs do contain other portions of the F protein (various 
lengths of the HRB, c-tail, signal peptides, and an HA tag).  Based on the cellular 
experiments completed (Fig 3.2 and 3.3), more dramatic reductions in protein 
expression and fusion activity correlated with presence of shorter lengths of the 
HRB region (SL construct elicited the largest effect, then the LL construct).  This 
suggests that these effects are not due to the HRB region.  While the cellular 
experiments cannot rule out the possibility that the HA tag, c-tail, or signal peptides 
present are not causing the examined effects, the peptides tested in the PIV5 
infection system (Fig 3.5) contained only the TM domain and still promoted a 
reduction in viral infection.  This demonstrates that the exogenous TM domain 
alone can create effects similar to those seen in the cellular experiments. In 
addition to recent work completed in suppression of hyperactive immune cells 
[225], inhibition or suppression of tumor growth in several cancers [226, 229, 230], 
and inhibition of oncogenic activation induced by Epstein Barr Virus [231], these 
experiments further support that effects seen are specific to destabilizing TM 
interactions.   
The effects on protein stabilization and fusion activity in the presence of the 
HRB construct were less dramatic than when the SL or LL construct was present.  
We have previously shown that including the full length HRB destabilizes HeV F 
TM-TM interactions [165], supporting the idea that the lower effectiveness of these 
constructs could be due to the full length HRB creating weakened TM interactions 
between the exogenous construct and the TM of the native F protein.  This may 
impair the ability of the HRB construct to interact with the native F protein, as 
shown by the failure to coIP (Fig 3.1C). Alternatively, the full length HRB on the 
exogenous TM construct could interact with HRA of the native protein [255], 
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reducing the ability to associate with the native F protein TM, or the HRB on the 
exogenous TM construct could be self-trimerizing, causing the exogenous TM 
proteins to traffic as a trimeric unit. In the infection assay which served as a proof 
of concept tool, a peptide containing only the TM domain could specifically affect 
viral infection.  Our cellular experiments presented here demonstrate that small 
portions of the protein ectodomain (HRB region) can be added without significantly 
effecting the reduction of viral protein mediated fusion. The inclusion of these small 
portions of this region may help with the peptide solubility of the highly hydrophobic 
TM peptides.   
F proteins of paramyxoviruses, and other enveloped viruses have specific 
sequence requirements for their TM domain, and simply substituting the TM 
domain of one paramyxovirus F protein into another related F protein can abolish 
membrane fusion of that F protein without effecting overall cell surface expression 
[162]. The specificity of the effect of exogenous TM protein was determined by co-
expressing PIV5 F with the HeV F TM containing proteins in cellular experiments, 
and co-expressing hMPV F with PIV5 F TM peptides in the infection system.  
Neither PIV5 F (Fig 3.4), nor hMPV F (Fig 3.5) demonstrated a significant effect 
on expression or function in the presence of a non-homologous exogenous TM 
construct or peptide. Interestingly, these PIV5 F and hMPV F proteins are 
predicted to have a heptad repeat leucine/isoleucine zipper motif in the TM domain 
similar to HeV F [161], so while this is an important oligomerization motif in TM-TM 
interactions for these proteins, there appears to be sequence specific requirements 
for these interactions happening beyond this motif.  These findings support the 
premise that the TM-TM interactions are sequence specific interactions and not 
simply the result of proximity to certain interaction motifs or hydrophobicity.  
The results from the PIV5 infection system, taken with the results from the 
HeV F cellular experiments highlight the critical nature of fusion protein TM-TM 
interactions for maintenance of viral infectivity, and demonstrate a potential for 
small molecule inhibitors that disrupt TM-TM interactions or modulators of lipid 
environment to serve as antiviral candidates. A study with paramyxoviruses found 
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that a broad-spectrum small molecule drug (JL103) could prevent membrane 
fusion by altering lipid architecture [256]. Changes in lipid environment caused by 
small molecule inhibitors may be able to alter fusion protein TM-TM interactions 
and, therefore, disrupt fusion protein function.  A recent study with Epstein-Barr 
virus showed that a small molecule targeting the TM domain could disrupt homo-
trimerization of the latent membrane protein-1, a step that is critical for oncogenic 
activation of the virus [231].  Other studies have shown that targeting antiviral 
peptides to the cell membrane with cholesterol enhanced efficacy [227]. The 
inclusion of some portion of the TM domain may be able to further enhance 
specificity in addition to physically anchoring the peptide.  Beyond viral proteins, 
the concept of disrupting TM-TM interactions may prove to be a viable therapeutic 
option. The tyrosine kinase receptor, ErbB2, was found to be overexpressed in 
high-grade inflammatory breast cancer. ErbB2 requires dimerization in order to 
trigger downstream signaling cascades that include the MAPK pathway. TM 
peptides that disrupt ErbB2 TM dimerization were found to reduce tumor cell 
growth and metastasis [224]. Other studies have demonstrated the potential use 
of small molecules that disrupt TM domain oligomerization to suppress tumor 
growth in glioma and metastasis by targeting the TM of Plexin-A1 [229], and inhibit 
tumor growth in melanoma by TM interactions in p75NTR [230]. The results 
presented may further help in development or improvement of antivirals and other 
TM targeting therapeutics.  More importantly, our results show the important role 
of TM-TM interactions in the stability of the viral fusion protein on a global level. 
Utilizing TM-TM interactions to disrupt fusion protein function may also extend 
beyond paramyxoviruses, as we have recently shown that TM-TM interactions 
occur for fusion proteins of the corona-, rhabdo-, orthomyxo-, and filoviridae 
families [184]. These studies further broaden our understanding of the hydrophobic 
TM domain, and demonstrate their functional role beyond serving as a hydrophobic 






Figure 3-1 HeV F TM constructs co-localize and interact with WT HeV F.   
A) The domain structure of the HeV F protein containing a fusion peptide (FP), two 
heptad repeat regions (HRA and HRB), a transmembrane domain (TM), and a C-
tail (CT).  General schematic of TM protein design is shown with amino acid sites 
indicated.  Each construct includes a signal peptide, the full TM and CT, an HA 
tag, and a linker region that has varying lengths of the HRB domain.  B) 
Immunofluorescence of co-expression of HeV F (green) and each of the TM 
constructs (red).  The inset shows a 4x zoom of the white box. C) Co-
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immunoprecipitation of HeV F with the TM constructs. Cells were starved for 45 
min, radiolabeled for 30 min, and chased for 1.5 hr prior to lysis and pulldown with 















Figure 3-2 Co-expression of HeV F with the TM proteins reduces expression, 
protein stability, and stable oligomerization  
A) Surface biotinylation was used to analyze the total and surface populations of 
HeV F when co-transfected with mock empty vector or each of the TM constructs.  
Proteins were radiolabeled for 3 hrs.  B) Relative HeV F protein expression was 
quantified using band densitometry (ImageQuant); experiments were performed in 
triplicate with the standard deviation shown.   C) Pulse-chase radiolabel IP was 
used to determine the effect the TM constructs had on WT HeV F over time.  
Proteins were radiolabeled for 30 min with indicated chase times noted above each 
panel in hours.  D) Various transfection ratios of the HeV F:TM constructs were 
tested in a radiolabel IP using the SL construct.  E)  The effect of exogenous TM 
constructs co-expression on HeV F protein oligomerization was analyzed by non-




Figure 3-3 Co-expression of HeV F with the TM proteins reduces fusion 
activity.  
A) To determine the fusion activity of HeV F in the presence of the TM constructs, 
cells were imaged for the presence of syncytia (indicated by the white arrows) at 
24 hr after transfection of HeV F with each of the TM constructs. B) Schematic of 
the reporter gene fusion assay experimental set up, showing experimental 
condition #1 with the TM constructs in the same cells as HeV F and G and 
experimental condition #2, in which the TM constructs are in the target (BSR/T7) 
cells.  Results from the luciferase reporter gene assay for condition #1 (C) and 
condition #2 (D). Results are representative of three independent experiments, 
with each performed in duplicate. Significance was determined by a student t-test, 








Figure 3-4 PIV5 F expression and fusion activity is not affected by HeV F TM 
proteins  
A) TM sequences of HeV and PIV5 F, predicted with TMHMM Server v2.0.  B) 
PIV5 F expression was determined when co-expressed with each of the HeV TM 
proteins by radiolabeled immunoprecipitation with pull down by anti-PIV5 F or anti-
HA.  Protein expression levels were determined by band density (C) Experiments 
were performed in triplicate.  D) Syncytium formation assay revealed that co-
expression TM constructs did not inhibit PIV5 F fusion activity.  Syncytia indicated 
by white arrows.  E) Immunofluorescence analysis of the co-expression of PIV5 F 







Figure 3-5 PIV5 F TM peptide inhibits PIV5 infection selectively.  
A. GFP expressing PIV5 or HMPV was incubated with TM peptide designed to 
target the PIV5 F TM domain, then cells were infected with treated virus. GFP cells 
were imaged 24hr later and counted for quantification via flow cytometry (B). 
Experiments were performed in triplicate. A student’s t-test was used to determine 






Figure 3-6 Model for TM peptide interaction with fusion protein.  
The introduction of homologous TM protein may cause the fusion protein to misfold 
or prematurely trigger, as a result of the exogenous TM protein interacting with the 











CHAPTER 4. THE N-TERMINAL RESIDUES OF THE HENDRA F 
TRANSMEMBRANE DOMAIN 
*This work completed was completed in collaboration with Hadley Neal, Dr. Juana 
Reyes-Zamora, and Kearstin Edmonds.  Hadley, Juana, Kearstin, and I all 
completed independent replicates of syncytia assays and reporter gene assays 
(Fig. 4.4a and 4.4b). Hadley, Kearstin, and I completed independent replicates of 
the surface biotinylation assay and pulse chase experiments (Fig. 4.1b/c/d and Fig. 
4.3b/c/d).  Fluorescent images were taken by me and processed by Dr. Carole 
Moncman (Fig. 4.2). All other experiments, as well as figure generation was 
completed by me.   
Introduction:  
Hendra virus (HeV) is a zoonotic, enveloped virus within the viral family 
Paramyxoviridae. HeV, similar to all enveloped viruses, uses surface glycoproteins 
to promote binding to a host cell and fusion with host cell membranes to facilitate 
viral entry [11, 50, 54, 257, 258].  In HeV, these proteins are termed the attachment 
protein (G), responsible for binding the host cell, and the fusion protein (F), 
responsible for merging the viral and host cell membranes. F is a trimeric 
transmembrane protein [259]. Following proteolytic cleavage, receptor binding, 
and receipt of a triggering signal, HeV F undergoes a large, dynamic 
conformational change enabling the viral and host cell membranes to merge [11, 
50, 258, 259]. In order to be cleaved by cellular cathepsins, HeV, and the closely 
related Nipah virus, F proteins undergo a unique trafficking pattern. They are 
initially synthesized, trafficked through the secretory pathway to the cellular 
surface, then are endocytosed to be cleaved by cathepsin L in recycling 
endosomes before being trafficked back to the cell surface [150, 151, 172, 173, 
260]. Throughout this trafficking, the F protein remains associated as a trimer [50, 
54, 69, 160]. Interactions within the transmembrane (TM) regions of F trimers have 
been implicated in protein stability and fusion function [160, 164, 165, 173, 261]. 
Additionally, residues S490 and Y498, have been demonstrated to be involved in 
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the endocytosis of F [173]. Previously alanine scanning mutagenesis of the C-
terminal end of the HeV F TM region has been performed [165], however this has 
not been completed for the N-terminal end of the TM region.  
Here we performed double-alanine scanning mutagenesis of the first 20 
amino acids of the TM region of HeV F and assessed the effect on protein stability, 
expression, proteolytic processing, and fusion.  Mutants altering residues S490 
and Y498 show defects in protein cleavage, surface expression and fusion, 
consistent with previous work showing these residues are important in protein 
endocytosis [173].  Additionally, a mutant altering S493 had lower protein surface 
expression, slightly lower cleavage, and significantly reduced fusion, again 
consistent with previous work [160].  Interestingly, we found that the alanine 
mutation of residues M491 and L492 significantly reduced fusion without altering 
protein expression, newly implicating these residues in the fusion process.  
Additionally, we demonstrate that alanine mutation of the remaining residues does 
not have an effect on protein expression, stability or fusion function. The work 
presented here, when considered with previously published work [160, 165, 172, 
173, 261], provides a comprehensive analysis of the entire HeV F TM region and 
identifies the critical residues within it.   
Results 
To assess the potential role of residues at the N-terminus of the HeV F 
protein TM region, double alanine scanning mutants were created (Fig. 4.1a).  
Surface biotinylation was then performed to determine the surface and total protein 
population of transiently transfected wild-type (WT) HeV F or mutant F (Fig. 4.1b). 
WT HeV F and most TM mutants were detected after immunoprecipitation as two 
bands, corresponding to F0 (un-cleaved F) and F1 (cleaved F) (Fig. 4.1b).  Using 
band densitometry, percent expression (Fig. 4.1d) and percent cleavage (Fig. 4.1c) 
were calculated for both surface and total protein populations and normalized to 
WT HeV F.  Mutants IS, SM, and LY all showed reduced surface expression 
compared to WT F.  SM also demonstrated lower total protein expression.  
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Additionally, mutants IS, SM, and LY all had a significant reduction in protein 
cleavage in both surface and protein populations.  Interestingly, the ML mutant had 
a slight, but significant reduction in cleavage in the surface protein population, 
while showing no cleavage differences in the total protein or overall protein 
expression. This suggests, consistent with previous studies, that mutant IS, SM, 
and LY have defects in the endocytosis process needed for proteolytic processing.  
When WT or mutant F protein expression was assessed using 
immunofluorescence, mutants IS, SM, LY, SI, and VL appear to have more 
staining near the nucleus, though at least some staining is observed throughout 
the cell in all samples (Fig. 4.2).  
Pulse-chase analysis was utilized to examine WT F or mutant protein 
cleavage kinetics and protein stability (Fig. 4.3a). Most TM mutants displayed no 
change in protein cleavage compared to WT F, however two showed lower 
cleavage at later chase time points (Fig. 4.3b).  At four and eight hours of chase, 
the SM mutant demonstrated a significant reduction in cleavage compared to WT 
F (p<0.01 at four hours and p<0.0001 at eight hours).  Additionally, the LY mutant 
exhibited a reduction in cleavage at eight hours of chase (p<0.01). Despite these 
two differences in cleavage, all TM mutants had similar protein turnover kinetics 
compared to WT F, with protein remaining stably expressed through 2 hours of 
chase.  After four and eight hours of chase, only about 40-50% of protein remains, 
and only about 10-15% remains after twenty-four hours (Fig. 4.3b).  This suggests 
that even mutations that alter F protein cleavage do not disrupt protein stability.   
HeV F associates as a trimer shortly after synthesis and remains in a 
trimeric association throughout protein trafficking and fusion. To assess the effect 
the TM mutations had on trimer stability WT HeV F or each mutant was transiently 
expressed and metabolically labeled. Following cell lysis, and 
immunoprecipitation, samples were treated at 60°C or 100°C prior to separation 
on non-reducing SDS-PAGE.  After either treatment temperature, WT HeV F 
migrated primarily as a monomer, although some dimer and trimer species were 
observed (Fig. 4.3d). Similar migration patterns were observed for each of the TM 
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mutants, suggesting that the introduced mutations were still able to form oligomeric 
species of the protein.  
To understand how the mutations created effected the overall fusion 
function of HeV F syncytia formation analysis and a luciferase reporter gene fusion 
assay were performed.  For the syncytia assay, WT HeV F or the TM mutants were 
transiently co-expressed with HeV G and imaged at 48 hours (Fig. 4.4a).  The 
formation of large syncytia was observed in WT samples, as well as mutants SL, 
II, VL, SI, and LC.  Very few syncytia were observed in samples IS and ML, and 
no syncytia were found in samples with mutant SM or LY (Fig. 4.4a). To quantitate 
fusion, a luciferase reporter gene assay was employed by transiently co-
expressing WT HeV F or each TM mutant with HeV G in Vero cells, and overlaying 
them with BSR/T7 cells. All samples were normalized to samples expressing WT 
HeV F and G.  Similar to the syncytia results, samples SL, II, VL, SI, and LC 
demonstrated fusion levels similar to WT (Fig. 4.4b).  Samples SM and LY did not 
exhibit any fusion about background levels (p<0.0001), and mutants IS and ML 
exhibited significantly reduced fusion levels (20% [p<0.01] and 50% [p<0.05], 
respectively) compared to WT.  The reduction in cleavage observed for mutants 
IS, SM, and LY is consistent with the significantly reduced protein expression and 
cleavage observed for these mutations (Fig. 4.1c and 4.1d).  However, the slight 
reduction in cleavage observed for the surface population of ML is not enough to 
account for the 50% reduction in fusion since previous work has shown that the 
amount of cleaved protein at the cell surface directly correlates to the amount of 
fusion [251]. 
Discussion 
The role of several residues within the N-terminus of the TM of HeV F have 
previously been explored.   Residues L488 (mutant SL), I495 (mutant II), and I502 
(mutant SI) were determined to be part of a Leucine-Isoleucine zipper (LI Zipper) 
motif that ran through the TM region [261].  Single mutations of each of these 
residues resulted in only minor protein expression, cleavage, and fusion activity 
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change [261] consistent with our study.  However, mutation of the entire LI zipper 
resulted in a significantly destabilized the pre-fusion conformation protein, thus 
abolishing the fusion activity of the protein [261].  Interestingly, including the 
neighboring residues (S, I, S) with mutations to the LI Zipper had no appreciable 
effect on protein expression, stability, or fusion function suggesting that these 
serine residues and isoleucine residue are dispensable for HeV F function (Fig. 
4.1, 4.3, 4.4).  Residues S490 (mutant IS) and Y498 (mutant LY) were 
demonstrated to play a role in protein endocytosis and subsequent recycling, with 
the hydroxyl group and aromatic nature being critical in each residue, respectively 
[173].  Efficient endocytosis and recycling of the HeV F protein was also shown to 
be critical for proper virus-like particle assembly, as endosomes are the likely 
location of HeV F association with HeV matrix protein during particle assembly 
[172]. Remarkably, inclusion of the neighboring residues methionine and leucine 
seemed to allow for slightly more protein cleavage and slightly enhanced stability 
compared to previous work on the single point mutations [173].  This suggest that 
mutation of the two neighboring residues may have compensatory effect, 
potentially restoring some of the protein endocytic recycling.  Residue S493 
(mutant SM) has been demonstrated to have slightly reduced cell surface 
expression and fusion levels reduced by about 80% in a previous study [160].  
Interestingly, when we included the neighboring methionine residue in the 
mutation, cell surface expression was further reduced and fusion activity was 
abolished, indicating a compounding effect when both the S and M are mutated.  
This may indicate both of these residues play critical roles in fusion, protein 
conformation, and stability.   
Residues M492 and L493 (mutant ML) had not previously been explored in 
the context of HeV F.  Residue M492 is predicted to lie on the contact interface 
between the protomers in the trimeric protein [173], suggesting it may have a role 
in TM-TM associations of this protein.  While this mutant is still able to form protein 
oligomers (Fig. 4.3d), it does exhibit a significant reduction in protein fusion (Fig. 
4.4b). The mutation of the large methionine and β-branched leucine residues to 
alanines may cause the protein trimer to pack together too tightly disrupting the 
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TM-TM dissociation needed to carry out fusion [164].  Alternatively, this mutation 
could increase the flexibility of the protein in this region, loosening TM-TM 
associations, causing the TM regions to dissociate too much during the fusion 
process, thus destabilizing protomer association during intermediate steps of 
fusion or these mutations disrupt interactions with the fusion peptides that are 
needed for fusion pore expansion.   
In addition to mutation of residues M492 and L493, this work also 
represents the first-time residues V499/L500 and L505/C506 were investigated.  
When the C-terminal end of the HeV F TM region was studied, mutations of β-
branched residues appeared to play a critical role.  Interestingly, both mutant VL 
and LC, which lie in the middle of the predicted HeV F TM and contain β-branched 
residues, demonstrate no change to protein expression or fusion activity indicating 
these residues are not critical. This suggests that these residues play a larger role 
in the C-terminus of the HeV F TM, potentially contributing to an increase in 
flexibility needed by that end [165]. This work, when partnered with previous 
studies [160, 165, 172, 173, 261], completes characterization of the entire HeV F 
TM region.  While this work has investigated HeV F protein stability, expression, 
and cell-cell fusion function, understanding the interactions of HeV F TM residues 
with viral proteins other than HeV G, or host proteins and membrane lipids remains 












Figure 4-1 Several HeV F TM mutants have impaired protein expression and 
protein cleavage 
(a) Alanine scanning mutations at the N-terminus of the HeV F TM were generated 
to assess the importance of these residues.  (b) Surface biotinylation was 
performed to analyze the surface and total population of HeV F for WT and each 
of the mutants created.  Cells were radiolabeled for 3 hours. Using band 
densitometry, percent expression (c) and percent cleavage (d) was measured for 
the total and surface protein. All measurements represent the average of three 
independent experiments ± SD, and all samples for protein expression were 
normalized to WT. Significance was determined by two-way ANOVA * = p < 0.05, 









Figure 4-2 HeV F TM mutants have a similar distribution to WT F in 
immunofluorescence.  
Immunofluorescence of WT HeV F or each of the mutants created (Green is F, 
Blue is DAPI) transiently expressed in Vero cells.  Insets represent enlargements 






















Figure 4-3 HeV F TM mutations at residues SM and LY decrease protein 
cleavage levels.   
(a) Vero cells were transfected with WT HeV F or the TMD mutant DNA, 
metabolically labeled for one hour, and chased for times indicated (hours).  Using 
band densitometry (b) percent cleavage and (c) percent stability were calculated. 
Graphs are shown as the average of three independent experiments ± SEM. d) 
Vero cells transiently expressing WT F or each TM mutant were metabolically 
labeled for 6 hours. Samples were treated at the indicated temperatures before 
separation on a non-reducing SDS-PAGE. Oligomers are labeled on the right 









Figure 4-4 Mutations at residues IS, ML, SM, and LY in the HeV F TM reduce 
fusion.   
(a) Vero cells were transfected with the HeV attachment protein (G), and WT HeV 
F or one of the TMD mutants. Syncytia formation was analyzed at 48 hpt. Black 
arrows indicate syncytia formation. Images are representative of 4 independent 
experiments. (b) A luciferase reporter gene assay was performed using BSR/T7 
cells overlaid onto Vero cells transfected with HeV G and WT HeV F or each of the 
TMD mutants at 24 hpt. Results are normalized to samples with WT HeV F and G 
and representative of 3 independent experiments ± SD, performed in duplicate.  
Significance was determined by one-way ANOVA. *  = p < 0.05, ** = p < 0.01, *** 





CHAPTER 5. EFFECT OF MUTATIONS IN THE SARS-COV-2 SPIKE PROTEIN 
ON PROTEIN STABILITY, CLEAVAGE, AND CELL-CELL FUSION 
FUNCTION 
*This chapter is from the submitted manuscript: Barrett CT, Neal HE, Edmonds 
K, Moncman CL, Thompson R, Branttie JM, Boggs KB, Wu CY, Leung DW, Dutch 
RE. 2021. Effect of mutations in the SARS-CoV-2 spike protein on protein stability, 
cleavage, and cell-cell fusion function. Submitted to J. Biol. Chem January 2021.   
 
*This work was completed with the help of several individuals.  Hadley Neal, 
Rachel Thompson, and Dr. Cheng-Yu Wu generated all of the SARS-CoV-2 
mutants used.  Kearstin Edmonds, Hadley Neal, and I all performed the pulse 
chase and surface biotinylation experiments (Fig. 5.1, Fig. 5.3b-g, Fig 5.4b-e, Fig 
5.6).  Kearstin Edmonds and I completed all of the reporter gene assays (Fig. 5.2c-
e, Fig. 5.3h/i, Fig. 5.4f, Fig. 5.8b). Hadley Neal and I performed all of the syncytia 
assays (Fig. 5.2 a/b, Fig. 5.9).  All fluorescent images were taken and processed 
by Dr. Carole Moncman. Jean Branttie and I performed the western blotting (Fig. 
5.8c).  All other experiments, figure generation, and writing were completed by me.  
Introduction 
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the 
causative viral agent of the ongoing coronavirus disease of 2019 (COVID-19) 
global pandemic. Thus far, COVID-19 has impacted over 86 million people 
globally, resulting in the death of more than one and a half million individuals [262].  
Due to the widespread global impact of this pandemic, a concerted effort has been 
made to rapidly develop a vaccine or antiviral treatment.   
The SARS-CoV-2 spike (S) protein is the major transmembrane 
glycoprotein studding the surface of the viral particle, and is exclusively 
responsible for viral attachment and cell entry, thus making it the major target of 
current vaccine strategies and antiviral therapeutics [263]. The S protein consists 
 93 
 
of two distinct subunits: the S1 subunit, which binds to the known host receptor, 
angiotensin converting enzyme 2 (ACE2) [181, 264-271], and the S2 subunit that 
promotes the viral-to-host cell membrane fusion event needed for viral infection 
[50, 263, 269, 272-277].  Most known coronavirus (CoV) S proteins undergo two 
post-translational proteolytic cleavage events, one at the border of the S1 and S2 
subunits, and one downstream within the S2 subunit (termed S2’) [50, 263, 273, 
275-280].   
Similar to several other CoVs, SARS-CoV-2 likely utilizes bats as a reservoir 
species, specifically Rhinolophus affinis or horseshoe bats [37, 271, 281-283].  
SARS-CoV-2 has 96% sequence identity to a CoV found in this bat population, 
RaTG13, with limited differences between them [283].  One difference is the 
polybasic, PRRA, insertion at the S1/S2 border which gives this site the canonical 
sequence requirements for cleavage by the cellular proprotein convertase furin 
[178, 284-286].  This change may be a key factor in the zoonotic transmission of 
SARS-CoV-2. The presence of a furin consensus sequence at the cleavage site 
has been observed in other human infecting CoVs [178, 287-289], including highly 
pathogenic forms of influenza [290, 291] and previous studies have demonstrated 
its functional significance. For SARS-CoV-2, the insertion is suggested to allow for 
expanded cellular tropism and infectivity [178, 179, 273, 292].  For most CoVs, 
cleavage at a downstream S2’ site may be carried out by a number of cellular 
proteases, including serine proteases like transmembrane serine protease 2 
(TMPRSS2), or endopeptidases, including members of the cathepsin family [273, 
274, 278-280].  
Following receptor binding by the S1 subunit and priming by proteolytic 
cleavage, the S2 subunit of S promotes the critical membrane fusion step of viral 
entry by undergoing dynamic conformational changes to promote merging of the 
viral and host cell membranes [179, 181, 182].  For entry of SARS-CoV-2, 
cleavage at the S1/S2 border (by furin or a similar protease), is critical for 
TMPRSS2 cleavage and entry at the plasma membrane. However, when S1/S2 
border cleavage is blocked, viral entry can be mediated through endosomal 
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compartments with proteolytic cleavage carried out by a member of the cathepsin 
family, similar to the entry pathway of SARS-CoV [179, 181, 182, 293, 294]. In 
addition to promoting virus-cell fusion during viral particle entry, S can also 
promote cell-cell fusion, a pathogenic effect observed in the lungs of COVID-19 
patients where neighboring cells fuse together to form large multi-nucleated cells, 
termed syncytia [234-237, 295, 296].  While the role of cellular proteases and S 
cleavage in viral entry is being extensively investigated, insight into the cleavage 
requirements for cell-cell fusion in SARS-CoV-2 remains more limited. Recent 
studies have suggested that S cleavage at the S1/S2 border is critical for cell-cell 
fusion, and TMPRSS2, while not required, appears to enhance this cell-cell fusion 
[182, 234, 297, 298].  However, relatively little is known about the timing and 
efficiency of these cleavage events, and how mutations in S may affect the 
process.  
Though CoVs mutate at a slower rate than most RNA viruses due to the 
presence of viral proofreading machinery, a meta-analysis of genomes of SARS-
CoV-2 strains found several mutations within S circulating in significant 
percentages of the analyzed populations [299, 300].  The most common mutation, 
now found in most of the global population, is an aspartate to glycine mutation at 
residue 614 (D614G) in the S1 subunit.  Additional mutations throughout the S1 
and S2 subunits of S have been found in a smaller percentage of the viral 
population.  Since S2 contains the fusion machinery, mutations in this region may 
have an impact on overall protein stability and fusion. Understanding the effects of 
mutations in this region will allow for a more comprehensive understanding of the 
overall S function.   
We tested wild-type (wt) SARS-CoV-2 S and variants in different host cell 
strains to analyze the effects on stability, proteolytic processing, and cell-cell 
fusion. Here we demonstrate that furin cleavage of S at the S1/S2 border is 
required for efficient cell-cell fusion, and that the presence of TMPRSS2 in target 
cells enhances S mediated cell-cell fusion, consistent with previous studies [182, 
297]. We also show that mutations of the cleavage sites at the S1/S2 border, S2’ 
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site, or a cathepsin L (cath L) cleavage site, conserved from SARS-CoV S, all 
reduce initial cleavage at the S1/S2 border during viral protein synthesis, 
suggesting that mutations downstream of the S1/S2 border likely alter the overall 
conformation of the protein.  Additionally, we identify two S2 subunit residues, one 
in the internal fusion peptide and another in the cytoplasmic tail, that alter protein 
fusion function when mutated without changing overall protein expression and 
cleavage, providing more insight into regions of the protein important for the 
regulation of the fusion process. Finally, we demonstrate protein turnover and 
cleavage kinetics in a range of host cells, as well as in the presence of several 
exogenous proteases, providing a more comprehensive picture of the S protein.   
Results  
Stability and proteolytic cleavage of SARS-CoV-2 Spike in Various Cell Lines  
To examine the stability and cleavage patterns of SARS-CoV-2 S in a range 
of mammalian cell lines, the following cells were transiently transfected with 
pCAGGS-S: Vero, A549, MEFs, Cath L- MEFS, and LoVo cells (a human colon 
carcinoma line that does not express functional furin). Stability of S and the timing 
of proteolytic processing were determined by pulse-chase labeling and 
immunoprecipitation.  S protein detected from immunoprecipitation was observed 
as two bands, a band around 150 kDa corresponding to an un-cleaved full-length 
species of the protein, labeled S, and a band around 97 kDa corresponding to a 
species of S cleaved at the border of the S1 and S2 subunits, labeled S2 (Fig. 
5.1a).  After a one-hour chase, a band corresponding to S2 was observed in Vero, 
A549, and both MEF cell lines (Fig. 5.1a).  In LoVo cells, a band corresponding to 
the S2 subunit did not appear until four hours of chase, verifying that lack of furin 
impedes efficient processing at S1/S2, and that the S1/S2 border can be cleaved 
by cellular protease other than furin (Fig. 5.1a) in a slower and less efficient 
process. Veros, A549s, MEFs, and Cath L- MEFs displayed similar cleavage 
patterns over time, while LoVo cells displayed significantly less cleavage at two 
and four hours.  LoVo cells had only 2% cleavage at two hours and 18% cleavage 
 96 
 
at four hours, compared to about 20-40% at two hours and 30-60% at four hours 
for all other cell types (p<0.05).  However, LoVo cells reached cleavage levels 
similar to the other cell lines at later chase time points (Fig. 5.1b). Bands smaller 
than 90 kDa that would correspond to cleavage at the S2’ site were not observed 
in any cell line. In the examined cell lines, expressed S remained stable through 
the first four hours (Fig. 5.1c). By 24 hours post label, only 20-30% of the original 
labeled protein remained for all cell lines.   
Several studies have examined the cellular proteases involved in the 
cleavage of S. Furin and TMPRSS2 appear to play key roles in cleavage at the 
S1/S2 border and S2’ site, respectively [178-180, 301, 302]. Additionally, 
lysosomal proteases such as cath L/B can be utilized for viral entry in TMPRSS2 
deficient cells [181, 293, 297].  To examine how higher expression levels of these 
proteases affect S stability and cleavage, Vero and A549 cells were transiently 
transfected with S alone or S with TMPRSS2, furin, or cath L.  Pulse-chase 
analysis demonstrated that the transient expression of TMPRSS2 or cath L did not 
affect the cleavage pattern of S (Fig. 5.1d and 5.1e, 5.7b), and a band 
corresponding to S2’ cleavage was not observed in either Veros or A549s. 
However, transient over-expression of furin increased the cleavage observed at 
the S1/S2 border in Veros at four and eight hours of chase (p<0.05) and at all times 
after zero for A549s (p<0.01 for one- and eight-hour chase, p<0.0001 for two- and 
four-hour chase times) (Fig. 5.1e and 5.1f). This suggests that the normal levels of 
cellular furin can eventually promote maximal levels of S1/S2 cleavage in both 
Veros and A549s, but over-expression of furin facilitates more rapid cleavage of 
the S1/S2 border.  Interestingly, in both experiments (Fig. 5.1a and 1d) some un-
cleaved S remains even after 24 hours, indicating that a small portion of the S 
population is not cleaved by furin or other endogenous proteases in these cell 
lines.  Finally, overall protein stability was not affected by co-expression of any 
tested proteases (Fig. 5.7b).   
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Spike Mediated Cell-Cell Fusion  
The S2 subunit of S mediates both viral-cell fusion and cell-cell fusion [234, 
235, 237], with cell-cell fusion readily observed both in a laboratory setting and in 
the lungs of SARS-CoV-2 infected patients [234-237, 295, 296]. To better 
understand the requirements and contribution of cellular proteases to S2 mediated 
cell-cell fusion, we performed syncytia and reporter gene assays.  For syncytia 
analysis, a small number of syncytia, were observed at 24 hpt in all samples (Fig. 
5.2a).  At 48 hpt, similar numbers of large syncytia were observed with S alone or 
S co-expressed with TMPRSS2 or cath L (Fig. 5.2b).  However, co-expression of 
S with furin resulted in increased syncytia formation. The cells exhibited nearly 
complete fusion, suggesting that the presence of exogenous furin further increases 
S mediated cell-cell fusion (Fig. 5.2b, panel 3).   
To quantitate S mediated cell-cell fusion, luciferase reporter gene fusion 
assays were performed (Fig. 5.8a), using a nine hour overlay that was determined 
to be optimal (Fig. 5.8b). To characterize the role of cellular proteases in the 
hACE2 expressing target cells, S-expressing effector cells were overlaid with 
target cells containing hACE2 alone or hACE2 with TMPRSS2, furin, or cath L.  
The amount of plasmid transfected was kept constant by supplementing with a 
plasmid encoding an empty expression vector (EV). When Vero cells were used 
as the S-expressing effector cell and TMPRSS2 was present in the target cells, a 
significant increase in fusion was observed. This is consistent with the concept that 
TMPRSS2 plays a role in fusion after or during the hACE2 (receptor) binding step 
in the fusion cascade (Fig. 5.2c) [181, 182, 272, 289, 297], although the presence 
of TMPRSS2 in these target cells also appeared to process hACE2 (Fig. 5.8c, also 
observed in[234]).  In samples with cath L or furin in the target cells, fusion levels 
were similar to hACE2+EV (Fig. 5.2c).  When A549 cells were used as the S-
expressing effector cell, none of the conditions produced statistically significant 
differences from background levels (Fig. 5.2c), so Vero cells were used as the 
effector cells for the remainder of the experiments performed.  
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Having analyzed the function of proteases in the target cells, we were also 
interested in the role of proteases present in the S-expressing effector cells.  To 
test this, EV, TMPRSS2, cath L, or furin were co-expressed with S and samples 
were overlaid with target cells expressing hACE2.  Similar to what we observed in 
syncytia assays, only co-expression of S and furin produced a statistically 
significant increase in fusion.  This increase is likely due to the increase in the 
amount of cleaved protein present when S is co-expressed with furin (Fig. 5.1e).    
Neuropilin-1 has been suggested as a co-receptor for SARS-CoV-2 S and 
may be important for the viral infection infiltrating the neuronal network [303-305].  
To assess the contribution of neuropilin in cell-cell fusion, effector cells were 
transfected with S and either EV, furin, neuropilin, or furin and neuropilin (F+N).  
Target cells were transfected with EV, hACE2, neuropilin, or hACE2 and 
neuropilin. However, no significant increase in fusion was observed when 
neuropilin was present in either the target or effector cells (Fig. 5.2e), suggesting 
that neuropilin does not appear to play a significant role in cell-cell mediated fusion.  
Interestingly, when neuropilin is co-expressed in S containing effector cells, there 
is no difference observed in fusion compared to samples with S+EV, suggesting 
that neuropilin also does not have an inhibitory effect (Fig. 5.2e).  Additionally, 
when neuropilin alone is expressed in the target cells, fusion levels above 
background levels are not observed.  This indicates that in cell-cell fusion, S 
binding hACE2 appears to be the major interaction during the receptor attachment 
function.   
Importance of CoV-2 cleavage sites 
Early protein sequence analysis of CoV-2 S protein demonstrated the 
presence of three potential cleavage sites [178]: a putative furin cleavage site at 
the S1/S2 border; a conserved site 10 residues downstream from the S1/S2 
border,  shown to be cleaved by cath L in SARS-CoV; and the S2’ site which is 
potentially cleaved by TMPRSS2 [178]. To functionally understand the role of each 
cleavage site in S cell-cell fusion, a series of mutants were made.  Alanine 
mutations of all the residues within each potential cleavage site (S1/S2 AAAAA, 
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Cath L AAAA, S2’ AA), and single alanine mutations at the terminal arginine of the 
S1/S2 border and S2’ site (S1/S2 PRRAA, S2’ KA) were created. Finally, a mutant 
with residues (PRRA) upstream of the S1/S2 border deleted (del. PRRA), leaving 
a single R residue at this site, was made, creating an S1/S2 border similar to 
SARS-CoV S (Fig. 5.3A).  Pulse-chase analysis (Fig. 5.3b) showed that all mutants 
had similar protein turnover compared to wt S in Veros. However, in A549s several 
mutants demonstrated more rapid protein turnover than wt S at later chase time 
points. Surprisingly, mutations at all three sites led to either a complete loss or 
significant delay in the proteolytic processing of the S protein at the S1/S2 border, 
indicated by the lack of a band corresponding to the S2 subunit.  This suggests 
that mutations at distal sites can strongly influence cleavage at S1/S2.  After an 
eight-hour chase, no cleavage at the S1/S2 border was observed for the mutants 
del. PRRA and S1/S2 AAAAA, confirming that deletion or mutation of the furin 
consensus prevents cleavage at this site.  For all other mutants, cleavage at the 
S1/S2 border reached 30-50% of wt levels in both Vero and A549 cells the eight-
hour time point (Fig. 5.3c and 5.3d). Accurate analysis of protein cleavage was not 
possible by the 24-hour time point, since only 20-30% of protein remained (Fig. 
5.7b).  Finally, surface biotinylation showed that both total and cell surface 
expression of all mutants were similar to wt S levels (Fig. 5.3e, f, and g).   
To assess the effects of the mutations on cell-cell fusion, syncytia formation 
assays in Vero cells were performed.  While syncytia were readily observed in all 
samples containing wt S, none of the mutants exhibited syncytia formation at 24 
or 48 hpt when expressed alone (Fig. 5.9, panel 2). Addition of TMPRSS2 did not 
recover syncytia formation in any mutant (Fig. 5.9, panel 3), and the addition of 
furin only recovered syncytia formation in the S1/S2 PRRAA mutant (Fig. 5.9, 
panel 4, syncytia denoted with black arrows).  To analyze this result, cells were 
lysed following the 48-hour imaging and protein levels examined by western blot. 
Results showed that co-expression of furin with the S1/S2 PRRAA mutant restored 
cleavage at the S1/S2 border, while all other mutants did not show cleavage at this 
site (data not shown).  This suggests that cleavage at the S1/S2 border is critical 
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for cell-cell fusion, and that the double R motif in the PRRAA mutant can be 
cleaved by over-expressed furin.   
Luciferase reporter gene analysis of fusion in Veros transfected with wt S 
or each mutant showed similar results to the syncytia assays, with none of the 
mutants showing fusion levels above background (Fig. 5.3h).  Interestingly, the S2’ 
AA mutant displayed high background levels, suggesting this mutant may have a 
conformational change, or characteristics that increase receptor binding or alter 
S2 trimeric association, leading to higher background signals. Reporter gene 
assays were also carried out with addition of transiently expressed furin in the S-
expressing effector cells, but no significant increases in fusion were observed.  
Since all cleavage mutants created reduced cleavage at the S1/S2 subunit border, 
the reductions in cell-cell fusion may be attributable to loss of cleavage at this site.   
Effect of Circulating S Mutations on Protein Stability, Cleavage, and Fusion 
An early examination revealed several mutations in the S protein gene in 
circulating viral strains [299, 300], including the D614G substitution now found in 
most of the global SARS-CoV-2 strains [299, 306-312]. The D614G mutation lies 
in the S1 subunit of the protein, just downstream of the receptor binding domain, 
and is proposed to play a critical role in receptor binding by alteration of the 
positioning of the receptor binding domain. Other mutations in circulating strains 
were found throughout the S2 subunit [300].  To assess the effect(s) of these 
mutations, we created the mutants D614G, A831V, D839Y/N/E, S943P, and 
P1263L (Fig. 5.4a).  Pulse-chase analysis in Vero and A549 cells (Fig. 5.4b, c) 
demonstrated that all circulating mutants tested exhibited protein turnover at 
similar rates as wt S in both cell lines (Fig. 5.7d). Surface biotinylation confirmed 
that all tested mutants displayed total protein and surface protein levels 
comparable to wt S, suggesting that none of the mutants caused major defects or 
enhancement of protein trafficking to the cell surface (Fig. 5.4d, e).  Syncytia 
formation and evaluation of protein location by immunofluorescence were similar 
between all mutants and wt S (Fig. 5.10).  Interestingly, cellular extensions 
containing the S protein were observed for the wt and each of the mutants (Fig. 
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5.10, white arrows) [313].  Finally, luciferase reporter gene assays were performed.  
While most of the mutants displayed fusion levels similar to wt S, three mutants 
exhibited significant changes (Fig. 5.4f).  D839Y and D839N displayed significantly 
reduced levels of fusion compared to wt (p<0.01 and p<0.05, respectively), and 
P1263L showed a significant increase in fusion compared to wt (p<0.05).  These 
changes in fusion cannot be attributed to differences in cell surface protein 
expression or cleavage levels, suggesting that residues near the internal fusion 
peptide, where D839 is located, and residues in the cytoplasmic tail, where P1263 
is located, may play an important role in controlling the fusion cascade. 
Trypsin accessibility and protein-protein association in select spike mutants   
Since all the S cleavage site mutants exhibited defects in cleavage at the 
S1/S2 border, we evaluated the accessibility of this site using a trypsin treatment 
assay to determine if the lack of cleavage was due to misfolding in the S1/S2 
border region.  Vero or A549 cells were transfected with wt S or each cleavage 
mutant and metabolically labeled.  Cell surface proteins were biotinylated and then 
cells were either left untreated or treated with 0.3 µg/μl of TPCK-Trypsin prior to 
lysis. When treated with exogenous TPCK-Trypsin, both the del. PRRA and S1/S2 
PRRAA mutants were efficiently cleaved at the S1/S2 border, shown by the 
appearance of a band corresponding to S2 in the lanes treated with trypsin (Fig. 
5.5a, quantified in Fig. 5.5b).  This suggests that the observed defects in cleavage 
at the S1/S2 border are not due to inaccessibility at the site, but rather to the 
removal of the furin consensus sequence.  Interestingly, mutations at the 
downstream cath L or S2’ potential cleavage sites also render defects in protein 
cleavage at the S1/S2 border site. However, treatment with exogenous trypsin did 
not significantly affect the amount of cleavage observed, a result consistent with a 
change in conformation that renders the S1/S2 border cleavage site inaccessible.   
CoV S proteins associate as homo-trimers shortly after synthesis and 
remain in this trimeric form throughout the fusion cascade [50, 272]. To determine 
if proteolytic processing affects the stability of S trimer association, Vero or A549 
cells transfected with wt S or mutants D614G, S1/S2 AAAAA, S2’AA, or wt S plus 
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additional furin, were metabolically labeled. After lysis and immunoprecipitation, 
samples were then treated at 50°C or 100°C prior to separation on non-reducing 
SDS-PAGE. When wt S was incubated at 50°C prior to separation, species that 
correspond to a full-length S monomer, dimer, and trimer were observed (Fig. 
5.5c).  Interestingly, species that fall in between sizes corresponding to a 
monomer, dimer, and trimer (Fig. 5.5c, red and purple *) were also observed.  
These intermediate species may be the result of dimers or trimers made up of a 
mixture of full-length S protomers and cleaved S protomers.  When wt S was 
incubated at 100°C prior to separation, bands corresponding only to full length S 
monomer, dimer, trimers, and cleaved S2 monomers were apparent.  Similar 
results were also observed in D614G samples, suggesting that species containing 
cleaved protomers may be less stable.  Consistent with this data, the S1/S2 
AAAAA mutant, which cannot undergo cleavage at the S1/S2 border site, migrated 
primarily as a trimeric species after 50°C incubation, with little monomer or dimer 
observed.  Additionally, when wt S was co-expressed with furin (shown to increase 
S cleavage in Fig. 5.1e and 5.1f), the predominant observed species was 
monomeric, after both 50°C and 100°C incubation.  Overall, these results suggest 
that cleavage at the S1/S2 border alters the stability of S trimeric association.   
Furin or furin-like proteases in bat cells can cleave the S1/S2 border of SARS-
CoV-2 spike  
Rhinolophus affinis horseshoe bats have been identified as the likely 
reservoir species for the novel SARS-CoV-2 [283].  To understand the proteolytic 
processing, expression, and stability of CoV-2 S in a cell line closely related to its 
reservoir host, we utilized Pteropus alecto fetus (pt. fetus) or lung (pt. lung) cells 
[240] that have a furin enzyme with ~90% sequence homology to bats in the 
Rhinolopus family. Our previous studies on paramyxovirus virus fusion protein 
cleavage have shown that efficient furin and cathepsin cleavage occurs in these 
cells, although the furin cleavage occurs with delayed kinetics compared to Vero 
cells or A549s [314].    
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Surface biotinylation demonstrated that wt S and the del. PRRA mutant 
were readily expressed at the surface at similar levels in both cell lines, with 
cleavage at the S1/S2 border only observed for wt S and not for the del. PRRA 
mutant (Fig. 5.6a and 5.6b).  Pulse-chase analysis showed that S expressed in 
both pt. lung and pt. fetus cells was cleaved at the S1/S2 border by one hour, with 
cleavage extent reaching approximately 40% at eight-hours, and 60% at 24 hours 
(Fig. 5.6c and 5.6d). Thus, furin or other proteases in P.alecto cells are able to 
process S, although this processing occurred more slowly than in other 
mammalian cell lines (compare to Fig. 5.1b).  Interestingly, some cleavage was 
also observed in both pt. lung and pt. fetus cells for the del. PRRA mutation (Fig. 
5.6c and 5.6d).  Additionally, the wt S and del. PRRA mutant were slightly less 
stable in the P. alecto cells, demonstrating about 30-50% protein remaining at eight 
hours, and about 20% at 24 hours (Fig. 5.6e). In contrast, previously used 
mammalian cells lines showed 60-90% of wt S remained at eight hours, with 30-
50% at 24 hours of chase (Fig. 5.1c).   
Discussion   
In this study, we present a detailed characterization of the cleavage 
patterns, protein stability, and cell-cell fusion function of the SARS-CoV-2 S 
protein, as well as analysis of mutations within the S2 subunit that may affect these 
important protein properties. Consistent with recently published work [178-180, 
298, 301, 315], our analysis confirms that S is readily cleaved at the S1/S2 border 
in a variety of mammalian cell lines. Additionally, we show for the first time, that 
cleavage occurs in a bat cell line similar to the SARS-CoV-2 reservoir species.  
While cleavage appears to be primarily carried about by the cellular protease furin, 
the sequence at this border does have the ability to be cleaved by other members 
of the pro-protein convertase family when furin is not present [298], and this likely 
accounts for the small amount of cleavage we observed in furin-negative LoVo 
cells.   
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Additionally, we carefully assessed the role different proteases play in cell-
cell fusion, finding that furin increases cell-cell fusion when present in the same 
cell as S, and TMPRSS2 increases cell-cell fusion when present in a target cell, 
consistent with previous studies [182, 297].  Interestingly, when cell-cell fusion 
assays were performed using A549 cells as the effector cell (Fig. 5.2c), high 
background fusion levels were observed.  This could be due to high endogenous 
levels of TMPRSS2 in this cell line compared to Vero cells that were ultimately 
used for this experiment (Fig. 5.8c).  High TMPRSS2 expression or exogenous 
treatment with trypsin has been shown to restore cell-cell fusion in low ACE2 
receptor expression environments for SARS-CoV S [316, 317].  It is also worth 
noting that the presence of TMPRSS2 in the target (BSR/T7) cells also appears to 
process hACE2 (Fig. 5.8c, [234]). Therefore, we cannot exclude the possibility that 
the increase in fusion observed when TMPRSS2 is present in these cells is due to 
an effect on hACE2. In addition to the effect of proteases on cell-cell fusion, we 
also assessed the effect of Neuropilin-1, which has been suggested to be a co-
receptor for SARS-CoV-2 viral entry and may be key for SARS-CoV-2 infiltration 
of the neuronal network [303-305]. We show that the presence of Neuropilin-1 with 
hACE2 in target cells does not impact S mediated cell-cell fusion (Fig. 5.2e).  
Additionally, co-expressing Neuropilin-1 with S in effector cells did not have an 
inhibitory effect on cell-cell fusion.  While reports suggest Neuropilin-1 plays a role 
in viral entry of SARS-CoV-2, this indicates it does not play a significant role in S 
cell-cell fusion in our assay, although this was not investigated in neuronal cells.     
The viral entry and cell-cell fusion pathways of SARS-CoV, MERS-CoV, and 
SARS-CoV-2 have several noteworthy commonalities, but do have marked 
differences. They all share the ability to facilitate entry through endosomal 
pathways, with S proteolytic activation mediated by endosomal/lysosomal 
proteases [179, 181, 182, 278, 293, 294, 318-321].  Additionally, they all can utilize 
cell surface (such as TMPRSS2) or extracellular proteases (trypsin) for S activation 
and subsequent viral entry [181, 182, 293, 298, 316, 321-327].  SARS-CoV-2 and 
MERS-CoV S differ from SARS-CoV S in that their S1/S2 border harbors a 
canonical furin cleavage motif [178, 284, 289], resulting in S pre-activation by furin 
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during synthesis and cellular trafficking, prior to reaching the cell surface or being 
incorporated into viral particles [179, 182, 278, 294, 324].  This pre-activation by 
furin likely enhances the ability of SARS-CoV-2 and MERS-CoV S to participate in 
cell-cell mediated fusion without over-expression of cell surface or extracellular 
proteases [182, 297]. Addition of this cleavage sequence in SARS-CoV S allows 
SARS-S to facilitate cell-cell fusion without exogenous proteases [182, 328]. We 
show an increase in both syncytia formation and luciferase reporter gene assay 
fusion when cleavage at the S1/S2 border is enhanced by overexpression of furin 
(Fig. 5.2b and 5.2c), confirming that furin cleavage of SARS-CoV-2 S plays a 
critical role in cell-cell fusion.  Interestingly, furin cleavage is not required for SARS-
CoV-2 infection [179, 181, 182, 298], although removal of the site or inhibition of 
furin does appear to attenuate the virus [179, 294, 298] and reduce cellular tropism 
[297].   
The presence of a furin consensus sequence is not only a marked 
difference between SARS-CoV and SARS-CoV-2, but it is also one of the 
differences between SARS-CoV-2 and a similar CoV circulating in a bat population 
[283].  Analysis of SARS-CoV-2 wt S in P. alecto cells demonstrates that this motif 
can be recognized and cleaved by furin in these cells (Fig. 5.6c and 5.6d), although 
the kinetics of this cleavage are noticeably slower than in other mammalian cell 
lines (compare to Fig. 5.1b).  Previous work has shown that the fusion proteins of 
Hendra virus, processed by cathepsins, and parainfluenza virus 5, processed by 
furin, are also cleaved in P. alecto cells [314].  Pulse-chase analysis in this prior 
study demonstrated an increase in processing kinetics, although this kinetic 
difference can be accounted for by differences in protease expression levels 
between different bat cell lines (pt. kidney cells in [314], and pt. lung and pt. fetus 
cells in our work), suggesting there may be cellular differences in protein trafficking 
or furin activity. Intriguingly, a CoV-2 S mutant with a deletion of the inserted PRRA 
residues still demonstrated some cleavage in both utilized bat cell lines (Fig. 5.6c 
and 5.6d), while not showing any in Veros or A549s (Fig. 5.3c and 5.3d). Earlier 
work on MERS-CoV S showed that furin or other proprotein convertases in bat 
cells can process MERS S S1/S2 border without the presence of a canonical 
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recognition motif [329]. Taken together, these results suggest that mutations in 
circulating bat CoVs that allow for human protease recognition at critical cleavage 
sites may be an important factor for zoonotic transmission of several CoVs.   
Two other potential cleavage sites have been identified in work with other 
CoVs. The S2’ site is essential for both SARS and MERS infection [272, 289, 330-
332] while a cath L activated site play a critical role for SARS-CoV S [273, 279, 
333, 334].  Interestingly, mutations made at the S2’ site of SARS-CoV-2 S 
significantly reduce S1/S2 border cleavage, both in our study and others (Fig. 5.3b-
d, [297, 335]), even though the sites are distal from each other.  A similar reduction 
in cleavage is observed when the conserved cathepsin site is mutated (Fig. 5.3b-
d). Our analysis of the published structures [264, 265, 336, 337] indicates that a 
full alanine mutation of this site may simply collapse the exposed S1/S2 loop.  Our 
finding that exogenous trypsin treatment of cells expressing the S2’ or cathepsin 
site mutants does not restore cleavage at the S1/S2 border (Fig. 5.5a and 5.5b) 
suggests that these mutations result in proteins with altered furin loop structure 
[336], rendering it inaccessible. However, these mutants are still synthesized and 
trafficked to the surface despite not being cleaved (Fig. 5.3e-g), thus this change 
in conformation is unlikely to have drastically misfolded the protein. These results 
suggest that there may be a dynamic interaction between the S1/S2 border and 
S2’ cleavage sites in SARS-CoV-2 S needed to facilitate viral entry and cell-cell 
fusion. This dynamic control could also be regulated by S receptor binding 
exposing cryptic protease sites, although studies analyzing this in SARS and 
MERS S conflict on this topic [278, 319, 326, 338, 339].   
We also assessed the effect on protein stability, cleavage, and cell-cell 
fusion function of a series of mutations in other regions of S.  The D614G mutation 
emerged during 2020, and is now found in most circulating strains globally [299].  
D614G has been shown to increase S incorporation into viral particles [340], 
increase receptor binding [341, 342], and reduce S1 subunit shedding and particle 
infectivity [343].  Importantly, the D614G mutant shifts S to favor a “heads up” 
conformation of the receptor binding domain [342, 344, 345]. In our study, the 
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D614G mutation did not impact the cell-cell fusion function (Fig. 5.4f), expression, 
or stability of the protein (Fig. 5.4d/e, and Fig. 5.7), consistent with one previous 
study [335].  Our fusion results however conflict with two previous studies that 
demonstrated D614G increases cell-cell fusion, measured by cell depletion in flow 
cytometry [341], and syncytia formation in 293T and Hela cells stably expressing 
hACE2 [346].  These discrepancies may be due to differences in experimental 
conditions or cell types utilized.  We are, however, the first to date to utilize a 
luciferase reporter gene assay to quantitate cell-cell fusion of a D614G S mutant.  
Using this assay, we also show that mutations found at two other residues 
(discovered in small, non-dominant population subsets [300]) alter the cell-cell 
fusion activity of S (Fig. 5.4f) without changing the overall protein expression or 
stability levels (Fig. 5.4d-e, Fig. 5.7d). Mutations at D839, a residue within the 
internal fusion peptide, to the polar amino acids, tyrosine or asparagine, 
significantly reduce fusion.  Interestingly, a mutation at this residue that conserves 
the negative charge, D839E, has no effect on fusion activity.  The negative charge 
at this residue may play a role in the regulation of S mediated fusion due to its 
location in the internal fusion peptide. Alternatively, this residue is in close 
proximity to C840, which may participate in a disulfide bond, so mutations at D839 
may disrupt this disulfide bond, destabilizing the protein and changing fusion 
activity.  Additionally, mutation of residue P1263 to a leucine significantly increases 
S mediated cell-cell fusion, suggesting that residues in the cytoplasmic tail may 
play a role in the S-promoted cell-cell fusion process.  Notably, a study that 
removed the entire S cytoplasmic tail still observed syncytia formation at levels 
similar to wt S [335], indicating that regulation by the cytoplasmic tail may be 
complex or that the role of the cytoplasmic tail in fusion is not regulation, but 
interaction with cellular host factors [347].   
In this work, we also provide critical insight into the kinetics of protein 
cleavage and overall stability of CoV-2 S. S protein processing at the S1/S2 border 
occurs within two hours of synthesis (Fig. 5.1a and 5.1b; one hour of label, one 
hour of chase) in several mammalian cell lines (Vero, MEF, A549), and continues 
to increase over time, reaching 60-80% protein cleavage by eight hours of chase 
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time, depending on the cell type.  Overexpression of furin increased the efficiency 
of S1/S2 border cleavage (Fig. 5.1d-f), and this increase in cleavage may account 
for the increase in cell-cell fusion observed when furin is co-expressed with S (Fig. 
5.2a-c, [182, 297]).  Additionally, we show that transiently transfected S is stable 
in several mammalian cells for 4-5 hours post-protein synthesis with demonstrable 
turnover after this point, (Fig. 5.1c, Fig. 5.7).  This protein turnover is similar to 
turnover rates seen in PIV5 fusion protein, also activated by cellular furin [348], 
and slightly slower turnover than Hendra fusion protein, activated by cellular 
cathepsins [164, 261].  Over-expression of cellular proteases that may process S 
did not affect these protein turnover rates.  Interestingly, analysis of S in non-
reducing conditions found that cleavage of the S1/S2 border appears to destabilize 
trimeric interactions (Fig. 5.5b).  In these non-reducing conditions, no differences 
were observed in oligomeric stability between wt S and the D614G S mutations, 
despite the D614G favoring a ‘heads up’ conformation [342, 344, 345] and Vero 
cells having sufficient levels of endogenous ACE2 to facilitate syncytia formation 
(Fig. 5.8c), suggesting that changes in receptor binding do not alter overall protein 
trimeric association.  Notably, in these non-reducing conditions after a 50°C 
treatment for wt S, the D614G mutant, and wt S+furin, bands between monomer, 
dimer, and trimer species are observed (Fig. 5.5b, indicated with *). These 
intermediate species are not observed after treatment at 100°C.  These may 
represent protein oligomers that are not identically cleaved and are therefore 
partially destabilized, a phenomenon proposed for MERS-CoV S [289], and murine 
hepatitis virus CoV S, [189]. Protein oligomers with differential proteolytic 
processing may also account for the small population of un-cleaved protein we 
observed at the cell surface in our experiments (Fig. 5.3e, Fig. 5.4d, Fig. 5.5a, and 
Fig. 5.6a).   
Through biochemical and cell biological analysis of the SARS-CoV-2 S 
protein, we have provided important observations about the stability, proteolytic 
processing, and requirements for cell-cell fusion of this highly sought-after 
therapeutic target. This information may be helpful in directing treatments that 
inhibit S protein fusion, or for discerning methods to stabilize CoV-2 S in 
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therapeutic development.  Additional studies are needed to understand the 
potential interplay between S cleavage sites and how that may contribute to S 
protein function, as well as to further investigate spike S2 subunit regions that are 







Figure 5-1 SARS-CoV-2 Spike is cleaved at the S1/S2 subunit border in a 
variety of cell lines.  
a) The indicated cell types transiently expressing S were metabolically 
labeled for one hour, and chased for times indicated (hours).  Band densitometry 
was used to quantify bands representing full length S or S cleaved at the S1/S2 
border (S2) (b) Percent cleavage [S2 divided by S plus S2] and (b) Overall protein 
stability [Total S, S plus S2, for each time point, normalized to time point 0] were 
calculated for spike in each cell line (n=3).  d) S alone, or S with proteases 
transiently expressed in Vero and A549 cells, cells were metabolically labeled, and 
 111 
 
chased for the times indicated (hours).  Percent cleavage was measured using 
band densitometry in both (e) Vero and (f) A549 cells (b, c, e, f are represented as 
























Figure 5-2 CoV-2 spike alone mediates cell-cell fusion.  
Veros expressing S and TMPRRS2, furin, or cathepsin L were imaged at 24 (a) 
and 48 (b) hpt for syncytia formation (black arrows). Magnification bar is 100μM.  
c) A luciferase reporter gene assay was performed with target cells (BSR/T7s 
expressing hACE2 and additional proteases) overlaid onto effector cells (Vero or 
A549s expressing S) for 9 hours. d) Luciferase reporter gene experiment was 
performed with additional proteases co-expressed with S in Veros and overlain 
with target cells expressing hACE2. e) The effect of Neuropilin in both target and 
effector (Vero) cells was examined with a luciferase reporter gene assay.  Effector 
cells expression is listed along the x-axis. Target cell expression is listed in the 
graph legend.  Results expressed as the percent fusion normalized to samples 
with S in the effector cells, and hACE2 only in the target cells (c-e are average ± 
SD for 3 independent experiments, performed in duplicate). Significance was 





Figure 5-3 Mutations at all three potential spike cleavage sites reduce 
cleavage at the S1/S2 subunit border.  
a) Full or partial alanine substitution mutations were made at each of the three 
potential cleavage sites. b) Plasmids expressing wt S or mutants were transfected 
into Veros and A549s, cells were metabolically labeled for one hour, and chased 
for the times indicated.  Percent cleavage was determined in (c) Veros and (d) 
A549s (average ± SD for 3 independent experiments) e) Surface biotinylation was 
performed on cells expressing wt S and each mutant. Cells were radiolabeled for 
6 hours.  Protein expression in (f) Vero and (g) A549 cells, results are normalized 
to wt S, and error bars represent the standard deviation (average ± SD for 3 
independent experiments). h) A luciferase reporter gene assay was performed 
using target cells expressing hACE2 and EV or TMPRRSS2, and effector (Vero) 
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cells with wt S or each mutant. i) Luciferase reporter gene analysis with cells 
expressing hACE2 and effector (Vero) cells transfected with S or S mutants and 
EV or furin expressing plasmids.  Results of both reporter gene assays are shown 
normalized to samples with wt S in the effector with hACE2 in target cells (average 























Figure 5-4 Spike S2 subunit mutations found in circulating strains variably 
affect spike mediated cell-cell fusion.   
a) Mutations in the S2 subunit of S identified in circulating SARS-CoV-2 strains, b) 
Wt S or the mutants were transfected into Veros and A549s, metabolically labeled 
for one hour, and chased for the times indicated.  Percent cleavage was 
determined in (c) Veros and A549s (average ± SD for 3 independent experiments).  
d) Surface biotinylation on cells expressing wt S or each mutant. e) Total and 
surface protein expression normalized to wt S (average ± SD for 3 independent 
experiments). f) A luciferase reporter gene assay was performed using target cells 
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expressing EV or hACE2, overlaid onto effector cells transfected with wt S or each 
mutant. Results are normalized to samples with wt S in the effector cells and 
hACE2 in target cells (average ± SD for 3 independent experiments, performed in 
























Figure 5-5 Mutations at downstream potential cleavage sites render the 
S1/S2 border cleavage site less accessible to proteases.   
a) Veros or A549s expressing wt S or S cleavage mutants were metabolically 
labeled for 6 hours. Surface proteins were biotinylated, and samples were either 
treated for 10 minutes with TPCK-Trypsin or left as untreated controls (as 
indicated).  b) Veros or A549s expressing indicated proteins were metabolically 
labeled for 6 hours.  Samples were treated at the indicated temperatures before 
separation on a nonreducing SDS-PAGE. Oligomers are labeled on the right based 
on size, and colored * represents potential intermediate species (n=3). Using band 
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densitometry to quantify the bands in (a), percent cleavage was measured in (c) 
Vero and (d) A549 cells for both the surface (top graphs) and total (bottom graphs) 
populations (average ± SD for 3 independent experiments). Significance was 


















Figure 5-6 Furin or furin-like proteases in pteropus bat cells can cleave the 
S1/S2 border site of SARS-CoV-2 Spike.   
a) Surface biotinylation was performed on pteropus lung and pteropus fetus cells 
transfected with wt S or the del. PRRA mutant.  b) Surface or total protein 
expression levels were quantified using band densitometry and normalized to wt 
S levels.  c) pt. lung and pt. fetus cells were transfected with wt S or del. PRRA 
mutant, metabolically labeled for one hour, and chased for the times indicated.  
Again, using band densitometry to quantify bands results were expressed as (d) 








Figure 5-7 SARS-CoV-2 protein stability comparisons.  
A) Wt S was transfected into Vero or A549 cells, metabolically labeled for one hour, 
and chased for times indicated.  Blots (shown in Fig 1a) were quantified using band 
densitometry.  Both percent cleavage and percent stability are shown. B) Overall 
protein stability at each time point from blots in Fig. 1D were quantified.  C) Overall 
protein stability at each time point from blots in Fig. 3B were quantified.  D) Overall 




Figure 5-8 SARS-CoV-2 Spike luciferase reporter gene assay controls 
A) The experimental schematic for the luciferase reporter gene fusion assay used 
throughout the manuscript is shown here.  In all experiments, the target cells used 
are BSR/T7 cells that constitutively express a T7 polymerase. Effector cells used 
are Vero cells in most experiments and A549 cells in Figure 2c.  B) Various overlay 
times were tested in a luciferase reporter gene assay, effector cells (Vero) were 
transfected with wt S, and target cells were transfected with empty vector (EV) or 
hACE2.  Results represent three independent experiments, each performed in 
duplicate.  Significance was determined by two-way ANOVA, ****; p<0.001.  C) 
Endogenous or transfection levels of TMPRSS2 and hACE2 were assessed in 












Figure 5-9 Mutations made at any of the three potential cleavage sites 
abolish syncytia formation.   
Vero cells were transfected with wt S or each of the cleavage mutants.  The first 
panel shows immunofluorescence of wt S or S cleavage mutants (green, 
magnification bar is 20μm).  The remaining panels show syncytia formation at 24 
hours post transfection with S or mutants co-expressed with EV, TMPRSS2, or 





















Figure 5-10 All circulating mutants form large syncytia, similar to wt spike.   
Immunofluorescence of wt S or the circulating mutants (S stained in green) 
transiently expressed in Vero cells. White arrows indicated S positive cellular 






CHAPTER 6. RSV FUSION PROTEIN CHARACTERIZATION  
Introduction 
Respiratory syncytial virus (RSV), a member of the Pneumoviridae family, 
was first isolated in 1956, and is one of the leading causes of respiratory tract 
infections in young children [30, 349-352]. Initial RSV infections occur in most 
people before the age of 5, with RSV continuing to cause reinfections throughout 
their lives. For young children, it is estimated that RSV causes 34 million infections 
and results in 3.4 million hospitalizations, making it one of the leading causes of 
hospitalizations for this population [350, 351, 353].  RSV also poses an increased 
risk for severe infections in premature infants, the elderly, and 
immunocompromised individuals [349-351, 354]. Despite this high risk and wide 
prevalence, there are no vaccines and only one approved treatment for RSV, a 
prophylactically given monoclonal antibody, Palivizumab (brand name: Synagis) 
[355, 356].  This treatment is extremely costly and comes in a 5-dose regimen.  
Due to these factors, this treatment is often reserved for high-risk infants and given 
monthly during RSV season[355].  
RSV strains are grouped into two subtypes, A and B, differing mainly in the 
sequences found in the attachment protein (G) [351, 357]. RSV A2 and A Long 
strains are the prototypic A subtype strains utilized for a majority of the RSV 
research [30, 358].  These strains were isolated in 1961 and 1956, respectively, 
and have been passaged in cell culture since that time [30]. CH-18537 isolated in 
1962 and B9320 isolated in 1977, serve as the prototypic laboratory strains from 
an RSV B lineage [357].  Despite the widespread use of these prototypic strains in 
RSV research, several studies have suggested they vary significantly from current 
circulating strains of RSV [358-363].  Even outside of traditional cell culture 
experiments, work in pediatric bronchial epithelial cells demonstrated differences 
in cytopathology and viral titers produce between lab grown and recent clinically 
isolated strains [362].    
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For a strain of RSV to facilitate viral entry, the RSV fusion (F) protein 
undergoes a large dynamic conformational change, in a similar mechanism as 
described for Hendra.  Like all class I fusion proteins, RSV F must be proteolytically 
processed prior to facilitating membrane fusion. Interestingly, RSV F possesses 
two cleavage sites 27 amino acids apart [154, 156]. The small peptide is not 
covalently linked to the protein when both sites are cleaved and is termed pep27.  
Each cleavage site contains an R-X-X-R motif, making them both canonical 
recognition sequences for the cellular proprotein convertase furin [152-154, 156]. 
Initial investigation of the cleavage sites demonstrated that proteolytic processing 
at one site appeared to occur independently of cleavage at the other, but that 
cleavage at both sites was required for fusion to occur [154, 156].  This work was 
completed in RSV F from strain A Long, but both cleavage motifs are present and 
completely conserved in F proteins from both A and B subtypes. To date, no 
studies have been done to investigate the coordination between the two cleavage 
sites in any RSV F from a subtype B lineage.  Additionally, the role of this first 
cleavage site remains unclear in the case of either subtype, since it does not 
expose a fusion peptide and resides within the F2 region which is thought to have 
a limited role in fusion function. Furthermore, the function of the released pep27 
remains uncharacterized. Our work on F isolated from both prototypic laboratory 
RSV strains, as well as F from recent clinical isolates sought to characterize 
differences that may be present in the RSV F protein from different strains.  
Ultimately, the goal was to better understand the fusion process that is facilitated 
by each RSV F, however our initial analysis discovered that robust laboratory RSV 
fusion assays did not exist, apart from simple syncytia analysis.  Because of this, 
our project also focused on developing a reproducible luciferase reporter fusion 
assay to better analyze fusion mechanisms of F from each RSV subtype, as well 
as to understand how antiviral treatments may affect the fusion process.   
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Results and Discussion  
Comparing the RSV F isolates  
To understand differences between the cleavage patterns and fusion 
function the following RSV F plasmids were utilized: pVAX-RSV F A2, pVAX-RSV 
F B9320, pCAGGs-RSV F A clinical, pCAGGs-RSV F B clinical, and pVAX-RSV F 
A2 P101Q.  RSV F A and B clinical were cloned from clinical samples taken by 
AstraZeneca. RSV F A2 P101Q is a single point mutant of RSV F A2, 
demonstrated to have an increase in fusion [364].  RSV F between subtypes A and 
B shares an approximately 90% sequence homology, while RSV F from clinical 
isolates have greater than a 97% sequence homology with their respective lab 
adapted isolate (Fig 6.1b).  Interestingly, variation in the RSV F protein between 
lab grown and current clinical isolates disproportionately falls in the F2 and pep27 
regions of the protein.  This region possesses four of the eight differences between 
RSV F B Clinical and B9320 and ten of the fifteen differences between RSV F A2 
and A clinical, despite only accounting for about 20% of the total protein. It has 
been shown that F2 is a critical determinant of host cell specificity, so this high 
variation is likely due to long time passage in cell culture compared to growth in a 
human host [365].   
To first assess expression differences between each of the isolates tested, 
Vero or HEp-2 cells were transfected with plasmids encoding for each of the 
proteins listed.  When separated by reducing SDS-PAGE, the RSV F protein was 
visualized as multiple bands: a band at 67-69 kDa corresponding to the uncleaved 
form (F0), one at approximately 57 kDa corresponding to a protein with cleavage 
at site 1 only (F1+), and a band at 49kDa corresponding to protein with cleavage at 
site 2 (F1). Occasionally bands corresponding to the F2 subunit, with or without 
pep27 attached were visualized around 30 kDa and 23kDa, respectively.  RSV F 
A2, B9320, and A2 P101Q demonstrated similar expression and cleavage patterns 
in both Vero and HEp-2 cells, however RSV F from both clinical isolates displayed 
significantly lower protein expression (Fig. 6.1c). Since RSV F expression of the 
clinical isolates was so low in a transfection system, we tested the F protein 
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expression during a viral infection.  RSV A2, A Clinical or B Clinical strains were 
used to infect HEp-2 or BSR cells at an MOI of 0.2 or 1 (as indicated).RSV B9320 
virus was not available, so this was not included. Twenty-four hours post infection 
(hpi) cells were metabolically labeled for three hours.  RSV F expression in cells 
infected with A2 and A clinical strains was similar in both cell lines (Fig. 6.1d).  RSV 
F expression in cells infected with RSV B Clinical demonstrated lower protein 
expression levels, however still much higher than in transfected cell experiments 
(Fig 6.1d). 
RSV F mediated cell-cell fusion 
To assess the RSV F fusion function, we performed both syncytia and 
luciferase reporter gene assays.  Since RSV F from A and B clinical isolates 
demonstrated low expression in cellular transfection experiments (Fig. 6.1c), they 
were excluded from fusion studies.  Vero cells transfected with plasmids encoding 
for RSV F A2, B9320, and A2 P101Q were imaged at 24 and 48 hours post 
transfection (hpt) (Fig. 6.2a).  At 24 hpt syncytia were observed in cells expressing 
RSV F A2 or A2 P101Q (Fig. 6.2a), with larger and more numerous syncytia 
observed at 48 hpt.  In cells transiently expressing RSV F B9320, no syncytia were 
apparent at 24 hpt, but some small syncytia were present at 48 hpt (Fig. 6.2a).  To 
better quantitate the fusion of each of these RSV F isolates, two luciferase reporter 
gene assays were performed.  In the first, BSR cells, which constitutively express 
a T7 polymerase, were overlaid onto Vero cells transfected with DNA for each RSV 
F isolate and a T7-promoted luciferase plasmid.  BSRs were overlaid for 9, 12, or 
24 hours (Fig. 6.2b).  High levels of fusion were observed in RSV F A2 P101Q at 
9 and 12 overlay times, however RSV F A2 and B9320 did not display fusion levels 
above the mock transfected background samples (EV) at either the 9 or 12 hour 
overlay (Fig. 6.2b).  After 24 hours of overlay, the background levels (EV) were 
very high in this experiment, so fusion levels of all isolates tested were not different 
from background levels at this overlay time (Fig. 6.2b).  Based on the few RSV F 
reporter gene fusion studies that have been previously published, we changed the 
conditions of the luciferase reporter gene experiment.  For this second experiment, 
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Vero cells were transfected with a T7-promoted luciferase plasmid and RSV F was 
transfected into the BSR cells that express the T7 polymerase.  24 hpt the Vero 
cells were lifted and overlaid on the BSR cells, again for 9, 12, or 24 hours (Fig. 
6.2c).  In this experimental set-up, there was a good signal to background ratio for 
each sample, at each overlay time measured (Fig. 6.2c).  RSV F A2 and A2 P101Q 
demonstrated fusion levels significantly higher than RSV F B9320 at each overlay 
time, consistent with the syncytia results (Fig. 6.2c).  While Fig. 6.2c represents 
four independent experiments, several other experiments using the exact same 
experimental conditions over the past 3 year have yield incredibly inconsistent 
results.   
In the decades of research analyzing RSV, there have only been two 
published studies which utilized F only reporter fusion studies [352, 366, 367].  
Both assays appear to require precise timing, and potentially longer cellular 
overlays than other closely related paramyxo- and pneumoviruses when a 
hyperfusogenic F variant is not utilized.  HMPV F, the most closely related virus 
that has more quantitative fusion study published, must be treated with exogenous 
trypsin to cleave F and subjected to a low pH pulse before fusion is observed [368].  
Manipulation of these factors (pH and exogenous trypsin) for RSV F did not result 
in any consistent fusion difference (data not shown) compared to untreated wells.  
Additionally, we readily observed syncytia in Vero and BSR cells for RSV F only, 
however when we attempted to perform a luciferase reporter assay with BSR cells 
overlaid onto Vero cells transfected with DNA for RSV F, we receive very low signal 
above background for anything other than an hyperfusogenic F (Fig. 6.2).  
However, when the cell types are reversed fusion appears more consistent.  Once 
primed and at the cell surface, class I proteins must receive a triggering signal to 
begin the fusion process, but what triggers RSV F is unknown [358, 369]. This 
triggering may be carried out by F binding to a receptor or this may be carried out 
by another viral or host protein entirely. If the trigger is F receptor binding, the 
inconsistent fusion studies may suggest that receptor used by RSV F, which has 
been proposed to be ICAM-1 [370], nucleolin [371], or TLR-4 [372], may have 
lower expression on BSR cells. Since any (or all three) of these receptors may 
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function as the RSV F receptor, additional fusion studies to investigate their 
contribution may be worthwhile. If the triggering signal is carried out by another 
protein entirely, that protein may not be expressed as sufficient levels in our 
attempted fusion assays.  Alternatively, RSV F protein may have an increased 
dependence on the attachment protein (G) or small hydrophobic (SH) protein for 
function, depending on cell type [360, 373-376]. Previous studies have 
demonstrated that RSV that lacks the G protein is still infectious, suggesting that 
G may be dispensable for viral entry [377], but this work was completed in a lab 
passaged RSV A strains, and may not be reflective of the biology of current clinical 
RSV infections.  However, our initial work co-expressing RSV F and G from the 
same subtype did not influence cell-cell fusion in either a syncytia or luciferase 
reporter gene assay (data not shown), supporting the same conclusion that G is 
dispensable for fusion.  Investigation of different stoichiometric ratios of these are 
needed and the ratios needed could vary between subtypes and/or lab grown vs 
clinically isolated fusion proteins.   
RSV F undergoes rapid post-translational cleavage 
To observe the timing and pattern of RSV F cleavage, pulse chase analysis 
was performed, again using RSV F A2 and B9320. Initial pulse-chase experiments 
performed as described for HeV F experiments (Chapter 4, 45-minute label) 
demonstrated that RSV F showed some proteolytic processing at the 0-time point 
(data not shown).  To better analyze processing of the RSV F protein, pulse-chase 
utilizing a 15-minute label period was performed, with chase times of 15 min, 30 
min, 1 hour, 2 hours, and 4 hours (Fig. 6.3a).  Interestingly, a faint band 
corresponding to cleaved protein (F1) was present after 15 min of chase, growing 
more apparent after 30 min of chase.  This was seen in both RSV F A2 and B9320.  
This suggests that RSV F is cleaved at both sites within 30 minutes of synthesis 
(15 min label, 15 min chase) and that most of the protein is processed by 1 hour 
post synthesis. This timing for proteolytic cleavage is much quicker than that 
observed for PIV5 F, which is also processed by furin.  PIV5 F does not 
demonstrate a majority cleavage of the protein population until the 2-hour chase 
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time. This suggests that RSV F may more rapidly traffic to the compartment that 
contains furin than does PIV5 F.  To understand how the cleavage changes in the 
presence of a chemical proprotein convertase inhibitor, a pulse chase experiment 
was performed in cells transfected with expression plasmids for the RSV F isolates 
and then treated with dec-RVKR-CMK during the experiment, with PIV5 F was 
again used as a control.  PIV5 F, RSV F A2 and B9320 all demonstrated a 
reduction in cleavage following treatment with dec-KVRK-CMK, however the PIV5 
F reduction was larger (Fig. 6.3b).  Interestingly, the presence of dec-KVRK-CMK 
appeared to alter the presence of the band corresponding to F1+ more than the 
band corresponding to F1 (Fig. 6.3a).  This may suggest that cleavage at the first 
site may be more readily carried out by furin or a member of the furin family, while 
the second site may be able to be processed by a larger number of cellular 
proteases.  To further assess the contribution of furin to protein cleavage, LoVo 
cells transiently expressing the RSV F isolates were examined. In LoVo cells, a 
reduction in cleavage was again seen, however a band corresponding to F1 was 
still observed, further confirming that other cellular proteases can process RSV F 
(Fig. 6.3c).  There was also a faint band corresponding to cleaved protein for PIV5 
F as well.  Additionally, bands corresponding to F1+ were not observed in RSV F 
A2 or F B9320 samples.   
RSV F from both A2 and B9320 has several predicted N-linked glycans 
(Table 6.1) [153].  Since RSV F is observed as several bands on a gel, potentially 
due to heterogenous glycosylation, we used PNGase F treatment to remove these 
glycans and more accurately observe the size of the RSV F protein products. Vero 
cells transiently expressing RSV F A2 or B9320 were metabolically labeled in a 
pulse chase experiment.   At each chase time, the cell lysates were either treated 
with PNGase F or were not (as indicated. Fig 6.4a).  Starting at the 1-hour chase 
time, untreated samples were primarily observed as two bands (indicated by red 
[F0] and blue [F1+] *, Fig. 6.4a). When treated with PNGase F, RSV F was observed 
as three distinct bands, likely corresponding to F0, F1+, and F1 cleavage products 
from largest to smallest respectively (Fig. 6.4a).  This pattern was consistent at 
each time point and for both RSV F A2 and F B9320.  Because our pulse chase 
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experiments suggested that RSV F was trafficking through the secretory pathway 
more rapidly than expected, we performed an Endoglycosidase H (Endo H).  Endo 
H resistance is not conferred until processing in the cis to medial Golgi apparatus.  
Pulse-chase analysis was performed on Vero cells transiently expressing RSV F 
A2 or F B9320, and then cell lysates were treated with Endo H or left untreated as 
a control.  When only a band corresponding to F0 was present (indicated by orange 
*), the protein appeared to be Endo H sensitive (Fig 6.4b).  However, once RSV F 
was processed (indicated by yellow *), the cleaved protein appeared to be Endo H 
resistant (Fig 6.4b). This observation was the same for RSV F A2 and RSV F 
B9320.  This indicates that the trafficking of the RSV F protein into the cis/medial 
Golgi occurs rapidly, consistent with the rapid cleavage that is observed, since furin 
is thought to be active in the trans-Golgi network. 
Cleavage at both RSV F sites appears to be required for cell-cell fusion 
The relationship of the two cleavage sites or even the function of the first 
cleavage site remains unknown.  To better understand the role of each cleavage 
site we created single or quadruple alanine mutations at each cleavage site in RSV 
F A2 or F B9320 (Fig. 6.5a). Both mutations at the first cleavage site did not alter 
protein expression in Vero or HEp-2 cells for RSV F A2 or B9320 (Fig. 6.5b and c, 
quantified in 6.5d and e).  A single alanine mutation at the second cleavage site 
slightly reduced protein expression in RSV F B9320 and has less of an effect on 
protein expression in RSV F A2 (Fig. 6.5b and c, quantified in 6.5d and e). The 
quadruple alanine mutation at site 2 was not observed (data not shown), though it 
is worth noting that the antibody used to immunoprecipitated these samples 
(Palivizumab) recognizes a conformational antigenic site that lies close to the 
fusion loop and pep27 of the neighboring protomer, so loss or reduction in 
observed protein expression could be due to lower antibody recognition of these 
mutants compared to the wild type (WT) protein [378-380].  Analysis with 
antibodies that recognize other sites or antibodies with non-conformational 
epitopes should be completed in future studies.  A loss of a band corresponding to 
F1+ was observed in mutations at the first cleavage for both RSV F A2 and F B9320 
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(Fig. 6.5b and c, quantified in 6.5f and g).  While a single alanine mutation at site 
two did not abolish cleavage at that site (there is a band corresponding to F1), it 
did increase the amount of protein observed with only the first site cleaved 
(increase in F1+) (Fig. 6.5b and c, quantified in 6.5f and g).  These observations 
were consistent in both Vero and HEp-2 cells. To assess the fusion function of 
these cleavage mutants a syncytia assay was performed.  No syncytia were 
observed for any cleavage mutant (Fig. 6.2a). This is particularly interestingly, 
since mutations that alter cleavage at just the first site still have protein that is 
cleaved in a way that the hydrophobic fusion peptide (FP) is accessible. 
Additionally, the single alanine mutation still demonstrated some protein that 
appeared to be cleaved at both cleavage sites but showed no syncytia formation.  
These results are consistent with two previous studies that analyzed the 
role of the cleavage sites in RSV F A2, showing that mutation of the first site 
rendered the protein non-functional [154, 156]. This suggests that either 
coordination between the two cleavage sites or the release of pep27 may be 
essential for protein fusion, though this remains unexplored. Previous work has 
suggested that key residues in the apical loop of F2 influence fusion function 
potentially by helping propagate the triggering signal through the F protein trimer 
[352].  If this is the case, the loss of cleavage at the first site, may enhance the 
rigidity or space constraints in this area, not allowing for subtle conformation 
changes to occur that would allow for signal transduction to the rest of the protein, 
resulting in loss of fusion mechanism.  There has also been evidence that the RSV 
F trimer may associate and dissociate somewhat at the cell surface in almost a 
‘breathing’ mechanism that allows it to sample its environment like Influenza HA 
[71, 381].  The presence of pep27 on the F2 subunit that occurs with loss of 
cleavage at the first site may inhibit this breathing action, effectively clamping the 
protein, not allowing the RSV F protein to properly test its environment, therefore 
losing the ability to facilitate fusion at the correct time.  Loss of cleavage at the 
S1/S2 border of SARS-CoV-2 causes the protomers within a trimeric unit to more 
tightly associate (Chapter 5, Fig. 5.5), perhaps indicating the loss of cleavage at 
the first site may have a similar effect in RSV F, thus creating too high of an energy 
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barrier for this protein to overcome to facilitate membrane fusion.  Further 
experimentation is needed to properly understand the mechanism that F2 and 
pep27 play is overall protein conformation and fusion function.  Because of the 
higher variability in this area of the F protein, it would be valuable to analyze the 
function of these regions in F proteins from multiple isolates of both clinical and lab 
grown lineage.  Information presented here in this chapter, as well as in future 
planned studies will help yield better insight into the fusion mechanisms of the RSV 
F protein.  Since there is no vaccine for this virus, and limited available treatments, 
deeper understanding of this protein that is critical for viral fusion may provide 


















Table 6 1 Size predictions of RSV F isolates and their cleavage products 
RSV F A2 





Size w/o signal 
peptide 
F0 63.3 4 73.3 70.8 
F1+ 51.4 2 56.4  
F1 48.1 0 48.1  
F2+ 15.3 4 25.3 22.8 
F2 12 2 17 14.5 
Pep27 3.3 2 8.3  
RSV F B9320 





Size w/o signal 
peptide 
F0 63.6 5 76.1 73.4 
F1+ 51.5 3 59  
F1 48.2 0 48.2  
F2+ 15.4 5 27.9 25.2 
F2 12.2 2 17.2 14.5 
Pep27 3.3 3 10.8  
RSV F A Clinical 





Size w/o signal 
peptide 
F0 63.3 5 76.3 73.7 
F1+ 51.4 3 58.9  
F1 48.1 0 48.1  
F2+ 15.2 5 27.7 25.1 
F2 11.9 2 16.9 14.3 
Pep27 3.3 3 10.8  
RSV F B Clinical 





Size w/o signal 
peptide 
F0 63.7 3 70.7 67.9 
F1+ 51.5 1 54  
F1 48.3  48.3  
F2+ 15.4 3 22.9 20.1 
F2 12.2 2 17.2 14.4 
Pep27 3.3 1 5.8  
Size predictions from ExPASy  
N-glycan predictions from NetNGlyc 1.0 Server  




Residues of predicted N-linked glycans* 
RSV F A2 RSV F 
B9320 
RSV F A 
Clinical 
RSV F B 
Clinical 
27 27 27 27 
70 70 70 70 
116 116 116 120 
126 120 120 126 
500 126 126 500 
 500 500  
Red indicates a non-jury agreement  
*N-glycan predictions from NetNGlyc 1.0 Server  
Residues of predicted O-linked glycans** 
RSV F A2 RSV F 
B9320 
RSV F A 
Clinical 
RSV F B 
Clinical 
99 100 None None 
103    
118    
244    
**O-glycan predictions from NetNGlyc 4.0 Server 
 
Table 6 2 Predicted N-linked glycans of RSV F isolates 
 




Figure 6-1 RSV F is over 88% conserved in different subtypes  
a) RSV F is synthesized as a monomeric unit containing a fusion peptide (FP), two 
heptad repeat regions (HRA and HRB), a transmembrane domain (TMD), and a 
cytoplasmic tail (CT). RSV F also contains two cleavage sites that possess the 
recognition motif for cleavage by furin.  If both sites are cleaved, a 27 amino acid 
peptide (pep27) is released.  b) The F protein from different RSV subtypes share 
about an 89% sequence homology.  Additionally, RSV F isolated from strains that 
have been grown in the lab long term (lab adapted) share a 97% and 99% 
sequence homology with their respective A and B subtype clinical isolates.  c) Vero 
or HEp-2 cells were transfected with plasmids encoded for each of the RSV F 
subtypes.  Cells were metabolically labeled for 3 hours.  d) HEp-2 or BSR cells 
were infected with RSV A2, A Clinical, or B Clinical strains.  24 hpi cells were 






Figure 6-2 RSV F readily forms syncytia in transfected cells.  
a) Vero cells were transfected with RSV F from lab adapted isolates or cleavage 
site mutants.  Cells were imaged at 24 and 48 hpt.  Black arrows indicate syncytia 
formation. b) A luciferase reporter gene assay was performed using Vero cells 
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(with a T7 promoted-luciferase plasmid) overlaid onto BSR cells (transfected with 
plasmids encoding for RSV F) at 24 h pt. c) Another reporter gene assay was 
performed this time using BSR cells overlaid onto Vero cells (transfected with 
plasmids for RSV F and T7-luciferase.  Results of b and c are normalized to WT 























Figure 6-3 Inhibition of cellular furin reduces RSV F cleavage.   
a) Vero cells transiently expressing RSV F were metabolically labeled for 15 
minutes, then chased for the times indicated (hours). This was also performed in 
the presence of 50µM dec-RVKR-cmk. b) Using band densitometry, reduction in 
protein cleavage was quantified in the presence of increasing levels of dec-RVKR-














Figure 6-4 Treatment with PNGase F and Endoglycosidase H reveal the RSV 
size and rapid trafficking rate.  
a) Vero cells transiently expressing RSV F were metabolically labeled for 15 
minutes and chased for times indicated (hours).  Cell lysates were treated with 
PNGase F to determine the size of the protein after removal of the N-linked 
glycans. b) Vero cells transiently expressing RSV F were metabolically labeled for 
15 minutes and chased for times indicated (minutes).  Cell lysates were treatment 









Figure 6-5 Mutations at the RSV F cleavage sites variably effect protein 
expression and reduce protein cleavage.  
a) Single or quadruple alanine mutants were created at the two protein cleavage 
sites in RSV F A2 and B9320.  Vero cells (b) or HEp-2 (c) transiently expressing 
RSV F or each of the cleavage mutants were metabolically labeled for 3 hours. 
Using band densitometry, protein expression (d/e) or protein cleavage (f and g) 
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was measured for each of the mutants.  Results are representative of 3 






CHAPTER 7. DISCUSSION AND FUTURE DIRECTIONS 
The work presented in this dissertation yields key molecular insights into 
the class I fusion proteins of important enveloped RNA viruses.  Using the HeV 
fusion protein, we demonstrated that the transmembrane domain (TMD) of this 
protein could be targeted to destabilize the protein and prevent fusion function, 
presenting it as a novel therapeutic target (Chapter 3). Additionally, through 
mutagenesis we discovered residues M491/L492 within the TMD appear to play a 
role in the overall fusion mechanism of the HeV F protein (Chapter 4), further 
presenting this region as more than simply a membrane anchor.  As the global 
pandemic shifted our focus to SARS-CoV-2 S, we discovered regions of the protein 
that may play a role in the fusion mechanism, as well as that proteolytic processing 
of the protein at the S1/S2 border appears to regulate trimer stability (Chapter 5).  
Lastly, we explored the mechanisms and cleavage patterns of RSV fusion proteins 
from different lineages, providing better understanding of how the fusion processes 
may differ between the RSV subtypes (Chapter 6). Collectively, this provides 
critical information on these class I fusion proteins, however several important 
research questions surrounding these important therapeutic targets remain 
unanswered. 
Current vaccine and anti-viral landscape for enveloped RNA viruses  
Measles virus, influenza virus, RSV, and the recently emerged SARS-CoV-
2 are just a few of the important human pathogens that are enveloped RNA viruses.  
Among these viruses, current therapeutic success is widely variable.  Measles was 
also among the first vaccines to be widely utilized, with a live attenuated vaccine 
being used since the early 1960s [382].  Most of these vaccines are thought to 
confer immunity for several years, if not a person’s entire life. We also have 
seasonal influenza vaccines that help protect against three or four influenza 
strains, though only short term, seasonal, protection is provided by each vaccine 
[383]. Most recently, SARS-CoV-2 has two vaccines that were granted 
“Emergency Use Authorization” by the FDA in late 2020 [41, 384]. Both of those 
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vaccines use messenger RNA encoding for a stabilized full-length S protein, using 
lipid nanoparticles to help deliver the RNA to host cells [385].  This is the first 
approved use of this vaccine technology; therefore, the length of protection provide 
is still unknown.  Despite large efforts, no current human vaccines exist for many 
other enveloped RNA viruses, like RSV, HMPV, Henipaviruses, and other human 
coronaviruses.   
Once a person becomes infected with one of these viruses, treatment 
options are limited.  Most treatments for viral infections involve simply treating the 
systemic symptoms caused by the virus, however there are a few anti-viral 
therapeutic options depending on the virus.  Several approved therapeutics target 
influenza virus, which target the viral neuraminidase to limit the spread or release 
of nascent viral particles from infected cells, but these need to be given shortly 
after viral infection to be effective [386].  For RSV, the only FDA approved 
treatment is a monoclonal antibody against the F protein [355].  Monoclonal 
antibody treatment or treatment with convalescent sera from previously infected 
patients, have also shown to be effective other respiratory viruses such as SARS-
CoV and SARS-CoV-2 [387-394], but these are costly to make or harvest, thus 
making them a first-world solution.   
Fusion protein regions as novel therapeutic targets  
In this dissertation, we present the TM region of the viral fusion proteins as 
a novel target (Chapter 3).  Our work demonstrates that viral treatment with 
peptides that mimic the TM region of F reduces viral infection by disrupting the viral 
fusion process.  Another study has also shown that targeting the TM region with 
peptides blocks function of the HIV envelope protein, again by interacting with the 
full-length proteins, disrupting TM-TM interactions, and thus interfering with the 
fusion mechanism [125]. Successfully targeting and disrupting TM-TM interactions 
has also been shown to work in non-viral systems such as disrupting the 
dimerization of neuropilin-1 to suppress tumor formation among others discussed 
further in the introduction to this dissertation [227-231]. While these studies provide 
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the proof of concept for targeting the TM domain, targeting the TM in practice 
presents some challenges. Because of the hydrophobic nature, TM peptides can 
be difficult to synthesize and solubilize in aqueous solutions [395], so inclusion of 
portion of regions external to the membrane spanning region (as we did in Chapter 
3) may help with this. Additionally an over-abundance of membrane proteins can 
lead to a disruption of the physical membrane barrier, causes toxicity to the cell 
[395]. To help mitigate these challenges, further research is needed to flush out 
delivery of these peptides or use of small molecules instead.   
Apart from the TM region, peptides or small molecules targeting other 
regions of viral fusion proteins are under investigation as anti-viral therapeutics.  
Several peptides that target regions of the influenza HA are being developed to 
help prevent conformational changes needed for influenza HA fusion [396, 397].  
For RSV treatment, there are several small molecule fusion inhibitors currently 
being investigated in clinical trials. Many of these small molecules function by 
binding to the same antigenic sites found in the pre-fusion RSV F conformation, 
thus locking the pre-fusion F in place [386, 396, 398-400]. These molecules 
interact with both the fusion peptide and the HRB region of RSV F to create 
stabilized pre-fusion F that is unable to undergo the conformational changes 
necessary to facilitate fusion. Some of the RSV F anti-viral therapeutics in 
development also target the HRB region, and work by interfering with the formation 
of the six-helix bundle needed to bring the viral and host cell membrane together 
[396, 398, 401]. There is also some evidence that the HRB peptides may also be 
able to serve as pan-viral inhibitors, since inhibitors created to the HRB of the 
paramyxovirus, PIV3 F protein also demonstrated an inhibitory effect against 
Hendra and Nipah [402]. Interestingly, inclusion of cholesterol on these peptides 
appeared to increase binding affinity indicating that inclusion of portion of the TM 
may also help.   
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Targeting the viral fusion protein proteolytic processing  
Class I viral fusion proteins must undergo a proteolytic cleavage event 
before being able to facilitate viral entry through the membrane fusion process [46].  
This cleavage event activates the protein, creating a metastable pre-fusion protein 
that can facilitate membrane fusion following the receipt of a triggering signal.  A 
host cell protease completes this cleavage. Therefore, inhibition of these host 
proteases presents another set of antiviral targets that may be applicable for 
treatment of a larger number of viral infections.  Despite the more than 500 human 
proteases that have been discovered [403], several viruses have evolved to use 
similar host cell proteases for this viral protein cleavage. SARS-CoV S, Hendra F, 
and Nipah F have all been shown to use the endosomal protease Cathepsin L 
[150, 175, 318, 319]. HMPV, SARS-CoV-2, SARS-CoV, MERS-CoV, and 
Influenza have all been shown to use the transmembrane serine protease 2 
(TMPRSS2) [148, 181, 316, 326, 404-407]. RSV, Measles, highly pathogenic 
forms of Influenza, and several humans CoVs possess the multi-basic cleavage 
recognition site motif for the proprotein convertase, furin or a member the furin 
family [152, 154, 156, 180, 404].  In fact, the presence of a recognition site for the 
non-tissue specific protease furin has been implicated for expanding cellular 
tropism in virus infection [285, 408].  These proteases have been investigated as 
druggable targets for other human disease such as heart disease, stroke 
treatment, and cancer treatment, but research investigating them as anti-virals 
remains limited.  Camostat is a broad-spectrum serine protease inhibitor approved 
for use in Japan for treatment of chronic pancreatitis and postoperative esophagus 
inflammation [409, 410]. Due to the rapid emergence of SARS-CoV-2 in early 
2020, there was a substantial amount of investigation into repurposing already 
existing drugs for as anti-viral treatments. In vitro studies demonstrated that 
camostat reduced SARS-CoV-2 infection [181], and there are currently several 
phase 1-2 clinical trials that are on-going to better understand its effectiveness in 
humans [411].  Interestingly, cell culture experiments suggest that SARS-CoV-2 
can utilize the cell surface or endosomal compartments for viral entry depending 
on the host proteases available [181].  
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Similarly, our work has suggested that both RSV F (Chapter 6) and SARS-
CoV-2 S (Chapter 5) demonstrate a reduction, but not a complete loss, of protein 
cleavage when active furin is not present. This may suggest that combination 
therapy, inhibiting of multiple cellular proteases [412], may be needed to fully inhibit 
viral entry, though more investigation into the safety and efficacy of these 
treatments is needed. Additionally, developing inhibitors for the member of the furin 
family or cathepsin family may also prove to be effect and broadly applicable anti-
viral treatments. To better understand this, a through investigation of what host 
proteases can process each fusion protein needs to be completed.  This could be 
done by creating a series of knockout cell lines similar to the Cathepsin L MEFs 
used in Chapter 5, or purifying the fusion proteins and performing exogenous 
protease treatment experiments. Results from the latter experiment would need to 
be confirmed in a cell culture system since TM proteins usually need to be 
manipulated or truncated before being purified.  Additionally, transfection 
experiments over expressing various host proteases could be completed in the 
LoVo cell line where a reduction in cleavage is observed (RSV F; Chapter 6 and 
SARS-CoV-2, Chapter 5). Alternative to developing protease inhibitors, in line with 
our work to target the HeV F TM region (Chapter 4), research could be done to 
develop small peptides or small molecules that interact with the cleavage sites of 
the fusion proteins to block protein cleavage. Since furin cleavage occurs in the 
trans-Golgi network, these molecules would need to interact with the fusion 
proteins shortly after synthesis to prevent the proteolytic processing.  
RSV- A unique challenge    
Since its discovery in the 1950s, there have been significant efforts to 
develop an effective RSV vaccine.  Currently, there nearly 20 candidates in Phase 
1-3 clinical trials in the United States, attempting to use technologies such as live 
attenuated viruses, particle-based vaccines, subunit vaccines, and recombinant 
vectors [54, 55]. In 2019, a vector-based vaccine, using an adenovirus vector 
expressing a prefusion RSV F, was granted “breakthrough therapy” designation by 
the FDA for use in adults above 60 [56].  There are also a few trials investigating 
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new options for more effective monoclonal antibody treatments, including one by 
AstraZeneca that was granted “breakthrough therapy” approval by the FDA in 2019 
[57-59].   Absent from current clinical trials is the use of inactivated virus, due to a 
tragically failed clinical trial using formalin inactivated RSV particle in children [55, 
60]. Vaccination with this virus resulted in more severe respiratory illness in several 
of the children who were vaccinated.   
 The challenge to finding an effective RSV vaccine for all ages could 
be due to several reasons.  In recent years there is increasing evidence that the 
prototypic RSV A and B strains used in laboratory research are not as clinically 
relevant as they once were [61-64].  Long term passage in cell culture has placed 
selective pressure on these viruses to better replicate in a cell culture dish than in 
the complex environment of the human airway. This may suggest that subtle 
differences exist between the fusion process or fusion requirements of the clinical 
strains compared to the prototypic RSV strains.  This could mean there are 
different cellular receptors or fusion triggers utilized, as these are not well 
characterized for RSV.  To help better understand these, creating and employing 
systems to readily study currently circulating RSV strains is needed for future 
research, both to investigate differences in the viral entry and the entire viral 
lifecycle. This could mean creating a recombinant viral system based on current 
clinical strains for RSV A and B that could be readily used in a laboratory setting. 
Though since previous work has demonstrated that clinical isolates replicate much 
less efficiently in cell culture, presenting additional challenges to studying them 
[63-65], it may mean using 3-D model systems like human airway epithelial tissues 
may need to be utilized more in preliminary studies to recapitulate the natural 
infection environment.  Since it appears there are going to continue to be RSV 
strain population changes, such as the attachment protein duplication that has 
arisen in clinical strains of the virus [66-68].  Future laboratory work can focus on 
understanding differences in the F protein mechanisms between different RSV 
subtypes. Dye transfer assays in the presence of RSV F antibodies to different 
antigenic sites can be utilized to help probe difference in fusion and hemi fusion 
states of RSV F in transfected cells.  Additionally, peptide binding assays using 
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peptides that mimic RSV F HRA and HRB for each subtype can be completed to 
biochemically understand the protein movement and triggering process in different 
cellular conditions (pH changes, membrane composition, etc) of F from each RSV 
subtype.     
RSV F peptide 27 and other fusion protein peptides  
Another area of RSV that warrants further investigation is the role of pep27, 
not covalently linked to the protein following cleavage at both F protein sites during 
cellular infection.  Studies have demonstrated when this region is deleted, the 
protein remains fusogenically functional, though to a qualitatively less extent than 
wild-type F [69].  However, other work, including our study (Chapter 6), shows that 
keeping pep27 linked to the F2 subunit renders the protein fusion inactive [46, 47].  
This may indicate that the release of pep27 provides conformational flexibility 
necessary to allow for the subunit association/dissociation needed or for triggering 
signal transduction through the protein. The small nature of pep27 and the data 
showing that it prevents membrane fusion when attached to F2 (Chapter 6,[46, 
47]) suggest this may have therapeutic implications.  If a small molecule could be 
created to replace the pocket left by pep27 in the pre-fusion structure, the protein 
may be locked in the pre-fusion conformation and unable to be triggered.  The RSV 
F prefusion structures published lack both binding sites and the entire pep27 [70, 
71], so elucidating the structure of the pocket left by the release of pep27 could be 
challenging.  However, finding a way to stabilize that region may help gain key 
information about the shape of that pocket may provide a new antigenic site to 
target on RSV F.  Additionally, further studies that seek to understand the role of 
the first cleavage site and track the subcellular localization of pep27 throughout 
the RSV viral infection would provide interesting insights into this small peptide, 
thus providing a more comprehensive vaccine target.  
Interestingly, SARS-CoV-2 and other human infecting coronaviruses also 
possess two cleavage sites [72], though they are about 100 amino acids apart 
compared to the 27 amino acids of pep27.  Our work (Chapter 5) suggests that 
cleavage at the first site (S1/S2 border) is required for cell-cell fusion, but the 
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function of the second site (S2’) remains evasive.  Other studies suggest that 
cleavage is required at both sites for SARS-CoV-2 and MERS-CoV to infect cells, 
and that this cleavage occurs following receptor binding [39]. This fits with our data, 
since the presence of TMPRSS2 in the same cells as hACE2 enhances cell-cell 
fusion in our experiments (Chapter 5).  Despite this enhancement and the 
numerous conditions tested, we did not readily observe the presence of a band 
that would correspond to S cleaved at S2’ (around 65 kDa), suggesting this 
cleavage may not be needed for SARS-CoV-2 cell-cell fusion, or that the overall S 
protein is unstable and degrades very quickly following cleavage at the S2’ site.  
Alternatively, the antibody used (S S2 subunit specific) could bind an epitope that 
is blocked in the post-fusion protein conformation. Pulse chase experiments using 
a series of different antibodies or with additional later timepoints may yield better 
insight in the timing of the S2’ cleavage. To better understand the role of the dual 
cleavage sites in general, antibodies could be created to the peptide region 
between these two cleavage sites to understand the localization during the fusion 
process and protein trafficking in both transfection experiments and infection 








hACE2 Human angiotensin converting 
enzyme 2 
bNAbs Broadly neutralizing antibodies 
Cath L Cathepsin L 
CoV Coronavirus 
COVID-19 Coronavirus disease of 2019 
Cryo-EM Cryo-electron microscopy 
CTD Cytoplasmic tail domain 
EBOV Ebola virus 
Env Envelope protein 
ER Endoplasmic reticulum 
F Fusion protein 
FP Fusion peptide 
FRET Forester resonance energy 
transfer 
G Attachment protein 
GP Glycoprotein 
HA Hemagglutinin 
HDX-MS Hydrogen-deuterium exchange 
mass spectrometry 
HeV Hendra Virus 
HIV-1 Human immunodeficiency virus 
type 1 
HMPV Human metapneumovirus 
Hpt Hours post transfection 
HR Heptad repeat 
HSV-1 Herpes simplex virus 1 
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MEFs Mouse embryonic fibroblasts 
MERS-CoV Middle eastern respiratory 
syndrome coronavirus 
MeV Measles virus 
MPER Membrane proximal external 
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NDV Newcastle disease virus 
NMR Nuclear magnetic resonance 
PC Phosphatidyl choline 
PE Phosphatidyl ethanolamine 
PIV5 Parainfluenza virus 5 
RSV Respiratory Syncytial Virus 
S Spike protein 
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SARS-CoV-2 Severe acute respiratory 
syndrome coronavirus 2 
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